[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fSLmnKKJUmhJV5QPd9bELD7SZEBL_UWEA-XgQm5_MuEc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":52,"rows":59},"LEO Pharma",[4],222,false,4,53,169393,5,7,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Psoriasis Vulgaris",59,{"name":18,"count":19},"Atopic Dermatitis",34,{"name":21,"count":22},"Actinic Keratosis",29,{"name":24,"count":25},"Healthy",17,{"name":27,"count":28},"Chronic Hand Eczema",9,{"name":30,"count":31},"Papulopustular Rosacea",6,{"name":33,"count":11},"Psoriasis",{"name":35,"count":8},"Psoriasis of Scalp",[37,42,47],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06311682","A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis","2026-10-20","Tralokinumab + TCS",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT07013201","A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg\u002Fg in Adult Participants With Mild to Severe Palmoplantar Pustulosis","2026-12-14","Delgocitinib cream",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT07335588","A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus","2028-03-10","Delgocitinib",[53,54,55,56,57,58],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[60,157,222,243,333,362,419,465,512,551,589,614,637,655,673,697,715,740,764,791,809,827,845,985,1063,1147,1231,1298,1337,1363,1405,1437,1479,1521,1553,1575,1612,1634,1662,1684,1702,1720,1747,1765,1783,1801,1819,1837,1855,1873,1891,1909,1927,1945,1963,1990,2008,2031,2058,2076,2100,2118,2144,2162,2180,2198,2216,2234,2258,2276,2299,2317,2335,2360,2378,2396,2414,2432,2507,2545,2609,2654,2700,2735,2761,2800,2835,2867,2896,2926,2948,2976,3006,3024,3046,3070,3088,3112,3130,3148,3166,3184,3202,3220,3238,3256,3274,3292,3310,3328,3346,3364,3382,3400,3426,3444,3462,3480,3498,3516,3539,3560,3582,3607,3625,3643,3661,3686,3708,3730,3748,3766,3784,3802,3820,3843,3866,3884,3902,3926,3944,3962,3980,4002,4020,4038,4056,4074,4092,4110,4148,4170,4206,4233,4261,4294,4318,4356,4374,4392,4410,4428,4446,4464,4482,4500,4524,4542,4560,4578,4596,4614,4632,4655,4673,4691,4709,4727,4745,4766,4787,4812,4830,4848,4869,4887,4905,4923,4941,4966,4984,5002,5020,5038,5056,5074,5092,5110,5133,5151,5175,5193,5211,5229,5254,5272,5290,5308,5326,5344,5362,5380,5398,5420,5438,5462,5480,5504,5525,5543,5565,5583,5601,5619,5637,5655,5678,5703,5721,5739,5762,5780,5798,5820,5841,5865,5886,5904,5981,6019,6053,6083,6118,6151,6174,6204,6222,6240,6258,6276,6294,6312,6336,6354,6372,6390,6412,6435,6460,6478,6501,6525],{"intervention":51,"totalTrials":61,"cells":62},8,{"EARLY_PHASE1":63,"PHASE1":76,"PHASE2":97,"PHASE3":99,"PHASE4":153,"NA":155},{"trials":64,"activeCount":75},[65],{"nctId":66,"briefTitle":67,"status":68,"phases":69,"primaryCompletion":70,"completion":70,"start":71,"enrollment":72,"conditions":73,"interventions":74},"NCT05050279","A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy People","COMPLETED",[53],"2022-01-04","2021-09-29",40,[24],[51],0,{"trials":77,"activeCount":75},[78,88],{"nctId":79,"briefTitle":80,"status":68,"phases":81,"primaryCompletion":82,"completion":82,"start":83,"enrollment":84,"conditions":85,"interventions":86},"NCT03826901","Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children",[54],"2021-10-29","2019-02-20",46,[18],[87],"delgocitinib",{"nctId":89,"briefTitle":90,"status":68,"phases":91,"primaryCompletion":92,"completion":92,"start":93,"enrollment":94,"conditions":95,"interventions":96},"NCT05486117","Pharmacokinetics of Delgocitinib 20 mg\u002Fg Cream in Subjects With Chronic Hand Eczema",[54],"2022-11-22","2022-09-06",15,[27],[51],{"trials":98,"activeCount":75},[],{"trials":100,"activeCount":152,"soonestReadout":50},[101,110,120,131,141],{"nctId":102,"briefTitle":103,"status":68,"phases":104,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":109},"NCT04949841","Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials",[56],"2023-09-18","2021-08-23",801,[27],[51],{"nctId":111,"briefTitle":112,"status":68,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":119},"NCT06004050","A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema",[56],"2024-12-16","2025-09-12","2023-09-05",362,[27],[51],{"nctId":121,"briefTitle":122,"status":68,"phases":123,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":129},"NCT05355818","Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema",[56],"2024-12-05","2024-12-17","2022-07-14",98,[27],[51,130],"Cream vehicle",{"nctId":48,"briefTitle":49,"status":132,"phases":133,"primaryCompletion":50,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":139},"RECRUITING",[56],"2028-12-29","2026-05-01",652,[138],"Lichen Sclerosus",[51,140],"Cream Vehicle",{"nctId":142,"briefTitle":143,"status":68,"phases":144,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":150},"NCT05259722","A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg\u002Fg Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema",[56],"2023-11-08","2023-12-05","2022-06-15",513,[27],[51,151],"Toctino",1,{"trials":154,"activeCount":75},[],{"trials":156,"activeCount":75},[],{"intervention":130,"totalTrials":31,"cells":158},{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":175,"PHASE3":189,"PHASE4":218,"NA":220},{"trials":160,"activeCount":75},[],{"trials":162,"activeCount":75},[163],{"nctId":164,"briefTitle":165,"status":68,"phases":166,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":172},"NCT01850849","Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream",[54],"2014-11","2014-12","2013-05",23,[18],[173,174],"LEO 39652 cream","cream vehicle",{"trials":176,"activeCount":75},[177],{"nctId":178,"briefTitle":179,"status":68,"phases":180,"primaryCompletion":181,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":186},"NCT00764751","Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris",[55],"2008-12","2009-01","2008-09",51,[15],[187,188,130],"LEO 19123 Cream","Dovonex® cream",{"trials":190,"activeCount":152,"soonestReadout":50},[191,201,205,214],{"nctId":192,"briefTitle":193,"status":68,"phases":194,"primaryCompletion":195,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":200},"NCT04872101","Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)",[56],"2022-12-27","2023-01-06","2021-05-25",473,[27],[46,130],{"nctId":121,"briefTitle":122,"status":68,"phases":202,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":203,"interventions":204},[56],[27],[51,130],{"nctId":206,"briefTitle":207,"status":68,"phases":208,"primaryCompletion":209,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":213},"NCT04871711","Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema",[56],"2022-10-31","2021-05-10",487,[27],[46,130],{"nctId":48,"briefTitle":49,"status":132,"phases":215,"primaryCompletion":50,"completion":134,"start":135,"enrollment":136,"conditions":216,"interventions":217},[56],[138],[51,140],{"trials":219,"activeCount":75},[],{"trials":221,"activeCount":75},[],{"intervention":41,"totalTrials":152,"cells":223},{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":230,"PHASE4":239,"NA":241},{"trials":225,"activeCount":75},[],{"trials":227,"activeCount":75},[],{"trials":229,"activeCount":75},[],{"trials":231,"activeCount":152,"soonestReadout":40},[232],{"nctId":38,"briefTitle":39,"status":132,"phases":233,"primaryCompletion":40,"completion":234,"start":235,"enrollment":236,"conditions":237,"interventions":238},[56],"2028-04-28","2024-06-10",195,[18],[41],{"trials":240,"activeCount":75},[],{"trials":242,"activeCount":75},[],{"intervention":46,"totalTrials":28,"cells":244},{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":268,"PHASE3":319,"PHASE4":329,"NA":331},{"trials":246,"activeCount":75},[],{"trials":248,"activeCount":75},[249,259],{"nctId":250,"briefTitle":251,"status":68,"phases":252,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":256,"interventions":257},"NCT04807751","Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream",[54],"2021-07-30","2021-03-25",60,[24],[46,258],"Delgocitinib cream vehicle",{"nctId":260,"briefTitle":261,"status":68,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":267},"NCT04361136","Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream",[54],"2020-05-30","2020-04-23",35,[24],[46,258],{"trials":269,"activeCount":152,"soonestReadout":45},[270,279,291,301,309],{"nctId":271,"briefTitle":272,"status":68,"phases":273,"primaryCompletion":274,"completion":274,"start":275,"enrollment":276,"conditions":277,"interventions":278},"NCT03725722","Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg\u002Fg Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.",[55],"2020-05-19","2018-12-28",251,[18],[46,258],{"nctId":280,"briefTitle":281,"status":282,"phases":283,"primaryCompletion":284,"completion":285,"start":286,"enrollment":287,"conditions":288,"interventions":290},"NCT03958955","Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.","TERMINATED",[55],"2020-04-15","2020-04-30","2019-07-09",27,[289],"Discoid Lupus Erythematosus",[46,258],{"nctId":292,"briefTitle":293,"status":68,"phases":294,"primaryCompletion":295,"completion":296,"start":297,"enrollment":265,"conditions":298,"interventions":300},"NCT05332366","A Trial to Assess the Effect of Delgocitinib Cream 20 mg\u002Fg on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia",[55],"2023-02-13","2023-05-22","2022-04-19",[299],"Frontal Fibrosing Alopecia",[46,258],{"nctId":43,"briefTitle":44,"status":132,"phases":302,"primaryCompletion":45,"completion":45,"start":303,"enrollment":304,"conditions":305,"interventions":307},[55],"2025-09-11",135,[306],"Palmoplantar Pustulosis",[46,308],"Vehicle cream",{"nctId":310,"briefTitle":311,"status":68,"phases":312,"primaryCompletion":313,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":318},"NCT03683719","Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg\u002Fg Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema",[55],"2020-03-06","2020-04-20","2018-11-28",258,[27],[46,258],{"trials":320,"activeCount":75},[321,325],{"nctId":192,"briefTitle":193,"status":68,"phases":322,"primaryCompletion":195,"completion":196,"start":197,"enrollment":198,"conditions":323,"interventions":324},[56],[27],[46,130],{"nctId":206,"briefTitle":207,"status":68,"phases":326,"primaryCompletion":209,"completion":209,"start":210,"enrollment":211,"conditions":327,"interventions":328},[56],[27],[46,130],{"trials":330,"activeCount":75},[],{"trials":332,"activeCount":75},[],{"intervention":308,"totalTrials":334,"cells":335},2,{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":350,"PHASE3":356,"PHASE4":358,"NA":360},{"trials":337,"activeCount":75},[],{"trials":339,"activeCount":75},[340],{"nctId":341,"briefTitle":342,"status":68,"phases":343,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":348},"NCT02103725","A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis",[54],"2014-09","2014-04",30,[18],[349,308],"pimecrolimus 10 mg\u002Fg cream",{"trials":351,"activeCount":152,"soonestReadout":45},[352],{"nctId":43,"briefTitle":44,"status":132,"phases":353,"primaryCompletion":45,"completion":45,"start":303,"enrollment":304,"conditions":354,"interventions":355},[55],[306],[46,308],{"trials":357,"activeCount":75},[],{"trials":359,"activeCount":75},[],{"trials":361,"activeCount":75},[],{"intervention":363,"totalTrials":8,"cells":364},"Brodalumab",{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":383,"NA":417},{"trials":366,"activeCount":75},[],{"trials":368,"activeCount":75},[],{"trials":370,"activeCount":75},[],{"trials":372,"activeCount":75},[373],{"nctId":374,"briefTitle":375,"status":282,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":381},"NCT04305327","Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis",[56],"2023-05-05","2022-12-07",12,[33],[363,382],"Ustekinumab",{"trials":384,"activeCount":75},[385,395,406],{"nctId":386,"briefTitle":387,"status":68,"phases":388,"primaryCompletion":389,"completion":390,"start":391,"enrollment":392,"conditions":393,"interventions":394},"NCT04306315","Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight",[57],"2025-08-25","2026-01-05","2022-07-21",385,[15],[363],{"nctId":396,"briefTitle":397,"status":68,"phases":398,"primaryCompletion":399,"completion":400,"start":401,"enrollment":402,"conditions":403,"interventions":404},"NCT03331835","A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis",[57],"2019-01-24","2019-03-21","2017-11-03",210,[15],[363,405],"Fumaric acid esters",{"nctId":407,"briefTitle":408,"status":282,"phases":409,"primaryCompletion":410,"completion":378,"start":411,"enrollment":412,"conditions":413,"interventions":415},"NCT04533737","Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab",[57],"2022-09-08","2020-12-17",113,[414,15,33],"Plaque Psoriasis",[363,416],"Guselkumab",{"trials":418,"activeCount":75},[],{"intervention":420,"totalTrials":421,"cells":422},"azelaic acid 15% gel",3,{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":427,"PHASE3":451,"PHASE4":453,"NA":463},{"trials":424,"activeCount":75},[],{"trials":426,"activeCount":75},[],{"trials":428,"activeCount":75},[429,441],{"nctId":430,"briefTitle":431,"status":68,"phases":432,"primaryCompletion":433,"completion":433,"start":434,"enrollment":435,"conditions":436,"interventions":438},"NCT00408330","A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face",[55],"2007-03","2006-12",48,[437],"Seborrheic Dermatitis on the Face",[439,440],"Azelaic Acid 15% Gel","Inactive 15% gel base",{"nctId":442,"briefTitle":443,"status":68,"phases":444,"primaryCompletion":433,"completion":433,"start":445,"enrollment":435,"conditions":446,"interventions":448},"NCT00403949","A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis",[55],"2006-11",[447],"Perioral Dermatitis",[449,450],"Azelaic acid 15% gel","Non-active base from azelaic acid 15% gel",{"trials":452,"activeCount":75},[],{"trials":454,"activeCount":75},[455],{"nctId":456,"briefTitle":457,"status":68,"phases":458,"primaryCompletion":459,"completion":459,"start":460,"enrollment":127,"conditions":461,"interventions":462},"NCT00417937","A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily",[57],"2007-06","2007-01",[30],[420,420],{"trials":464,"activeCount":75},[],{"intervention":466,"totalTrials":421,"cells":467},"Ingenol Mebutate Gel, 0.015%",{"EARLY_PHASE1":468,"PHASE1":470,"PHASE2":472,"PHASE3":474,"PHASE4":487,"NA":510},{"trials":469,"activeCount":75},[],{"trials":471,"activeCount":75},[],{"trials":473,"activeCount":75},[],{"trials":475,"activeCount":75},[476],{"nctId":477,"briefTitle":478,"status":68,"phases":479,"primaryCompletion":480,"completion":480,"start":481,"enrollment":482,"conditions":483,"interventions":484},"NCT01600014","Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp",[56],"2014-02","2012-05",463,[21],[485,486],"Ingenol mebutate gel, 0.015%","Vehicle gel",{"trials":488,"activeCount":75},[489,500],{"nctId":490,"briefTitle":491,"status":68,"phases":492,"primaryCompletion":493,"completion":493,"start":494,"enrollment":495,"conditions":496,"interventions":498},"NCT02406014","Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp",[57],"2016-06","2015-04",502,[497],"Actinic Keratosis (AK)",[466,499],"Diclofenac sodium gel 3%",{"nctId":501,"briefTitle":502,"status":68,"phases":503,"primaryCompletion":504,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":508},"NCT01926496","Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%",[57],"2019-07-11","2013-09-11",485,[497],[466,509],"Imiquimod Cream, 5%",{"trials":511,"activeCount":75},[],{"intervention":513,"totalTrials":334,"cells":514},"Innohep®",{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":521,"PHASE4":534,"NA":549},{"trials":516,"activeCount":75},[],{"trials":518,"activeCount":75},[],{"trials":520,"activeCount":75},[],{"trials":522,"activeCount":75},[523],{"nctId":524,"briefTitle":525,"status":68,"phases":526,"primaryCompletion":345,"completion":527,"start":528,"enrollment":529,"conditions":530,"interventions":532},"NCT01130025","Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer",[56],"2014-05","2010-08",900,[531],"Venous Thromboembolism",[533,513],"Warfarin",{"trials":535,"activeCount":75},[536],{"nctId":537,"briefTitle":538,"status":68,"phases":539,"primaryCompletion":540,"completion":541,"start":542,"enrollment":543,"conditions":544,"interventions":546},"NCT00277394","Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis",[57],"2008-05","2008-07","2005-12",541,[545],"Deep Vein Thrombosis",[547,548],"innohep®","Heparin",{"trials":550,"activeCount":75},[],{"intervention":552,"totalTrials":334,"cells":553},"Fucidin® cream",{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":575,"NA":587},{"trials":555,"activeCount":75},[],{"trials":557,"activeCount":75},[],{"trials":559,"activeCount":75},[],{"trials":561,"activeCount":75},[562],{"nctId":563,"briefTitle":564,"status":282,"phases":565,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":571},"NCT03395132","Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis\u002FEczema",[56],"2019-05-09","2018-07-31",68,[570],"Infected Atopic Dermatitis\u002FEczema",[572,552,573,574],"Fucicort® Lipid cream","Fucicort® Lipid cream vehicle","betamethasone (Lianbang Beisong®) cream",{"trials":576,"activeCount":75},[577],{"nctId":578,"briefTitle":579,"status":282,"phases":580,"primaryCompletion":581,"completion":581,"start":582,"enrollment":583,"conditions":584,"interventions":586},"NCT00986856","Fucidin® Cream in the Treatment of Impetigo",[57],"2005-03","2004-05",58,[585],"Impetigo",[552],{"trials":588,"activeCount":75},[],{"intervention":590,"totalTrials":152,"cells":591},"Methylprednisolone Aceponate",{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":598,"PHASE4":600,"NA":612},{"trials":593,"activeCount":75},[],{"trials":595,"activeCount":75},[],{"trials":597,"activeCount":75},[],{"trials":599,"activeCount":75},[],{"trials":601,"activeCount":75},[602],{"nctId":603,"briefTitle":604,"status":68,"phases":605,"primaryCompletion":606,"completion":607,"start":581,"enrollment":608,"conditions":609,"interventions":611},"NCT00185510","Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis",[57],"2006-05","2006-06",250,[610],"Dermatitis, Atopic",[590],{"trials":613,"activeCount":75},[],{"intervention":615,"totalTrials":152,"cells":616},"Calcipotriol,",{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":625,"NA":635},{"trials":618,"activeCount":75},[],{"trials":620,"activeCount":75},[],{"trials":622,"activeCount":75},[],{"trials":624,"activeCount":75},[],{"trials":626,"activeCount":75},[627],{"nctId":628,"briefTitle":629,"status":68,"phases":630,"completion":542,"start":631,"enrollment":632,"conditions":633,"interventions":634},"NCT00216892","Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris",[57],"2005-04",1032,[15],[615],{"trials":636,"activeCount":75},[],{"intervention":405,"totalTrials":152,"cells":638},{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":645,"PHASE4":647,"NA":653},{"trials":640,"activeCount":75},[],{"trials":642,"activeCount":75},[],{"trials":644,"activeCount":75},[],{"trials":646,"activeCount":75},[],{"trials":648,"activeCount":75},[649],{"nctId":396,"briefTitle":397,"status":68,"phases":650,"primaryCompletion":399,"completion":400,"start":401,"enrollment":402,"conditions":651,"interventions":652},[57],[15],[363,405],{"trials":654,"activeCount":75},[],{"intervention":499,"totalTrials":152,"cells":656},{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":661,"PHASE3":663,"PHASE4":665,"NA":671},{"trials":658,"activeCount":75},[],{"trials":660,"activeCount":75},[],{"trials":662,"activeCount":75},[],{"trials":664,"activeCount":75},[],{"trials":666,"activeCount":75},[667],{"nctId":490,"briefTitle":491,"status":68,"phases":668,"primaryCompletion":493,"completion":493,"start":494,"enrollment":495,"conditions":669,"interventions":670},[57],[497],[466,499],{"trials":672,"activeCount":75},[],{"intervention":674,"totalTrials":152,"cells":675},"Calcipotriol plus betamethasone dipropionate ointment",{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":682,"PHASE4":684,"NA":695},{"trials":677,"activeCount":75},[],{"trials":679,"activeCount":75},[],{"trials":681,"activeCount":75},[],{"trials":683,"activeCount":75},[],{"trials":685,"activeCount":75},[686],{"nctId":687,"briefTitle":688,"status":68,"phases":689,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":694},"NCT00248456","Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgaris",[57],"2006-02","2005-10",320,[15],[674],{"trials":696,"activeCount":75},[],{"intervention":509,"totalTrials":152,"cells":698},{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":705,"PHASE4":707,"NA":713},{"trials":700,"activeCount":75},[],{"trials":702,"activeCount":75},[],{"trials":704,"activeCount":75},[],{"trials":706,"activeCount":75},[],{"trials":708,"activeCount":75},[709],{"nctId":501,"briefTitle":502,"status":68,"phases":710,"primaryCompletion":504,"completion":504,"start":505,"enrollment":506,"conditions":711,"interventions":712},[57],[497],[466,509],{"trials":714,"activeCount":75},[],{"intervention":716,"totalTrials":152,"cells":717},"Daivonex® scalp solution",{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":722,"PHASE3":724,"PHASE4":726,"NA":738},{"trials":719,"activeCount":75},[],{"trials":721,"activeCount":75},[],{"trials":723,"activeCount":75},[],{"trials":725,"activeCount":75},[],{"trials":727,"activeCount":75},[728],{"nctId":729,"briefTitle":730,"status":68,"phases":731,"primaryCompletion":732,"completion":732,"start":733,"enrollment":734,"conditions":735,"interventions":736},"NCT02533973","Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population",[57],"2018-03-06","2015-09",951,[15],[737,716],"Xamiol® gel",{"trials":739,"activeCount":75},[],{"intervention":741,"totalTrials":152,"cells":742},"Cyclosporine A",{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":751,"NA":762},{"trials":744,"activeCount":75},[],{"trials":746,"activeCount":75},[],{"trials":748,"activeCount":75},[],{"trials":750,"activeCount":75},[],{"trials":752,"activeCount":75},[753],{"nctId":754,"briefTitle":755,"status":756,"phases":757,"primaryCompletion":758,"completion":758,"start":759,"enrollment":75,"conditions":760,"interventions":761},"NCT03710044","Investigation of Flare and Remission in Subjects With Atopic Dermatitis","WITHDRAWN",[57],"2020-08","2019-01-14",[18],[741],{"trials":763,"activeCount":75},[],{"intervention":765,"totalTrials":152,"cells":766},"Metronidazole",{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":773,"PHASE4":775,"NA":789},{"trials":768,"activeCount":75},[],{"trials":770,"activeCount":75},[],{"trials":772,"activeCount":75},[],{"trials":774,"activeCount":75},[],{"trials":776,"activeCount":75},[777],{"nctId":778,"briefTitle":779,"status":68,"phases":780,"primaryCompletion":781,"completion":782,"start":783,"enrollment":784,"conditions":785,"interventions":786},"NCT00855595","Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea",[57],"2009-04","2009-07","2009-02",207,[30],[787,765,788],"Azelaic acid","Doxycycline",{"trials":790,"activeCount":75},[],{"intervention":788,"totalTrials":152,"cells":792},{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":797,"PHASE3":799,"PHASE4":801,"NA":807},{"trials":794,"activeCount":75},[],{"trials":796,"activeCount":75},[],{"trials":798,"activeCount":75},[],{"trials":800,"activeCount":75},[],{"trials":802,"activeCount":75},[803],{"nctId":778,"briefTitle":779,"status":68,"phases":804,"primaryCompletion":781,"completion":782,"start":783,"enrollment":784,"conditions":805,"interventions":806},[57],[30],[787,765,788],{"trials":808,"activeCount":75},[],{"intervention":416,"totalTrials":152,"cells":810},{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":817,"PHASE4":819,"NA":825},{"trials":812,"activeCount":75},[],{"trials":814,"activeCount":75},[],{"trials":816,"activeCount":75},[],{"trials":818,"activeCount":75},[],{"trials":820,"activeCount":75},[821],{"nctId":407,"briefTitle":408,"status":282,"phases":822,"primaryCompletion":410,"completion":378,"start":411,"enrollment":412,"conditions":823,"interventions":824},[57],[414,15,33],[363,416],{"trials":826,"activeCount":75},[],{"intervention":548,"totalTrials":152,"cells":828},{"EARLY_PHASE1":829,"PHASE1":831,"PHASE2":833,"PHASE3":835,"PHASE4":837,"NA":843},{"trials":830,"activeCount":75},[],{"trials":832,"activeCount":75},[],{"trials":834,"activeCount":75},[],{"trials":836,"activeCount":75},[],{"trials":838,"activeCount":75},[839],{"nctId":537,"briefTitle":538,"status":68,"phases":840,"primaryCompletion":540,"completion":541,"start":542,"enrollment":543,"conditions":841,"interventions":842},[57],[545],[547,548],{"trials":844,"activeCount":75},[],{"intervention":846,"totalTrials":379,"cells":847},"Tralokinumab",{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":865,"PHASE3":889,"PHASE4":981,"NA":983},{"trials":849,"activeCount":75},[],{"trials":851,"activeCount":75},[852],{"nctId":853,"briefTitle":854,"status":68,"phases":855,"primaryCompletion":856,"completion":857,"start":858,"enrollment":72,"conditions":859,"interventions":860},"NCT03556592","Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4",[54],"2020-03-16","2020-06-20","2018-08-13",[18],[846,861,533,862,863,864],"Caffeine","Omeprazole","Metoprolol","Midazolam Hydrochloride",{"trials":866,"activeCount":75},[867,877],{"nctId":868,"briefTitle":869,"status":68,"phases":870,"primaryCompletion":871,"completion":872,"start":873,"enrollment":874,"conditions":875,"interventions":876},"NCT05388760","Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)",[55],"2023-10-20","2026-04-29","2022-09-07",28,[18],[846],{"nctId":878,"briefTitle":879,"status":68,"phases":880,"primaryCompletion":881,"completion":882,"start":883,"enrollment":884,"conditions":885,"interventions":886},"NCT03562377","Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)",[55],"2019-09-17","2019-11-22","2018-07-13",215,[18],[846,887,888],"Tdap vaccine","Meningococcal vaccine",{"trials":890,"activeCount":75},[891,902,912,922,932,942,952,962,971],{"nctId":892,"briefTitle":893,"status":68,"phases":894,"primaryCompletion":895,"completion":896,"start":897,"enrollment":898,"conditions":899,"interventions":901},"NCT05958407","A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy",[56],"2025-05-05","2025-09-22","2023-08-28",235,[18,900],"Atopic Hand Eczema",[846],{"nctId":903,"briefTitle":904,"status":68,"phases":905,"primaryCompletion":284,"completion":906,"start":907,"enrollment":908,"conditions":909,"interventions":910},"NCT03526861","Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).",[56],"2021-03-16","2018-06-19",301,[18],[846,911],"Placebos",{"nctId":913,"briefTitle":914,"status":68,"phases":915,"primaryCompletion":916,"completion":917,"start":918,"enrollment":919,"conditions":920,"interventions":921},"NCT03131648","Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)",[56],"2018-08-07","2019-10-10","2017-05-30",802,[18],[846],{"nctId":923,"briefTitle":924,"status":68,"phases":925,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":930,"interventions":931},"NCT03363854","Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3",[56],"2019-03-08","2019-09-26","2018-02-22",380,[18],[846],{"nctId":933,"briefTitle":934,"status":68,"phases":935,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":940,"interventions":941},"NCT03160885","Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)",[56],"2018-09-04","2019-08-14","2017-06-12",794,[18],[846],{"nctId":943,"briefTitle":944,"status":68,"phases":945,"primaryCompletion":946,"completion":947,"start":948,"enrollment":949,"conditions":950,"interventions":951},"NCT05194540","Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)",[56],"2023-06-06","2023-06-21","2022-01-13",136,[18],[846],{"nctId":953,"briefTitle":954,"status":68,"phases":955,"primaryCompletion":956,"completion":957,"start":958,"enrollment":959,"conditions":960,"interventions":961},"NCT03761537","Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7",[56],"2020-04-21","2020-09-28","2018-12-13",277,[18],[846],{"nctId":963,"briefTitle":964,"status":68,"phases":965,"primaryCompletion":966,"completion":966,"start":967,"enrollment":968,"conditions":969,"interventions":970},"NCT03587805","Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND",[56],"2024-07-03","2018-03-18",1672,[18],[846],{"nctId":972,"briefTitle":973,"status":68,"phases":974,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":979,"interventions":980},"NCT04587453","Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis",[56],"2021-07-06","2021-07-15","2020-10-27",106,[18],[846],{"trials":982,"activeCount":75},[],{"trials":984,"activeCount":75},[],{"intervention":486,"totalTrials":12,"cells":986},{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":1005,"PHASE4":1059,"NA":1061},{"trials":988,"activeCount":75},[],{"trials":990,"activeCount":75},[],{"trials":992,"activeCount":75},[993],{"nctId":994,"briefTitle":995,"status":68,"phases":996,"primaryCompletion":997,"completion":481,"start":998,"enrollment":72,"conditions":999,"interventions":1001},"NCT01461655","Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris",[55],"2012-04","2011-11",[1000],"Acne Vulgaris",[1002,1003,1004,1002],"marketed topical retinoid","marketed topical NSAID","vehicle gel",{"trials":1006,"activeCount":75},[1007,1018,1028,1032,1042,1050],{"nctId":1008,"briefTitle":1009,"status":68,"phases":1010,"primaryCompletion":1011,"completion":1012,"start":1013,"enrollment":1014,"conditions":1015,"interventions":1016},"NCT02547363","Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up",[56],"2016-08-17","2017-08","2015-11",373,[21],[1017,486],"LEO 43204 gel",{"nctId":1019,"briefTitle":1020,"status":68,"phases":1021,"primaryCompletion":1022,"completion":1023,"start":1024,"enrollment":1025,"conditions":1026,"interventions":1027},"NCT02549339","Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up",[56],"2016-08-05","2017-08-10","2015-11-13",383,[21],[1017,486],{"nctId":477,"briefTitle":478,"status":68,"phases":1029,"primaryCompletion":480,"completion":480,"start":481,"enrollment":482,"conditions":1030,"interventions":1031},[56],[21],[485,486],{"nctId":1033,"briefTitle":1034,"status":68,"phases":1035,"primaryCompletion":1036,"completion":1036,"start":1037,"enrollment":1038,"conditions":1039,"interventions":1040},"NCT00031096","Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne",[56],"2002-07","2002-01",879,[1000],[1041,486],"Azelaic Acid Gel 15%",{"nctId":1043,"briefTitle":1009,"status":68,"phases":1044,"primaryCompletion":1045,"completion":1012,"start":1013,"enrollment":1046,"conditions":1047,"interventions":1048},"NCT02549352",[56],"2016-09-22",391,[21],[1049,486],"LEO43204 gel",{"nctId":1051,"briefTitle":1052,"status":68,"phases":1053,"primaryCompletion":1054,"completion":1055,"start":1013,"enrollment":1056,"conditions":1057,"interventions":1058},"NCT02547233","Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up",[56],"2016-11","2017-11",437,[21],[1017,486],{"trials":1060,"activeCount":75},[],{"trials":1062,"activeCount":75},[],{"intervention":1064,"totalTrials":12,"cells":1065},"LEO 90100",{"EARLY_PHASE1":1066,"PHASE1":1068,"PHASE2":1082,"PHASE3":1121,"PHASE4":1143,"NA":1145},{"trials":1067,"activeCount":75},[],{"trials":1069,"activeCount":75},[1070],{"nctId":1071,"briefTitle":1072,"status":68,"phases":1073,"primaryCompletion":1074,"completion":1075,"start":1076,"enrollment":1077,"conditions":1078,"interventions":1079},"NCT01935869","Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100",[54],"2013-11","2013-12","2013-08",224,[15],[1064,1080,1081],"Vehicle","Petrolatum ointment",{"trials":1083,"activeCount":75},[1084,1091,1103,1112],{"nctId":1085,"briefTitle":1086,"status":68,"phases":1087,"primaryCompletion":169,"completion":169,"start":481,"enrollment":1088,"conditions":1089,"interventions":1090},"NCT01600222","Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris",[55],37,[15],[1064],{"nctId":1092,"briefTitle":1093,"status":68,"phases":1094,"primaryCompletion":1095,"completion":1096,"start":481,"enrollment":1097,"conditions":1098,"interventions":1099},"NCT01536886","LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris",[55],"2012-09","2012-11",376,[15],[1064,1100,1101,1102],"Betamethasone plus calcipotriol","Ointment vehicle","LEO 90100 vehicle",{"nctId":1104,"briefTitle":1105,"status":68,"phases":1106,"primaryCompletion":1107,"completion":1107,"start":1108,"enrollment":1109,"conditions":1110,"interventions":1111},"NCT02387853","Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis",[55],"2018-03-28","2016-03",117,[15],[1064],{"nctId":1113,"briefTitle":1114,"status":68,"phases":1115,"primaryCompletion":1095,"completion":1096,"start":481,"enrollment":1116,"conditions":1117,"interventions":1118},"NCT01536938","LEO 90100 in the Treatment of Psoriasis Vulgaris",[55],303,[15],[1064,1119,1120],"Calcipotriol","Betamethasone",{"trials":1122,"activeCount":75},[1123,1132],{"nctId":1124,"briefTitle":1125,"status":68,"phases":1126,"primaryCompletion":1127,"completion":1074,"start":1128,"enrollment":1129,"conditions":1130,"interventions":1131},"NCT01866163","LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris",[56],"2013-10","2013-06",426,[15],[1064,1080],{"nctId":1133,"briefTitle":1134,"status":68,"phases":1135,"primaryCompletion":1136,"completion":1137,"start":947,"enrollment":1138,"conditions":1139,"interventions":1141},"NCT05919082","A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis",[56],"2024-02-23","2024-03-05",604,[1140],"Stable Plaque Psoriasis",[1064,1142],"Daivobet® ointment",{"trials":1144,"activeCount":75},[],{"trials":1146,"activeCount":75},[],{"intervention":1148,"totalTrials":31,"cells":1149},"LEO 90100 aerosol foam",{"EARLY_PHASE1":1150,"PHASE1":1152,"PHASE2":1167,"PHASE3":1193,"PHASE4":1227,"NA":1229},{"trials":1151,"activeCount":75},[],{"trials":1153,"activeCount":75},[1154],{"nctId":1155,"briefTitle":1156,"status":68,"phases":1157,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":1161,"interventions":1162},"NCT02973776","Vasoconstriction Trial With LEO 90100 Aerosol Foam",[54],"2017-02","2016-12",36,[15],[1148,1163,1164,1165,1166],"Dermoval®\u002FDermovate®","Diprosone","Elocon","Locoid",{"trials":1168,"activeCount":75},[1169,1183],{"nctId":1170,"briefTitle":1171,"status":68,"phases":1172,"primaryCompletion":1173,"completion":1173,"start":494,"enrollment":1174,"conditions":1175,"interventions":1177},"NCT02416258","A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)",[55],"2015-06",50,[1176],"Skin and Connective Tissue Diseases",[1178,1179,1148,1180,1181,1182],"LP0113 aerosol spray","Aerosol spray vehicle","Betamethasone dipropionate aerosol spray","Calcipotriol aerosol spray","Daivobet® gel",{"nctId":1184,"briefTitle":1185,"status":68,"phases":1186,"primaryCompletion":1187,"completion":1187,"start":1188,"enrollment":265,"conditions":1189,"interventions":1190},"NCT02518048","A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris",[55],"2016-01","2015-08",[1176],[1191,1192],"LEO 90100 Aerosol foam","Betesil® 2.25 mg",{"trials":1194,"activeCount":75},[1195,1205,1217],{"nctId":1196,"briefTitle":1197,"status":68,"phases":1198,"primaryCompletion":1199,"completion":1199,"start":1200,"enrollment":1201,"conditions":1202,"interventions":1203},"NCT02899962","LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris",[56],"2019-06-26","2017-02-15",722,[15],[1148,1204],"LEO 90100 aerosol foam vehicle",{"nctId":1206,"briefTitle":1207,"status":68,"phases":1208,"primaryCompletion":1209,"completion":1209,"start":1210,"enrollment":1211,"conditions":1212,"interventions":1213},"NCT02132936","LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris",[56],"2015-02","2014-06",504,[15],[1148,1214,1215,1216],"Aerosol foam vehicle","Calcipotriol BDP gel","Gel vehicle",{"nctId":1218,"briefTitle":1219,"status":68,"phases":1220,"primaryCompletion":1221,"completion":1221,"start":1222,"enrollment":1223,"conditions":1224,"interventions":1225},"NCT02310646","Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris",[56],"2015-07","2015-01",219,[15],[1226,1182],"LEO 90100 Aerosol Foam",{"trials":1228,"activeCount":75},[],{"trials":1230,"activeCount":75},[],{"intervention":1142,"totalTrials":11,"cells":1232},{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1249,"PHASE3":1288,"PHASE4":1294,"NA":1296},{"trials":1234,"activeCount":75},[],{"trials":1236,"activeCount":75},[1237],{"nctId":1238,"briefTitle":1239,"status":68,"phases":1240,"primaryCompletion":1127,"completion":1127,"start":1241,"enrollment":265,"conditions":1242,"interventions":1243},"NCT01946386","A Vasoconstriction Study With LEO 90100",[54],"2013-09",[15],[1244,1245,1246,1142,1247,1248],"LEO 90100 Aerosol, foam","Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle","LEO 90100 Aerosol, foam, vehicle","Dermovate® cream","Synalar® ointment",{"trials":1250,"activeCount":75},[1251,1265,1277],{"nctId":1252,"briefTitle":1253,"status":68,"phases":1254,"primaryCompletion":1255,"completion":1256,"start":182,"enrollment":1257,"conditions":1258,"interventions":1259},"NCT00845481","A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris",[55],"2009-03","2009-05",24,[15],[1142,1260,1261,1262,1263,1264],"Betnovat® ointment","Diprosalic ointment","Dermovat ointment","Elocon ointment","Daivobet® ointment vehicle",{"nctId":1266,"briefTitle":1267,"status":68,"phases":1268,"primaryCompletion":1256,"completion":782,"start":781,"enrollment":1257,"conditions":1269,"interventions":1270},"NCT00875277","A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products",[55],[15],[1271,1272,1273,1274,1275,1276],"LEO 29102 cream","LEO 29102 Cream Vehicle","Betamethasone Dipropionate Cream","LEO 29102 Plus Calcipotriol Cream","LEO 29102 Plus Betamethasone Dipropionate","Daivobet® Ointment",{"nctId":1278,"briefTitle":1279,"status":68,"phases":1280,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":1257,"conditions":1283,"interventions":1284},"NCT01347255","A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris",[55],"2011-06","2011-05",[15],[1285,1286,1287,1142],"LEO90100 cutaneous spray, ointment","LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate","LEO 90100 cutaneous spray, ointment, vehicle",{"trials":1289,"activeCount":75},[1290],{"nctId":1133,"briefTitle":1134,"status":68,"phases":1291,"primaryCompletion":1136,"completion":1137,"start":947,"enrollment":1138,"conditions":1292,"interventions":1293},[56],[1140],[1064,1142],{"trials":1295,"activeCount":75},[],{"trials":1297,"activeCount":75},[],{"intervention":1299,"totalTrials":421,"cells":1300},"Calcipotriol plus betamethasone dipropionate",{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1307,"PHASE4":1333,"NA":1335},{"trials":1302,"activeCount":75},[],{"trials":1304,"activeCount":75},[],{"trials":1306,"activeCount":75},[],{"trials":1308,"activeCount":75},[1309,1317,1325],{"nctId":1310,"briefTitle":1311,"status":68,"phases":1312,"completion":606,"start":1313,"enrollment":1314,"conditions":1315,"interventions":1316},"NCT00243464","Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis",[56],"2005-09",300,[35],[1299],{"nctId":1318,"briefTitle":1319,"status":68,"phases":1320,"completion":1313,"start":1321,"enrollment":1322,"conditions":1323,"interventions":1324},"NCT00216840","Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis",[56],"2004-12",1350,[35],[1299],{"nctId":1326,"briefTitle":1327,"status":68,"phases":1328,"completion":1313,"start":1329,"enrollment":1330,"conditions":1331,"interventions":1332},"NCT00216827","Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis",[56],"2004-11",1485,[35],[1299],{"trials":1334,"activeCount":75},[],{"trials":1336,"activeCount":75},[],{"intervention":1017,"totalTrials":421,"cells":1338},{"EARLY_PHASE1":1339,"PHASE1":1341,"PHASE2":1343,"PHASE3":1345,"PHASE4":1359,"NA":1361},{"trials":1340,"activeCount":75},[],{"trials":1342,"activeCount":75},[],{"trials":1344,"activeCount":75},[],{"trials":1346,"activeCount":75},[1347,1351,1355],{"nctId":1008,"briefTitle":1009,"status":68,"phases":1348,"primaryCompletion":1011,"completion":1012,"start":1013,"enrollment":1014,"conditions":1349,"interventions":1350},[56],[21],[1017,486],{"nctId":1019,"briefTitle":1020,"status":68,"phases":1352,"primaryCompletion":1022,"completion":1023,"start":1024,"enrollment":1025,"conditions":1353,"interventions":1354},[56],[21],[1017,486],{"nctId":1051,"briefTitle":1052,"status":68,"phases":1356,"primaryCompletion":1054,"completion":1055,"start":1013,"enrollment":1056,"conditions":1357,"interventions":1358},[56],[21],[1017,486],{"trials":1360,"activeCount":75},[],{"trials":1362,"activeCount":75},[],{"intervention":1364,"totalTrials":421,"cells":1365},"Vehicle foam",{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1370,"PHASE3":1390,"PHASE4":1401,"NA":1403},{"trials":1367,"activeCount":75},[],{"trials":1369,"activeCount":75},[],{"trials":1371,"activeCount":75},[1372,1381],{"nctId":1373,"briefTitle":1374,"status":68,"phases":1375,"primaryCompletion":528,"completion":528,"start":1376,"enrollment":1377,"conditions":1378,"interventions":1379},"NCT01025635","Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea",[55],"2009-12",401,[30],[1380,1364],"Azelaic acid foam 15%",{"nctId":1382,"briefTitle":1383,"status":68,"phases":1384,"primaryCompletion":1385,"completion":1385,"start":1386,"enrollment":1387,"conditions":1388,"interventions":1389},"NCT00617903","Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea",[55],"2008-06","2008-01",83,[30],[787,1364],{"trials":1391,"activeCount":75},[1392],{"nctId":1393,"briefTitle":1394,"status":68,"phases":1395,"primaryCompletion":1396,"completion":1396,"start":1095,"enrollment":1397,"conditions":1398,"interventions":1399},"NCT01555463","Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea",[56],"2014-01",961,[30],[1400,1364],"Azelaic acid foam, 15%",{"trials":1402,"activeCount":75},[],{"trials":1404,"activeCount":75},[],{"intervention":1080,"totalTrials":421,"cells":1406},{"EARLY_PHASE1":1407,"PHASE1":1409,"PHASE2":1415,"PHASE3":1417,"PHASE4":1433,"NA":1435},{"trials":1408,"activeCount":75},[],{"trials":1410,"activeCount":75},[1411],{"nctId":1071,"briefTitle":1072,"status":68,"phases":1412,"primaryCompletion":1074,"completion":1075,"start":1076,"enrollment":1077,"conditions":1413,"interventions":1414},[54],[15],[1064,1080,1081],{"trials":1416,"activeCount":75},[],{"trials":1418,"activeCount":75},[1419,1423],{"nctId":1124,"briefTitle":1125,"status":68,"phases":1420,"primaryCompletion":1127,"completion":1074,"start":1128,"enrollment":1129,"conditions":1421,"interventions":1422},[56],[15],[1064,1080],{"nctId":1424,"briefTitle":1425,"status":68,"phases":1426,"primaryCompletion":1427,"completion":1427,"start":1428,"enrollment":1429,"conditions":1430,"interventions":1431},"NCT01541553","A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp",[56],"2013-07","2012-03",367,[21],[1080,1432],"Ingenol metabute",{"trials":1434,"activeCount":75},[],{"trials":1436,"activeCount":75},[],{"intervention":1438,"totalTrials":421,"cells":1439},"LEO 90100 foam",{"EARLY_PHASE1":1440,"PHASE1":1442,"PHASE2":1463,"PHASE3":1465,"PHASE4":1475,"NA":1477},{"trials":1441,"activeCount":75},[],{"trials":1443,"activeCount":75},[1444,1453],{"nctId":1445,"briefTitle":1446,"status":68,"phases":1447,"primaryCompletion":1448,"completion":1448,"start":1449,"enrollment":583,"conditions":1450,"interventions":1451},"NCT03476746","Dermatopharmacokinetic Trial of LEO 90100 Foam",[54],"2018-07-01","2018-03-20",[24],[1438,1452],"Dovobet® ointment",{"nctId":1454,"briefTitle":1455,"status":68,"phases":1456,"primaryCompletion":1457,"completion":1457,"start":1458,"enrollment":1459,"conditions":1460,"interventions":1461},"NCT03442244","Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects",[54],"2018-02-20","2018-01-30",20,[15],[1438,1462],"Vehicle of LEO 90100 foam",{"trials":1464,"activeCount":75},[],{"trials":1466,"activeCount":75},[1467],{"nctId":1468,"briefTitle":1469,"status":68,"phases":1470,"primaryCompletion":1471,"completion":1471,"start":399,"enrollment":1472,"conditions":1473,"interventions":1474},"NCT03806790","Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris",[56],"2019-06-10",182,[15],[1438,1452],{"trials":1476,"activeCount":75},[],{"trials":1478,"activeCount":75},[],{"intervention":1480,"totalTrials":421,"cells":1481},"LEO 80185 gel",{"EARLY_PHASE1":1482,"PHASE1":1484,"PHASE2":1495,"PHASE3":1506,"PHASE4":1517,"NA":1519},{"trials":1483,"activeCount":75},[],{"trials":1485,"activeCount":75},[1486],{"nctId":1487,"briefTitle":1488,"status":68,"phases":1489,"primaryCompletion":1490,"completion":1490,"start":1013,"enrollment":1491,"conditions":1492,"interventions":1493},"NCT02605057","Dermatopharmacokinetic Trial of LEO 80185 Gel",[54],"2016-07",32,[15],[1480,1494],"Dovobet(r) Ointment",{"trials":1496,"activeCount":75},[1497],{"nctId":1498,"briefTitle":1499,"status":68,"phases":1500,"primaryCompletion":1501,"completion":1502,"start":1396,"enrollment":1503,"conditions":1504,"interventions":1505},"NCT02038569","An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects",[55],"2018-02","2018-02-13",125,[15],[1480],{"trials":1507,"activeCount":75},[1508],{"nctId":1509,"briefTitle":1510,"status":68,"phases":1511,"primaryCompletion":493,"completion":493,"start":1512,"enrollment":1513,"conditions":1514,"interventions":1515},"NCT02668692","LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis",[56],"2016-02",213,[15],[1480,1516],"Dovobet ® ointment",{"trials":1518,"activeCount":75},[],{"trials":1520,"activeCount":75},[],{"intervention":1522,"totalTrials":334,"cells":1523},"Calcipotriol plus hydrocortisone",{"EARLY_PHASE1":1524,"PHASE1":1526,"PHASE2":1528,"PHASE3":1537,"PHASE4":1549,"NA":1551},{"trials":1525,"activeCount":75},[],{"trials":1527,"activeCount":75},[],{"trials":1529,"activeCount":75},[1530],{"nctId":1531,"briefTitle":1532,"status":68,"phases":1533,"primaryCompletion":1376,"completion":1376,"start":540,"enrollment":1534,"conditions":1535,"interventions":1536},"NCT00704262","Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds",[55],33,[15],[1522],{"trials":1538,"activeCount":75},[1539],{"nctId":1540,"briefTitle":1541,"status":68,"phases":1542,"primaryCompletion":1543,"completion":1543,"start":540,"enrollment":1544,"conditions":1545,"interventions":1546},"NCT00691002","Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds",[56],"2010-01",1245,[15],[1522,1547,1548,1119],"LEO 80190 Vehicle","Hydrocortisone",{"trials":1550,"activeCount":75},[],{"trials":1552,"activeCount":75},[],{"intervention":533,"totalTrials":334,"cells":1554},{"EARLY_PHASE1":1555,"PHASE1":1557,"PHASE2":1563,"PHASE3":1565,"PHASE4":1571,"NA":1573},{"trials":1556,"activeCount":75},[],{"trials":1558,"activeCount":75},[1559],{"nctId":853,"briefTitle":854,"status":68,"phases":1560,"primaryCompletion":856,"completion":857,"start":858,"enrollment":72,"conditions":1561,"interventions":1562},[54],[18],[846,861,533,862,863,864],{"trials":1564,"activeCount":75},[],{"trials":1566,"activeCount":75},[1567],{"nctId":524,"briefTitle":525,"status":68,"phases":1568,"primaryCompletion":345,"completion":527,"start":528,"enrollment":529,"conditions":1569,"interventions":1570},[56],[531],[533,513],{"trials":1572,"activeCount":75},[],{"trials":1574,"activeCount":75},[],{"intervention":1576,"totalTrials":334,"cells":1577},"Tacalcitol ointment",{"EARLY_PHASE1":1578,"PHASE1":1580,"PHASE2":1582,"PHASE3":1584,"PHASE4":1608,"NA":1610},{"trials":1579,"activeCount":75},[],{"trials":1581,"activeCount":75},[],{"trials":1583,"activeCount":75},[],{"trials":1585,"activeCount":75},[1586,1596],{"nctId":1587,"briefTitle":1588,"status":68,"phases":1589,"primaryCompletion":783,"completion":781,"start":1590,"enrollment":1591,"conditions":1592,"interventions":1593},"NCT00670241","Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris",[56],"2008-04",458,[15],[1594,1595,1576],"calcipotriol and betamethasone","LEO 80185 vehicle",{"nctId":1597,"briefTitle":1598,"status":68,"phases":1599,"primaryCompletion":1600,"completion":782,"start":1601,"enrollment":1602,"conditions":1603,"interventions":1604},"NCT00640822","Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds",[56],"2009-06","2008-02",782,[15],[1605,1606,1607],"Calcipotriol plus hydrocortisone ointment vehicle","Tacalcitol Ointment","Calcipotriol plus hydrocortisone ointment",{"trials":1609,"activeCount":75},[],{"trials":1611,"activeCount":75},[],{"intervention":1452,"totalTrials":334,"cells":1613},{"EARLY_PHASE1":1614,"PHASE1":1616,"PHASE2":1622,"PHASE3":1624,"PHASE4":1630,"NA":1632},{"trials":1615,"activeCount":75},[],{"trials":1617,"activeCount":75},[1618],{"nctId":1445,"briefTitle":1446,"status":68,"phases":1619,"primaryCompletion":1448,"completion":1448,"start":1449,"enrollment":583,"conditions":1620,"interventions":1621},[54],[24],[1438,1452],{"trials":1623,"activeCount":75},[],{"trials":1625,"activeCount":75},[1626],{"nctId":1468,"briefTitle":1469,"status":68,"phases":1627,"primaryCompletion":1471,"completion":1471,"start":399,"enrollment":1472,"conditions":1628,"interventions":1629},[56],[15],[1438,1452],{"trials":1631,"activeCount":75},[],{"trials":1633,"activeCount":75},[],{"intervention":1548,"totalTrials":334,"cells":1635},{"EARLY_PHASE1":1636,"PHASE1":1638,"PHASE2":1640,"PHASE3":1642,"PHASE4":1658,"NA":1660},{"trials":1637,"activeCount":75},[],{"trials":1639,"activeCount":75},[],{"trials":1641,"activeCount":75},[],{"trials":1643,"activeCount":75},[1644,1654],{"nctId":1645,"briefTitle":1646,"status":68,"phases":1647,"primaryCompletion":1648,"completion":1649,"start":1650,"enrollment":72,"conditions":1651,"interventions":1652},"NCT01007591","A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas",[56],"2010-06","2010-12","2009-10",[15],[1653,1548],"LEO 80190",{"nctId":1540,"briefTitle":1541,"status":68,"phases":1655,"primaryCompletion":1543,"completion":1543,"start":540,"enrollment":1544,"conditions":1656,"interventions":1657},[56],[15],[1522,1547,1548,1119],{"trials":1659,"activeCount":75},[],{"trials":1661,"activeCount":75},[],{"intervention":1119,"totalTrials":334,"cells":1663},{"EARLY_PHASE1":1664,"PHASE1":1666,"PHASE2":1668,"PHASE3":1674,"PHASE4":1680,"NA":1682},{"trials":1665,"activeCount":75},[],{"trials":1667,"activeCount":75},[],{"trials":1669,"activeCount":75},[1670],{"nctId":1113,"briefTitle":1114,"status":68,"phases":1671,"primaryCompletion":1095,"completion":1096,"start":481,"enrollment":1116,"conditions":1672,"interventions":1673},[55],[15],[1064,1119,1120],{"trials":1675,"activeCount":75},[1676],{"nctId":1540,"briefTitle":1541,"status":68,"phases":1677,"primaryCompletion":1543,"completion":1543,"start":540,"enrollment":1544,"conditions":1678,"interventions":1679},[56],[15],[1522,1547,1548,1119],{"trials":1681,"activeCount":75},[],{"trials":1683,"activeCount":75},[],{"intervention":911,"totalTrials":152,"cells":1685},{"EARLY_PHASE1":1686,"PHASE1":1688,"PHASE2":1690,"PHASE3":1692,"PHASE4":1698,"NA":1700},{"trials":1687,"activeCount":75},[],{"trials":1689,"activeCount":75},[],{"trials":1691,"activeCount":75},[],{"trials":1693,"activeCount":75},[1694],{"nctId":903,"briefTitle":904,"status":68,"phases":1695,"primaryCompletion":284,"completion":906,"start":907,"enrollment":908,"conditions":1696,"interventions":1697},[56],[18],[846,911],{"trials":1699,"activeCount":75},[],{"trials":1701,"activeCount":75},[],{"intervention":1204,"totalTrials":152,"cells":1703},{"EARLY_PHASE1":1704,"PHASE1":1706,"PHASE2":1708,"PHASE3":1710,"PHASE4":1716,"NA":1718},{"trials":1705,"activeCount":75},[],{"trials":1707,"activeCount":75},[],{"trials":1709,"activeCount":75},[],{"trials":1711,"activeCount":75},[1712],{"nctId":1196,"briefTitle":1197,"status":68,"phases":1713,"primaryCompletion":1199,"completion":1199,"start":1200,"enrollment":1201,"conditions":1714,"interventions":1715},[56],[15],[1148,1204],{"trials":1717,"activeCount":75},[],{"trials":1719,"activeCount":75},[],{"intervention":1721,"totalTrials":152,"cells":1722},"Calcipotriol plus betamethasone",{"EARLY_PHASE1":1723,"PHASE1":1725,"PHASE2":1727,"PHASE3":1729,"PHASE4":1743,"NA":1745},{"trials":1724,"activeCount":75},[],{"trials":1726,"activeCount":75},[],{"trials":1728,"activeCount":75},[],{"trials":1730,"activeCount":75},[1731],{"nctId":1732,"briefTitle":1733,"status":68,"phases":1734,"primaryCompletion":1735,"completion":1735,"start":1736,"enrollment":1737,"conditions":1738,"interventions":1739},"NCT01188928","LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and\u002For Limbs)",[56],"2011-03","2010-09",1152,[15],[1721,1740,1741,1742],"Betamethasone-17,21-dipropionate","Calcipotriene","Topical suspension vehicle",{"trials":1744,"activeCount":75},[],{"trials":1746,"activeCount":75},[],{"intervention":1740,"totalTrials":152,"cells":1748},{"EARLY_PHASE1":1749,"PHASE1":1751,"PHASE2":1753,"PHASE3":1755,"PHASE4":1761,"NA":1763},{"trials":1750,"activeCount":75},[],{"trials":1752,"activeCount":75},[],{"trials":1754,"activeCount":75},[],{"trials":1756,"activeCount":75},[1757],{"nctId":1732,"briefTitle":1733,"status":68,"phases":1758,"primaryCompletion":1735,"completion":1735,"start":1736,"enrollment":1737,"conditions":1759,"interventions":1760},[56],[15],[1721,1740,1741,1742],{"trials":1762,"activeCount":75},[],{"trials":1764,"activeCount":75},[],{"intervention":1741,"totalTrials":152,"cells":1766},{"EARLY_PHASE1":1767,"PHASE1":1769,"PHASE2":1771,"PHASE3":1773,"PHASE4":1779,"NA":1781},{"trials":1768,"activeCount":75},[],{"trials":1770,"activeCount":75},[],{"trials":1772,"activeCount":75},[],{"trials":1774,"activeCount":75},[1775],{"nctId":1732,"briefTitle":1733,"status":68,"phases":1776,"primaryCompletion":1735,"completion":1735,"start":1736,"enrollment":1737,"conditions":1777,"interventions":1778},[56],[15],[1721,1740,1741,1742],{"trials":1780,"activeCount":75},[],{"trials":1782,"activeCount":75},[],{"intervention":1742,"totalTrials":152,"cells":1784},{"EARLY_PHASE1":1785,"PHASE1":1787,"PHASE2":1789,"PHASE3":1791,"PHASE4":1797,"NA":1799},{"trials":1786,"activeCount":75},[],{"trials":1788,"activeCount":75},[],{"trials":1790,"activeCount":75},[],{"trials":1792,"activeCount":75},[1793],{"nctId":1732,"briefTitle":1733,"status":68,"phases":1794,"primaryCompletion":1735,"completion":1735,"start":1736,"enrollment":1737,"conditions":1795,"interventions":1796},[56],[15],[1721,1740,1741,1742],{"trials":1798,"activeCount":75},[],{"trials":1800,"activeCount":75},[],{"intervention":1214,"totalTrials":152,"cells":1802},{"EARLY_PHASE1":1803,"PHASE1":1805,"PHASE2":1807,"PHASE3":1809,"PHASE4":1815,"NA":1817},{"trials":1804,"activeCount":75},[],{"trials":1806,"activeCount":75},[],{"trials":1808,"activeCount":75},[],{"trials":1810,"activeCount":75},[1811],{"nctId":1206,"briefTitle":1207,"status":68,"phases":1812,"primaryCompletion":1209,"completion":1209,"start":1210,"enrollment":1211,"conditions":1813,"interventions":1814},[56],[15],[1148,1214,1215,1216],{"trials":1816,"activeCount":75},[],{"trials":1818,"activeCount":75},[],{"intervention":1215,"totalTrials":152,"cells":1820},{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1825,"PHASE3":1827,"PHASE4":1833,"NA":1835},{"trials":1822,"activeCount":75},[],{"trials":1824,"activeCount":75},[],{"trials":1826,"activeCount":75},[],{"trials":1828,"activeCount":75},[1829],{"nctId":1206,"briefTitle":1207,"status":68,"phases":1830,"primaryCompletion":1209,"completion":1209,"start":1210,"enrollment":1211,"conditions":1831,"interventions":1832},[56],[15],[1148,1214,1215,1216],{"trials":1834,"activeCount":75},[],{"trials":1836,"activeCount":75},[],{"intervention":1216,"totalTrials":152,"cells":1838},{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1843,"PHASE3":1845,"PHASE4":1851,"NA":1853},{"trials":1840,"activeCount":75},[],{"trials":1842,"activeCount":75},[],{"trials":1844,"activeCount":75},[],{"trials":1846,"activeCount":75},[1847],{"nctId":1206,"briefTitle":1207,"status":68,"phases":1848,"primaryCompletion":1209,"completion":1209,"start":1210,"enrollment":1211,"conditions":1849,"interventions":1850},[56],[15],[1148,1214,1215,1216],{"trials":1852,"activeCount":75},[],{"trials":1854,"activeCount":75},[],{"intervention":1400,"totalTrials":152,"cells":1856},{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1861,"PHASE3":1863,"PHASE4":1869,"NA":1871},{"trials":1858,"activeCount":75},[],{"trials":1860,"activeCount":75},[],{"trials":1862,"activeCount":75},[],{"trials":1864,"activeCount":75},[1865],{"nctId":1393,"briefTitle":1394,"status":68,"phases":1866,"primaryCompletion":1396,"completion":1396,"start":1095,"enrollment":1397,"conditions":1867,"interventions":1868},[56],[30],[1400,1364],{"trials":1870,"activeCount":75},[],{"trials":1872,"activeCount":75},[],{"intervention":1041,"totalTrials":152,"cells":1874},{"EARLY_PHASE1":1875,"PHASE1":1877,"PHASE2":1879,"PHASE3":1881,"PHASE4":1887,"NA":1889},{"trials":1876,"activeCount":75},[],{"trials":1878,"activeCount":75},[],{"trials":1880,"activeCount":75},[],{"trials":1882,"activeCount":75},[1883],{"nctId":1033,"briefTitle":1034,"status":68,"phases":1884,"primaryCompletion":1036,"completion":1036,"start":1037,"enrollment":1038,"conditions":1885,"interventions":1886},[56],[1000],[1041,486],{"trials":1888,"activeCount":75},[],{"trials":1890,"activeCount":75},[],{"intervention":1432,"totalTrials":152,"cells":1892},{"EARLY_PHASE1":1893,"PHASE1":1895,"PHASE2":1897,"PHASE3":1899,"PHASE4":1905,"NA":1907},{"trials":1894,"activeCount":75},[],{"trials":1896,"activeCount":75},[],{"trials":1898,"activeCount":75},[],{"trials":1900,"activeCount":75},[1901],{"nctId":1424,"briefTitle":1425,"status":68,"phases":1902,"primaryCompletion":1427,"completion":1427,"start":1428,"enrollment":1429,"conditions":1903,"interventions":1904},[56],[21],[1080,1432],{"trials":1906,"activeCount":75},[],{"trials":1908,"activeCount":75},[],{"intervention":1594,"totalTrials":152,"cells":1910},{"EARLY_PHASE1":1911,"PHASE1":1913,"PHASE2":1915,"PHASE3":1917,"PHASE4":1923,"NA":1925},{"trials":1912,"activeCount":75},[],{"trials":1914,"activeCount":75},[],{"trials":1916,"activeCount":75},[],{"trials":1918,"activeCount":75},[1919],{"nctId":1587,"briefTitle":1588,"status":68,"phases":1920,"primaryCompletion":783,"completion":781,"start":1590,"enrollment":1591,"conditions":1921,"interventions":1922},[56],[15],[1594,1595,1576],{"trials":1924,"activeCount":75},[],{"trials":1926,"activeCount":75},[],{"intervention":1595,"totalTrials":152,"cells":1928},{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1933,"PHASE3":1935,"PHASE4":1941,"NA":1943},{"trials":1930,"activeCount":75},[],{"trials":1932,"activeCount":75},[],{"trials":1934,"activeCount":75},[],{"trials":1936,"activeCount":75},[1937],{"nctId":1587,"briefTitle":1588,"status":68,"phases":1938,"primaryCompletion":783,"completion":781,"start":1590,"enrollment":1591,"conditions":1939,"interventions":1940},[56],[15],[1594,1595,1576],{"trials":1942,"activeCount":75},[],{"trials":1944,"activeCount":75},[],{"intervention":1049,"totalTrials":152,"cells":1946},{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1953,"PHASE4":1959,"NA":1961},{"trials":1948,"activeCount":75},[],{"trials":1950,"activeCount":75},[],{"trials":1952,"activeCount":75},[],{"trials":1954,"activeCount":75},[1955],{"nctId":1043,"briefTitle":1009,"status":68,"phases":1956,"primaryCompletion":1045,"completion":1012,"start":1013,"enrollment":1046,"conditions":1957,"interventions":1958},[56],[21],[1049,486],{"trials":1960,"activeCount":75},[],{"trials":1962,"activeCount":75},[],{"intervention":1964,"totalTrials":152,"cells":1965},"TMB-001",{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1972,"PHASE4":1986,"NA":1988},{"trials":1967,"activeCount":75},[],{"trials":1969,"activeCount":75},[],{"trials":1971,"activeCount":75},[],{"trials":1973,"activeCount":75},[1974],{"nctId":1975,"briefTitle":1976,"status":68,"phases":1977,"primaryCompletion":1978,"completion":1979,"start":1980,"enrollment":1981,"conditions":1982,"interventions":1984},"NCT05295732","The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis",[56],"2024-06-17","2024-09-23","2022-06-21",153,[1983],"Ichthyosis",[1964,1985],"Matching Vehicle",{"trials":1987,"activeCount":75},[],{"trials":1989,"activeCount":75},[],{"intervention":1985,"totalTrials":152,"cells":1991},{"EARLY_PHASE1":1992,"PHASE1":1994,"PHASE2":1996,"PHASE3":1998,"PHASE4":2004,"NA":2006},{"trials":1993,"activeCount":75},[],{"trials":1995,"activeCount":75},[],{"trials":1997,"activeCount":75},[],{"trials":1999,"activeCount":75},[2000],{"nctId":1975,"briefTitle":1976,"status":68,"phases":2001,"primaryCompletion":1978,"completion":1979,"start":1980,"enrollment":1981,"conditions":2002,"interventions":2003},[56],[1983],[1964,1985],{"trials":2005,"activeCount":75},[],{"trials":2007,"activeCount":75},[],{"intervention":2009,"totalTrials":152,"cells":2010},"Calcipotriene\u002Fbetamethasone gel and ointment",{"EARLY_PHASE1":2011,"PHASE1":2013,"PHASE2":2015,"PHASE3":2017,"PHASE4":2027,"NA":2029},{"trials":2012,"activeCount":75},[],{"trials":2014,"activeCount":75},[],{"trials":2016,"activeCount":75},[],{"trials":2018,"activeCount":75},[2019],{"nctId":2020,"briefTitle":2021,"status":68,"phases":2022,"completion":2023,"start":542,"enrollment":2024,"conditions":2025,"interventions":2026},"NCT00279162","Efficacy and Safety of Calcipotriene\u002FBetamethasone Gel\u002FOintment in Psoriasis",[56],"2007-07",160,[33],[2009],{"trials":2028,"activeCount":75},[],{"trials":2030,"activeCount":75},[],{"intervention":2032,"totalTrials":152,"cells":2033},"HL 10",{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2038,"PHASE3":2040,"PHASE4":2054,"NA":2056},{"trials":2035,"activeCount":75},[],{"trials":2037,"activeCount":75},[],{"trials":2039,"activeCount":75},[],{"trials":2041,"activeCount":75},[2042],{"nctId":2043,"briefTitle":2044,"status":282,"phases":2045,"primaryCompletion":2046,"completion":2047,"start":2048,"enrollment":2049,"conditions":2050,"interventions":2053},"NCT00742482","Efficacy and Safety of 3 Doses of HL10 Given at Fixed Time Intervals Compared to Standard Therapy",[56],"2005-01","2005-06","2003-01",418,[2051,2052],"Acute Lung Injury","Acute Respiratory Distress Syndrome",[2032],{"trials":2055,"activeCount":75},[],{"trials":2057,"activeCount":75},[],{"intervention":382,"totalTrials":152,"cells":2059},{"EARLY_PHASE1":2060,"PHASE1":2062,"PHASE2":2064,"PHASE3":2066,"PHASE4":2072,"NA":2074},{"trials":2061,"activeCount":75},[],{"trials":2063,"activeCount":75},[],{"trials":2065,"activeCount":75},[],{"trials":2067,"activeCount":75},[2068],{"nctId":374,"briefTitle":375,"status":282,"phases":2069,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":2070,"interventions":2071},[56],[33],[363,382],{"trials":2073,"activeCount":75},[],{"trials":2075,"activeCount":75},[],{"intervention":2077,"totalTrials":152,"cells":2078},"Calcipotriol plus betamethasone dipropionate gel",{"EARLY_PHASE1":2079,"PHASE1":2081,"PHASE2":2083,"PHASE3":2085,"PHASE4":2096,"NA":2098},{"trials":2080,"activeCount":75},[],{"trials":2082,"activeCount":75},[],{"trials":2084,"activeCount":75},[],{"trials":2086,"activeCount":75},[2087],{"nctId":2088,"briefTitle":2089,"status":68,"phases":2090,"completion":2091,"start":2092,"enrollment":2093,"conditions":2094,"interventions":2095},"NCT00216879","Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis",[56],"2006-07","2005-02",800,[35],[2077],{"trials":2097,"activeCount":75},[],{"trials":2099,"activeCount":75},[],{"intervention":1653,"totalTrials":152,"cells":2101},{"EARLY_PHASE1":2102,"PHASE1":2104,"PHASE2":2106,"PHASE3":2108,"PHASE4":2114,"NA":2116},{"trials":2103,"activeCount":75},[],{"trials":2105,"activeCount":75},[],{"trials":2107,"activeCount":75},[],{"trials":2109,"activeCount":75},[2110],{"nctId":1645,"briefTitle":1646,"status":68,"phases":2111,"primaryCompletion":1648,"completion":1649,"start":1650,"enrollment":72,"conditions":2112,"interventions":2113},[56],[15],[1653,1548],{"trials":2115,"activeCount":75},[],{"trials":2117,"activeCount":75},[],{"intervention":2119,"totalTrials":152,"cells":2120},"ingenol disoxate gel 0.018%",{"EARLY_PHASE1":2121,"PHASE1":2123,"PHASE2":2125,"PHASE3":2127,"PHASE4":2140,"NA":2142},{"trials":2122,"activeCount":75},[],{"trials":2124,"activeCount":75},[],{"trials":2126,"activeCount":75},[],{"trials":2128,"activeCount":75},[2129],{"nctId":2130,"briefTitle":2131,"status":282,"phases":2132,"primaryCompletion":2133,"completion":2133,"start":2134,"enrollment":2135,"conditions":2136,"interventions":2138},"NCT03115476","A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp",[56],"2018-03-12","2017-06-16",563,[21,2137],"Squamous Cell Carcinoma",[2119,2139],"ingenol disoxate gel 0.037%",{"trials":2141,"activeCount":75},[],{"trials":2143,"activeCount":75},[],{"intervention":2139,"totalTrials":152,"cells":2145},{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2150,"PHASE3":2152,"PHASE4":2158,"NA":2160},{"trials":2147,"activeCount":75},[],{"trials":2149,"activeCount":75},[],{"trials":2151,"activeCount":75},[],{"trials":2153,"activeCount":75},[2154],{"nctId":2130,"briefTitle":2131,"status":282,"phases":2155,"primaryCompletion":2133,"completion":2133,"start":2134,"enrollment":2135,"conditions":2156,"interventions":2157},[56],[21,2137],[2119,2139],{"trials":2159,"activeCount":75},[],{"trials":2161,"activeCount":75},[],{"intervention":572,"totalTrials":152,"cells":2163},{"EARLY_PHASE1":2164,"PHASE1":2166,"PHASE2":2168,"PHASE3":2170,"PHASE4":2176,"NA":2178},{"trials":2165,"activeCount":75},[],{"trials":2167,"activeCount":75},[],{"trials":2169,"activeCount":75},[],{"trials":2171,"activeCount":75},[2172],{"nctId":563,"briefTitle":564,"status":282,"phases":2173,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":2174,"interventions":2175},[56],[570],[572,552,573,574],{"trials":2177,"activeCount":75},[],{"trials":2179,"activeCount":75},[],{"intervention":573,"totalTrials":152,"cells":2181},{"EARLY_PHASE1":2182,"PHASE1":2184,"PHASE2":2186,"PHASE3":2188,"PHASE4":2194,"NA":2196},{"trials":2183,"activeCount":75},[],{"trials":2185,"activeCount":75},[],{"trials":2187,"activeCount":75},[],{"trials":2189,"activeCount":75},[2190],{"nctId":563,"briefTitle":564,"status":282,"phases":2191,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":2192,"interventions":2193},[56],[570],[572,552,573,574],{"trials":2195,"activeCount":75},[],{"trials":2197,"activeCount":75},[],{"intervention":574,"totalTrials":152,"cells":2199},{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2204,"PHASE3":2206,"PHASE4":2212,"NA":2214},{"trials":2201,"activeCount":75},[],{"trials":2203,"activeCount":75},[],{"trials":2205,"activeCount":75},[],{"trials":2207,"activeCount":75},[2208],{"nctId":563,"briefTitle":564,"status":282,"phases":2209,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":2210,"interventions":2211},[56],[570],[572,552,573,574],{"trials":2213,"activeCount":75},[],{"trials":2215,"activeCount":75},[],{"intervention":1516,"totalTrials":152,"cells":2217},{"EARLY_PHASE1":2218,"PHASE1":2220,"PHASE2":2222,"PHASE3":2224,"PHASE4":2230,"NA":2232},{"trials":2219,"activeCount":75},[],{"trials":2221,"activeCount":75},[],{"trials":2223,"activeCount":75},[],{"trials":2225,"activeCount":75},[2226],{"nctId":1509,"briefTitle":1510,"status":68,"phases":2227,"primaryCompletion":493,"completion":493,"start":1512,"enrollment":1513,"conditions":2228,"interventions":2229},[56],[15],[1480,1516],{"trials":2231,"activeCount":75},[],{"trials":2233,"activeCount":75},[],{"intervention":2235,"totalTrials":152,"cells":2236},"Ingenol mebutate gel 0.05 %",{"EARLY_PHASE1":2237,"PHASE1":2239,"PHASE2":2241,"PHASE3":2243,"PHASE4":2254,"NA":2256},{"trials":2238,"activeCount":75},[],{"trials":2240,"activeCount":75},[],{"trials":2242,"activeCount":75},[],{"trials":2244,"activeCount":75},[2245],{"nctId":2246,"briefTitle":2247,"status":68,"phases":2248,"primaryCompletion":1396,"completion":1396,"start":2249,"enrollment":2250,"conditions":2251,"interventions":2252},"NCT01787383","A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face\u002FScalp and Trunk\u002FExtremities",[56],"2013-02",200,[21],[2235,2253],"Ingenol mebutate gel 0.015 %",{"trials":2255,"activeCount":75},[],{"trials":2257,"activeCount":75},[],{"intervention":2253,"totalTrials":152,"cells":2259},{"EARLY_PHASE1":2260,"PHASE1":2262,"PHASE2":2264,"PHASE3":2266,"PHASE4":2272,"NA":2274},{"trials":2261,"activeCount":75},[],{"trials":2263,"activeCount":75},[],{"trials":2265,"activeCount":75},[],{"trials":2267,"activeCount":75},[2268],{"nctId":2246,"briefTitle":2247,"status":68,"phases":2269,"primaryCompletion":1396,"completion":1396,"start":2249,"enrollment":2250,"conditions":2270,"interventions":2271},[56],[21],[2235,2253],{"trials":2273,"activeCount":75},[],{"trials":2275,"activeCount":75},[],{"intervention":2277,"totalTrials":152,"cells":2278},"Calcipotriol scalp solution",{"EARLY_PHASE1":2279,"PHASE1":2281,"PHASE2":2283,"PHASE3":2285,"PHASE4":2295,"NA":2297},{"trials":2280,"activeCount":75},[],{"trials":2282,"activeCount":75},[],{"trials":2284,"activeCount":75},[],{"trials":2286,"activeCount":75},[2287],{"nctId":2288,"briefTitle":2289,"status":68,"phases":2290,"primaryCompletion":1735,"completion":1735,"start":1736,"enrollment":2291,"conditions":2292,"interventions":2294},"NCT01195831","Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis",[56],244,[2293],"Scalp Psoriasis",[737,2277],{"trials":2296,"activeCount":75},[],{"trials":2298,"activeCount":75},[],{"intervention":1605,"totalTrials":152,"cells":2300},{"EARLY_PHASE1":2301,"PHASE1":2303,"PHASE2":2305,"PHASE3":2307,"PHASE4":2313,"NA":2315},{"trials":2302,"activeCount":75},[],{"trials":2304,"activeCount":75},[],{"trials":2306,"activeCount":75},[],{"trials":2308,"activeCount":75},[2309],{"nctId":1597,"briefTitle":1598,"status":68,"phases":2310,"primaryCompletion":1600,"completion":782,"start":1601,"enrollment":1602,"conditions":2311,"interventions":2312},[56],[15],[1605,1606,1607],{"trials":2314,"activeCount":75},[],{"trials":2316,"activeCount":75},[],{"intervention":1607,"totalTrials":152,"cells":2318},{"EARLY_PHASE1":2319,"PHASE1":2321,"PHASE2":2323,"PHASE3":2325,"PHASE4":2331,"NA":2333},{"trials":2320,"activeCount":75},[],{"trials":2322,"activeCount":75},[],{"trials":2324,"activeCount":75},[],{"trials":2326,"activeCount":75},[2327],{"nctId":1597,"briefTitle":1598,"status":68,"phases":2328,"primaryCompletion":1600,"completion":782,"start":1601,"enrollment":1602,"conditions":2329,"interventions":2330},[56],[15],[1605,1606,1607],{"trials":2332,"activeCount":75},[],{"trials":2334,"activeCount":75},[],{"intervention":2336,"totalTrials":152,"cells":2337},"LEO 90105 = calcipotriol + betamethasone dipropionate",{"EARLY_PHASE1":2338,"PHASE1":2340,"PHASE2":2342,"PHASE3":2344,"PHASE4":2356,"NA":2358},{"trials":2339,"activeCount":75},[],{"trials":2341,"activeCount":75},[],{"trials":2343,"activeCount":75},[],{"trials":2345,"activeCount":75},[2346],{"nctId":2347,"briefTitle":2348,"status":68,"phases":2349,"primaryCompletion":997,"completion":997,"start":2350,"enrollment":2351,"conditions":2352,"interventions":2353},"NCT01422434","LEO 90105 Ointment in Japanese Subjects With Psoriasis",[56],"2011-07",676,[33],[2336,2354,2355],"Dovonex® = calcipotriol","Rinderon® - DP = betamethasone dipropionate",{"trials":2357,"activeCount":75},[],{"trials":2359,"activeCount":75},[],{"intervention":2354,"totalTrials":152,"cells":2361},{"EARLY_PHASE1":2362,"PHASE1":2364,"PHASE2":2366,"PHASE3":2368,"PHASE4":2374,"NA":2376},{"trials":2363,"activeCount":75},[],{"trials":2365,"activeCount":75},[],{"trials":2367,"activeCount":75},[],{"trials":2369,"activeCount":75},[2370],{"nctId":2347,"briefTitle":2348,"status":68,"phases":2371,"primaryCompletion":997,"completion":997,"start":2350,"enrollment":2351,"conditions":2372,"interventions":2373},[56],[33],[2336,2354,2355],{"trials":2375,"activeCount":75},[],{"trials":2377,"activeCount":75},[],{"intervention":2355,"totalTrials":152,"cells":2379},{"EARLY_PHASE1":2380,"PHASE1":2382,"PHASE2":2384,"PHASE3":2386,"PHASE4":2392,"NA":2394},{"trials":2381,"activeCount":75},[],{"trials":2383,"activeCount":75},[],{"trials":2385,"activeCount":75},[],{"trials":2387,"activeCount":75},[2388],{"nctId":2347,"briefTitle":2348,"status":68,"phases":2389,"primaryCompletion":997,"completion":997,"start":2350,"enrollment":2351,"conditions":2390,"interventions":2391},[56],[33],[2336,2354,2355],{"trials":2393,"activeCount":75},[],{"trials":2395,"activeCount":75},[],{"intervention":151,"totalTrials":152,"cells":2397},{"EARLY_PHASE1":2398,"PHASE1":2400,"PHASE2":2402,"PHASE3":2404,"PHASE4":2410,"NA":2412},{"trials":2399,"activeCount":75},[],{"trials":2401,"activeCount":75},[],{"trials":2403,"activeCount":75},[],{"trials":2405,"activeCount":75},[2406],{"nctId":142,"briefTitle":143,"status":68,"phases":2407,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":2408,"interventions":2409},[56],[27],[51,151],{"trials":2411,"activeCount":75},[],{"trials":2413,"activeCount":75},[],{"intervention":1547,"totalTrials":152,"cells":2415},{"EARLY_PHASE1":2416,"PHASE1":2418,"PHASE2":2420,"PHASE3":2422,"PHASE4":2428,"NA":2430},{"trials":2417,"activeCount":75},[],{"trials":2419,"activeCount":75},[],{"trials":2421,"activeCount":75},[],{"trials":2423,"activeCount":75},[2424],{"nctId":1540,"briefTitle":1541,"status":68,"phases":2425,"primaryCompletion":1543,"completion":1543,"start":540,"enrollment":1544,"conditions":2426,"interventions":2427},[56],[15],[1522,1547,1548,1119],{"trials":2429,"activeCount":75},[],{"trials":2431,"activeCount":75},[],{"intervention":2433,"totalTrials":31,"cells":2434},"LEO 32731",{"EARLY_PHASE1":2435,"PHASE1":2437,"PHASE2":2489,"PHASE3":2501,"PHASE4":2503,"NA":2505},{"trials":2436,"activeCount":75},[],{"trials":2438,"activeCount":75},[2439,2449,2458,2472,2480],{"nctId":2440,"briefTitle":2441,"status":68,"phases":2442,"primaryCompletion":2443,"completion":2443,"start":2444,"enrollment":1491,"conditions":2445,"interventions":2447},"NCT03126578","Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam",[54],"2017-10-20","2017-05-31",[2446],"Drug Interaction Potentiation",[2433,2448],"Midazolam",{"nctId":2450,"briefTitle":2451,"status":68,"phases":2452,"primaryCompletion":2453,"completion":1096,"start":1735,"enrollment":2454,"conditions":2455,"interventions":2457},"NCT01310049","LEO 32731 - A Study in Healthy Male Subjects",[54],"2012-08",111,[2456],"Healthy Subjects",[2433],{"nctId":2459,"briefTitle":2460,"status":68,"phases":2461,"primaryCompletion":2462,"completion":2462,"start":2463,"enrollment":2464,"conditions":2465,"interventions":2466},"NCT03812198","A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People",[54],"2019-06-13","2019-01-22",66,[24],[2467,2468,2469,2470,2471,2433],"LEO 32731 modified release","LEO 32731 blend, hard","LEO 32731 API, hard","LEO 32731 soft","LEO 32731 gastro-resistant",{"nctId":2473,"briefTitle":2474,"status":282,"phases":2475,"primaryCompletion":2476,"completion":2476,"start":2477,"enrollment":379,"conditions":2478,"interventions":2479},"NCT02753218","A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects",[54],"2016-05","2016-04",[15],[2448,2433],{"nctId":2481,"briefTitle":2482,"status":68,"phases":2483,"primaryCompletion":2484,"completion":2484,"start":2485,"enrollment":2486,"conditions":2487,"interventions":2488},"NCT03231124","Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.",[54],"2017-08-22","2017-07-25",26,[15],[2433],{"trials":2490,"activeCount":75},[2491],{"nctId":2492,"briefTitle":2493,"status":68,"phases":2494,"primaryCompletion":2495,"completion":2496,"start":2497,"enrollment":1160,"conditions":2498,"interventions":2499},"NCT02888236","LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris",[55],"2017-06-20","2017-07-06","2016-09",[15],[2433,2500],"LEO 32731 Placebo",{"trials":2502,"activeCount":75},[],{"trials":2504,"activeCount":75},[],{"trials":2506,"activeCount":75},[],{"intervention":258,"totalTrials":31,"cells":2508},{"EARLY_PHASE1":2509,"PHASE1":2511,"PHASE2":2521,"PHASE3":2539,"PHASE4":2541,"NA":2543},{"trials":2510,"activeCount":75},[],{"trials":2512,"activeCount":75},[2513,2517],{"nctId":250,"briefTitle":251,"status":68,"phases":2514,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":2515,"interventions":2516},[54],[24],[46,258],{"nctId":260,"briefTitle":261,"status":68,"phases":2518,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":2519,"interventions":2520},[54],[24],[46,258],{"trials":2522,"activeCount":75},[2523,2527,2531,2535],{"nctId":271,"briefTitle":272,"status":68,"phases":2524,"primaryCompletion":274,"completion":274,"start":275,"enrollment":276,"conditions":2525,"interventions":2526},[55],[18],[46,258],{"nctId":280,"briefTitle":281,"status":282,"phases":2528,"primaryCompletion":284,"completion":285,"start":286,"enrollment":287,"conditions":2529,"interventions":2530},[55],[289],[46,258],{"nctId":292,"briefTitle":293,"status":68,"phases":2532,"primaryCompletion":295,"completion":296,"start":297,"enrollment":265,"conditions":2533,"interventions":2534},[55],[299],[46,258],{"nctId":310,"briefTitle":311,"status":68,"phases":2536,"primaryCompletion":313,"completion":314,"start":315,"enrollment":316,"conditions":2537,"interventions":2538},[55],[27],[46,258],{"trials":2540,"activeCount":75},[],{"trials":2542,"activeCount":75},[],{"trials":2544,"activeCount":75},[],{"intervention":2546,"totalTrials":11,"cells":2547},"LEO 138559",{"EARLY_PHASE1":2548,"PHASE1":2550,"PHASE2":2571,"PHASE3":2603,"PHASE4":2605,"NA":2607},{"trials":2549,"activeCount":75},[],{"trials":2551,"activeCount":75},[2552,2561],{"nctId":2553,"briefTitle":2554,"status":68,"phases":2555,"primaryCompletion":2556,"completion":2556,"start":2557,"enrollment":1257,"conditions":2558,"interventions":2559},"NCT05099133","A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects",[54],"2022-06-28","2021-11-03",[18],[2546,2560],"LEO 138559 Placebo",{"nctId":2562,"briefTitle":2563,"status":68,"phases":2564,"primaryCompletion":2565,"completion":2565,"start":2566,"enrollment":2567,"conditions":2568,"interventions":2569},"NCT03514511","Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis",[54],"2021-03-02","2018-05-07",47,[18],[2546,2570],"LEO 138559 placebo",{"trials":2572,"activeCount":75},[2573,2584,2593],{"nctId":2574,"briefTitle":2575,"status":68,"phases":2576,"primaryCompletion":2577,"completion":2578,"start":2579,"enrollment":2580,"conditions":2581,"interventions":2582},"NCT05470114","A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD",[55],"2023-06-07","2023-10-09","2022-05-19",13,[18],[2546,2583],"Dupixent®",{"nctId":2585,"briefTitle":2586,"status":68,"phases":2587,"primaryCompletion":2588,"completion":2589,"start":2590,"enrollment":583,"conditions":2591,"interventions":2592},"NCT04922021","An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.",[55],"2022-06-02","2022-09-26","2021-07-14",[18],[2546,2570],{"nctId":2594,"briefTitle":2595,"status":68,"phases":2596,"primaryCompletion":2597,"completion":2598,"start":2599,"enrollment":2600,"conditions":2601,"interventions":2602},"NCT05923099","A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis",[55],"2024-12-11","2025-04-09","2023-09-20",262,[18],[2546],{"trials":2604,"activeCount":75},[],{"trials":2606,"activeCount":75},[],{"trials":2608,"activeCount":75},[],{"intervention":2610,"totalTrials":8,"cells":2611},"LEO 43204",{"EARLY_PHASE1":2612,"PHASE1":2614,"PHASE2":2624,"PHASE3":2648,"PHASE4":2650,"NA":2652},{"trials":2613,"activeCount":75},[],{"trials":2615,"activeCount":75},[2616],{"nctId":2617,"briefTitle":2618,"status":68,"phases":2619,"primaryCompletion":493,"completion":493,"start":1512,"enrollment":2620,"conditions":2621,"interventions":2622},"NCT02650505","A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel",[54],233,[21],[2610,2623],"LEO 43204 Vehicle",{"trials":2625,"activeCount":75},[2626,2634,2641],{"nctId":2627,"briefTitle":2628,"status":68,"phases":2629,"primaryCompletion":2630,"completion":2630,"start":527,"enrollment":2631,"conditions":2632,"interventions":2633},"NCT02100813","Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis",[54,55],"2015-03",220,[21],[2610],{"nctId":2635,"briefTitle":2636,"status":68,"phases":2637,"primaryCompletion":2638,"completion":2638,"start":527,"enrollment":1077,"conditions":2639,"interventions":2640},"NCT02120456","Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis",[54,55],"2015-05",[21],[2610],{"nctId":2642,"briefTitle":2643,"status":68,"phases":2644,"primaryCompletion":1221,"completion":1188,"start":2630,"enrollment":2645,"conditions":2646,"interventions":2647},"NCT02305888","Safety of LEO 43204 for Actinic Keratosis Applied on Face\u002FChest, Scalp and Trunk\u002FExtremities, Respectively",[55],189,[21],[2610],{"trials":2649,"activeCount":75},[],{"trials":2651,"activeCount":75},[],{"trials":2653,"activeCount":75},[],{"intervention":2655,"totalTrials":8,"cells":2656},"LEO 29102",{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2684,"PHASE3":2694,"PHASE4":2696,"NA":2698},{"trials":2658,"activeCount":75},[],{"trials":2660,"activeCount":75},[2661,2669,2677],{"nctId":2662,"briefTitle":2663,"status":282,"phases":2664,"primaryCompletion":2665,"completion":2665,"start":2666,"enrollment":583,"conditions":2667,"interventions":2668},"NCT01447758","Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.",[54],"2013-03","2011-09",[18],[2655,1272],{"nctId":2670,"briefTitle":2671,"status":68,"phases":2672,"primaryCompletion":1096,"completion":1096,"start":2673,"enrollment":2674,"conditions":2675,"interventions":2676},"NCT01423656","Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102",[54],"2011-08",102,[18],[2655],{"nctId":2678,"briefTitle":2679,"status":68,"phases":2680,"primaryCompletion":1600,"completion":1600,"start":1255,"enrollment":2681,"conditions":2682,"interventions":2683},"NCT00891709","LEO 29102 Single and Multiple Dose Study by Dermal Application",[54],64,[18],[2655],{"trials":2685,"activeCount":75},[2686],{"nctId":2687,"briefTitle":2688,"status":68,"phases":2689,"primaryCompletion":1648,"completion":1648,"start":1376,"enrollment":2690,"conditions":2691,"interventions":2692},"NCT01037881","LEO 29102 Cream in the Treatment of Atopic Dermatitis",[55],183,[18],[2655,2693],"Elidel®",{"trials":2695,"activeCount":75},[],{"trials":2697,"activeCount":75},[],{"trials":2699,"activeCount":75},[],{"intervention":2701,"totalTrials":421,"cells":2702},"LEO 90105",{"EARLY_PHASE1":2703,"PHASE1":2705,"PHASE2":2719,"PHASE3":2729,"PHASE4":2731,"NA":2733},{"trials":2704,"activeCount":75},[],{"trials":2706,"activeCount":75},[2707,2713],{"nctId":2708,"briefTitle":2709,"status":68,"phases":2710,"primaryCompletion":1649,"completion":1649,"start":1649,"enrollment":1459,"conditions":2711,"interventions":2712},"NCT01293357","A Study Evaluating Skin Irritation, Phototoxicity and Safety After Administration of LEO 90105 on Intact Skin of Healthy Japanese Male Subjects",[54],[24],[2701],{"nctId":2714,"briefTitle":2715,"status":68,"phases":2716,"primaryCompletion":1735,"completion":1735,"start":1735,"enrollment":379,"conditions":2717,"interventions":2718},"NCT01293383","A Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects",[54],[24],[2701],{"trials":2720,"activeCount":75},[2721],{"nctId":2722,"briefTitle":2723,"status":68,"phases":2724,"primaryCompletion":2725,"completion":2725,"start":2726,"enrollment":2580,"conditions":2727,"interventions":2728},"NCT01768013","The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris",[54,55],"2012-10","2012-07",[15],[2701],{"trials":2730,"activeCount":75},[],{"trials":2732,"activeCount":75},[],{"trials":2734,"activeCount":75},[],{"intervention":2570,"totalTrials":421,"cells":2736},{"EARLY_PHASE1":2737,"PHASE1":2739,"PHASE2":2749,"PHASE3":2755,"PHASE4":2757,"NA":2759},{"trials":2738,"activeCount":75},[],{"trials":2740,"activeCount":75},[2741,2745],{"nctId":2553,"briefTitle":2554,"status":68,"phases":2742,"primaryCompletion":2556,"completion":2556,"start":2557,"enrollment":1257,"conditions":2743,"interventions":2744},[54],[18],[2546,2560],{"nctId":2562,"briefTitle":2563,"status":68,"phases":2746,"primaryCompletion":2565,"completion":2565,"start":2566,"enrollment":2567,"conditions":2747,"interventions":2748},[54],[18],[2546,2570],{"trials":2750,"activeCount":75},[2751],{"nctId":2585,"briefTitle":2586,"status":68,"phases":2752,"primaryCompletion":2588,"completion":2589,"start":2590,"enrollment":583,"conditions":2753,"interventions":2754},[55],[18],[2546,2570],{"trials":2756,"activeCount":75},[],{"trials":2758,"activeCount":75},[],{"trials":2760,"activeCount":75},[],{"intervention":2762,"totalTrials":421,"cells":2763},"LEO 80185",{"EARLY_PHASE1":2764,"PHASE1":2766,"PHASE2":2768,"PHASE3":2794,"PHASE4":2796,"NA":2798},{"trials":2765,"activeCount":75},[],{"trials":2767,"activeCount":75},[],{"trials":2769,"activeCount":75},[2770,2778,2786],{"nctId":2771,"briefTitle":2772,"status":68,"phases":2773,"primaryCompletion":2453,"completion":2725,"start":2774,"enrollment":2775,"conditions":2776,"interventions":2777},"NCT01083758","Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis",[55],"2010-04",31,[2293],[2762],{"nctId":2779,"briefTitle":2780,"status":68,"phases":2781,"primaryCompletion":2666,"completion":2782,"start":2783,"enrollment":2674,"conditions":2784,"interventions":2785},"NCT01229098","Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris",[55],"2011-10","2010-10",[15],[2762],{"nctId":2787,"briefTitle":2788,"status":68,"phases":2789,"primaryCompletion":2453,"completion":2725,"start":2790,"enrollment":2791,"conditions":2792,"interventions":2793},"NCT01120223","Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis",[55],"2010-05",78,[2293],[2762],{"trials":2795,"activeCount":75},[],{"trials":2797,"activeCount":75},[],{"trials":2799,"activeCount":75},[],{"intervention":2801,"totalTrials":421,"cells":2802},"LEO 22811",{"EARLY_PHASE1":2803,"PHASE1":2805,"PHASE2":2820,"PHASE3":2829,"PHASE4":2831,"NA":2833},{"trials":2804,"activeCount":75},[],{"trials":2806,"activeCount":75},[2807,2813],{"nctId":2808,"briefTitle":2809,"status":68,"phases":2810,"primaryCompletion":1649,"completion":1649,"start":1736,"enrollment":94,"conditions":2811,"interventions":2812},"NCT01211964","LEO 22811 - Single Dose Bioavailability Study of Tablet Versus Oral Solution in Healthy Subjects",[54],[24],[2801],{"nctId":2814,"briefTitle":2815,"status":68,"phases":2816,"primaryCompletion":1650,"completion":2817,"start":182,"enrollment":583,"conditions":2818,"interventions":2819},"NCT00833872","LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects",[54],"2009-11",[15],[2801],{"trials":2821,"activeCount":75},[2822],{"nctId":2823,"briefTitle":2824,"status":68,"phases":2825,"primaryCompletion":1735,"completion":2350,"start":2790,"enrollment":2826,"conditions":2827,"interventions":2828},"NCT01116895","A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris",[55],63,[15],[2801],{"trials":2830,"activeCount":75},[],{"trials":2832,"activeCount":75},[],{"trials":2834,"activeCount":75},[],{"intervention":1271,"totalTrials":421,"cells":2836},{"EARLY_PHASE1":2837,"PHASE1":2839,"PHASE2":2855,"PHASE3":2861,"PHASE4":2863,"NA":2865},{"trials":2838,"activeCount":75},[],{"trials":2840,"activeCount":75},[2841,2848],{"nctId":2842,"briefTitle":2843,"status":68,"phases":2844,"primaryCompletion":2790,"completion":2790,"start":1650,"enrollment":1160,"conditions":2845,"interventions":2846},"NCT01005823","A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis",[54],[18],[1271,2847],"LEO 29102 placebo cream",{"nctId":2849,"briefTitle":2850,"status":68,"phases":2851,"primaryCompletion":1650,"completion":1650,"start":2852,"enrollment":1491,"conditions":2853,"interventions":2854},"NCT00958516","Assessment of the Phototoxic Potential of LEO 29102 Cream",[54],"2009-09",[18],[1271],{"trials":2856,"activeCount":75},[2857],{"nctId":1266,"briefTitle":1267,"status":68,"phases":2858,"primaryCompletion":1256,"completion":782,"start":781,"enrollment":1257,"conditions":2859,"interventions":2860},[55],[15],[1271,1272,1273,1274,1275,1276],{"trials":2862,"activeCount":75},[],{"trials":2864,"activeCount":75},[],{"trials":2866,"activeCount":75},[],{"intervention":2868,"totalTrials":334,"cells":2869},"Cromoglicate",{"EARLY_PHASE1":2870,"PHASE1":2872,"PHASE2":2874,"PHASE3":2890,"PHASE4":2892,"NA":2894},{"trials":2871,"activeCount":75},[],{"trials":2873,"activeCount":75},[],{"trials":2875,"activeCount":75},[2876,2883],{"nctId":2877,"briefTitle":2878,"status":282,"phases":2879,"primaryCompletion":2249,"completion":2249,"start":2725,"enrollment":12,"conditions":2880,"interventions":2882},"NCT01701843","Cromoglicate in Mastocytosis",[55],[2881],"Mastocytosis",[2868],{"nctId":2884,"briefTitle":2885,"status":68,"phases":2886,"primaryCompletion":2887,"completion":169,"start":1096,"enrollment":346,"conditions":2888,"interventions":2889},"NCT01722812","Cromoglicate in Psoriasis",[55],"2013-04",[33],[2868],{"trials":2891,"activeCount":75},[],{"trials":2893,"activeCount":75},[],{"trials":2895,"activeCount":75},[],{"intervention":2897,"totalTrials":334,"cells":2898},"Calcipotriol and LEO80122",{"EARLY_PHASE1":2899,"PHASE1":2901,"PHASE2":2903,"PHASE3":2920,"PHASE4":2922,"NA":2924},{"trials":2900,"activeCount":75},[],{"trials":2902,"activeCount":75},[],{"trials":2904,"activeCount":75},[2905,2914],{"nctId":2906,"briefTitle":2907,"status":68,"phases":2908,"completion":433,"start":2909,"enrollment":2910,"conditions":2911,"interventions":2913},"NCT00404196","LEO19123 Cream in the Treatment of Hand Eczema",[55],"2006-10",75,[2912],"Hand Eczema",[2897],{"nctId":2915,"briefTitle":2916,"status":68,"phases":2917,"completion":459,"start":2909,"enrollment":2910,"conditions":2918,"interventions":2919},"NCT00392067","LEO19123 Cream in the Treatment of Atopic Dermatitis",[55],[18],[2897],{"trials":2921,"activeCount":75},[],{"trials":2923,"activeCount":75},[],{"trials":2925,"activeCount":75},[],{"intervention":1272,"totalTrials":334,"cells":2927},{"EARLY_PHASE1":2928,"PHASE1":2930,"PHASE2":2936,"PHASE3":2942,"PHASE4":2944,"NA":2946},{"trials":2929,"activeCount":75},[],{"trials":2931,"activeCount":75},[2932],{"nctId":2662,"briefTitle":2663,"status":282,"phases":2933,"primaryCompletion":2665,"completion":2665,"start":2666,"enrollment":583,"conditions":2934,"interventions":2935},[54],[18],[2655,1272],{"trials":2937,"activeCount":75},[2938],{"nctId":1266,"briefTitle":1267,"status":68,"phases":2939,"primaryCompletion":1256,"completion":782,"start":781,"enrollment":1257,"conditions":2940,"interventions":2941},[55],[15],[1271,1272,1273,1274,1275,1276],{"trials":2943,"activeCount":75},[],{"trials":2945,"activeCount":75},[],{"trials":2947,"activeCount":75},[],{"intervention":2949,"totalTrials":334,"cells":2950},"Betamethasone dipropionate cream",{"EARLY_PHASE1":2951,"PHASE1":2953,"PHASE2":2964,"PHASE3":2970,"PHASE4":2972,"NA":2974},{"trials":2952,"activeCount":75},[],{"trials":2954,"activeCount":75},[2955],{"nctId":2956,"briefTitle":2957,"status":68,"phases":2958,"primaryCompletion":1221,"completion":1221,"start":1209,"enrollment":346,"conditions":2959,"interventions":2960},"NCT02376049","A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)",[54],[18],[2961,2949,2962,2963],"Pimecrolimus cream","Clobetasol propionate cream","Glaxal Base cream vehicle",{"trials":2965,"activeCount":75},[2966],{"nctId":1266,"briefTitle":1267,"status":68,"phases":2967,"primaryCompletion":1256,"completion":782,"start":781,"enrollment":1257,"conditions":2968,"interventions":2969},[55],[15],[1271,1272,1273,1274,1275,1276],{"trials":2971,"activeCount":75},[],{"trials":2973,"activeCount":75},[],{"trials":2975,"activeCount":75},[],{"intervention":2977,"totalTrials":334,"cells":2978},"LEO 124249",{"EARLY_PHASE1":2979,"PHASE1":2981,"PHASE2":2983,"PHASE3":3000,"PHASE4":3002,"NA":3004},{"trials":2980,"activeCount":75},[],{"trials":2982,"activeCount":75},[],{"trials":2984,"activeCount":75},[2985,2994],{"nctId":2986,"briefTitle":2987,"status":282,"phases":2988,"primaryCompletion":2989,"completion":2989,"start":2990,"enrollment":2580,"conditions":2991,"interventions":2993},"NCT03325296","Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg\u002Fg for 12 Weeks on Eyebrow Alopecia Areata.",[55],"2018-05-16","2017-10-30",[2992],"Alopecia Areata",[2977],{"nctId":2995,"briefTitle":2996,"status":68,"phases":2997,"primaryCompletion":1159,"completion":1159,"start":1187,"enrollment":72,"conditions":2998,"interventions":2999},"NCT02561585","LEO 124249 Ointment in the Treatment of Alopecia Areata",[55],[2992],[2977],{"trials":3001,"activeCount":75},[],{"trials":3003,"activeCount":75},[],{"trials":3005,"activeCount":75},[],{"intervention":2500,"totalTrials":152,"cells":3007},{"EARLY_PHASE1":3008,"PHASE1":3010,"PHASE2":3012,"PHASE3":3018,"PHASE4":3020,"NA":3022},{"trials":3009,"activeCount":75},[],{"trials":3011,"activeCount":75},[],{"trials":3013,"activeCount":75},[3014],{"nctId":2492,"briefTitle":2493,"status":68,"phases":3015,"primaryCompletion":2495,"completion":2496,"start":2497,"enrollment":1160,"conditions":3016,"interventions":3017},[55],[15],[2433,2500],{"trials":3019,"activeCount":75},[],{"trials":3021,"activeCount":75},[],{"trials":3023,"activeCount":75},[],{"intervention":3025,"totalTrials":152,"cells":3026},"Calcipotriene plus betamethasone dipropionate ointment",{"EARLY_PHASE1":3027,"PHASE1":3029,"PHASE2":3031,"PHASE3":3040,"PHASE4":3042,"NA":3044},{"trials":3028,"activeCount":75},[],{"trials":3030,"activeCount":75},[],{"trials":3032,"activeCount":75},[3033],{"nctId":3034,"briefTitle":3035,"status":68,"phases":3036,"primaryCompletion":3037,"completion":3037,"start":782,"enrollment":1534,"conditions":3038,"interventions":3039},"NCT00817219","Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris",[55],"2011-12",[15],[3025],{"trials":3041,"activeCount":75},[],{"trials":3043,"activeCount":75},[],{"trials":3045,"activeCount":75},[],{"intervention":3047,"totalTrials":152,"cells":3048},"LEO 124249 ointment",{"EARLY_PHASE1":3049,"PHASE1":3051,"PHASE2":3053,"PHASE3":3064,"PHASE4":3066,"NA":3068},{"trials":3050,"activeCount":75},[],{"trials":3052,"activeCount":75},[],{"trials":3054,"activeCount":75},[3055],{"nctId":3056,"briefTitle":3057,"status":68,"phases":3058,"primaryCompletion":1490,"completion":3059,"start":1512,"enrollment":3060,"conditions":3061,"interventions":3062},"NCT02664805","Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema",[55],"2016-10",91,[27],[3047,3063],"LEO 124249 ointment vehicle",{"trials":3065,"activeCount":75},[],{"trials":3067,"activeCount":75},[],{"trials":3069,"activeCount":75},[],{"intervention":3063,"totalTrials":152,"cells":3071},{"EARLY_PHASE1":3072,"PHASE1":3074,"PHASE2":3076,"PHASE3":3082,"PHASE4":3084,"NA":3086},{"trials":3073,"activeCount":75},[],{"trials":3075,"activeCount":75},[],{"trials":3077,"activeCount":75},[3078],{"nctId":3056,"briefTitle":3057,"status":68,"phases":3079,"primaryCompletion":1490,"completion":3059,"start":1512,"enrollment":3060,"conditions":3080,"interventions":3081},[55],[27],[3047,3063],{"trials":3083,"activeCount":75},[],{"trials":3085,"activeCount":75},[],{"trials":3087,"activeCount":75},[],{"intervention":3089,"totalTrials":152,"cells":3090},"Antithrombin alfa",{"EARLY_PHASE1":3091,"PHASE1":3093,"PHASE2":3095,"PHASE3":3106,"PHASE4":3108,"NA":3110},{"trials":3092,"activeCount":75},[],{"trials":3094,"activeCount":75},[],{"trials":3096,"activeCount":75},[3097],{"nctId":3098,"briefTitle":3099,"status":282,"phases":3100,"primaryCompletion":1255,"completion":1255,"start":2023,"enrollment":3101,"conditions":3102,"interventions":3104},"NCT00506519","Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis",[55],25,[3103],"Disseminated Intravascular Coagulation",[3089,3105],"Control",{"trials":3107,"activeCount":75},[],{"trials":3109,"activeCount":75},[],{"trials":3111,"activeCount":75},[],{"intervention":3105,"totalTrials":152,"cells":3113},{"EARLY_PHASE1":3114,"PHASE1":3116,"PHASE2":3118,"PHASE3":3124,"PHASE4":3126,"NA":3128},{"trials":3115,"activeCount":75},[],{"trials":3117,"activeCount":75},[],{"trials":3119,"activeCount":75},[3120],{"nctId":3098,"briefTitle":3099,"status":282,"phases":3121,"primaryCompletion":1255,"completion":1255,"start":2023,"enrollment":3101,"conditions":3122,"interventions":3123},[55],[3103],[3089,3105],{"trials":3125,"activeCount":75},[],{"trials":3127,"activeCount":75},[],{"trials":3129,"activeCount":75},[],{"intervention":187,"totalTrials":152,"cells":3131},{"EARLY_PHASE1":3132,"PHASE1":3134,"PHASE2":3136,"PHASE3":3142,"PHASE4":3144,"NA":3146},{"trials":3133,"activeCount":75},[],{"trials":3135,"activeCount":75},[],{"trials":3137,"activeCount":75},[3138],{"nctId":178,"briefTitle":179,"status":68,"phases":3139,"primaryCompletion":181,"completion":182,"start":183,"enrollment":184,"conditions":3140,"interventions":3141},[55],[15],[187,188,130],{"trials":3143,"activeCount":75},[],{"trials":3145,"activeCount":75},[],{"trials":3147,"activeCount":75},[],{"intervention":188,"totalTrials":152,"cells":3149},{"EARLY_PHASE1":3150,"PHASE1":3152,"PHASE2":3154,"PHASE3":3160,"PHASE4":3162,"NA":3164},{"trials":3151,"activeCount":75},[],{"trials":3153,"activeCount":75},[],{"trials":3155,"activeCount":75},[3156],{"nctId":178,"briefTitle":179,"status":68,"phases":3157,"primaryCompletion":181,"completion":182,"start":183,"enrollment":184,"conditions":3158,"interventions":3159},[55],[15],[187,188,130],{"trials":3161,"activeCount":75},[],{"trials":3163,"activeCount":75},[],{"trials":3165,"activeCount":75},[],{"intervention":2583,"totalTrials":152,"cells":3167},{"EARLY_PHASE1":3168,"PHASE1":3170,"PHASE2":3172,"PHASE3":3178,"PHASE4":3180,"NA":3182},{"trials":3169,"activeCount":75},[],{"trials":3171,"activeCount":75},[],{"trials":3173,"activeCount":75},[3174],{"nctId":2574,"briefTitle":2575,"status":68,"phases":3175,"primaryCompletion":2577,"completion":2578,"start":2579,"enrollment":2580,"conditions":3176,"interventions":3177},[55],[18],[2546,2583],{"trials":3179,"activeCount":75},[],{"trials":3181,"activeCount":75},[],{"trials":3183,"activeCount":75},[],{"intervention":1100,"totalTrials":152,"cells":3185},{"EARLY_PHASE1":3186,"PHASE1":3188,"PHASE2":3190,"PHASE3":3196,"PHASE4":3198,"NA":3200},{"trials":3187,"activeCount":75},[],{"trials":3189,"activeCount":75},[],{"trials":3191,"activeCount":75},[3192],{"nctId":1092,"briefTitle":1093,"status":68,"phases":3193,"primaryCompletion":1095,"completion":1096,"start":481,"enrollment":1097,"conditions":3194,"interventions":3195},[55],[15],[1064,1100,1101,1102],{"trials":3197,"activeCount":75},[],{"trials":3199,"activeCount":75},[],{"trials":3201,"activeCount":75},[],{"intervention":1101,"totalTrials":152,"cells":3203},{"EARLY_PHASE1":3204,"PHASE1":3206,"PHASE2":3208,"PHASE3":3214,"PHASE4":3216,"NA":3218},{"trials":3205,"activeCount":75},[],{"trials":3207,"activeCount":75},[],{"trials":3209,"activeCount":75},[3210],{"nctId":1092,"briefTitle":1093,"status":68,"phases":3211,"primaryCompletion":1095,"completion":1096,"start":481,"enrollment":1097,"conditions":3212,"interventions":3213},[55],[15],[1064,1100,1101,1102],{"trials":3215,"activeCount":75},[],{"trials":3217,"activeCount":75},[],{"trials":3219,"activeCount":75},[],{"intervention":1102,"totalTrials":152,"cells":3221},{"EARLY_PHASE1":3222,"PHASE1":3224,"PHASE2":3226,"PHASE3":3232,"PHASE4":3234,"NA":3236},{"trials":3223,"activeCount":75},[],{"trials":3225,"activeCount":75},[],{"trials":3227,"activeCount":75},[3228],{"nctId":1092,"briefTitle":1093,"status":68,"phases":3229,"primaryCompletion":1095,"completion":1096,"start":481,"enrollment":1097,"conditions":3230,"interventions":3231},[55],[15],[1064,1100,1101,1102],{"trials":3233,"activeCount":75},[],{"trials":3235,"activeCount":75},[],{"trials":3237,"activeCount":75},[],{"intervention":1380,"totalTrials":152,"cells":3239},{"EARLY_PHASE1":3240,"PHASE1":3242,"PHASE2":3244,"PHASE3":3250,"PHASE4":3252,"NA":3254},{"trials":3241,"activeCount":75},[],{"trials":3243,"activeCount":75},[],{"trials":3245,"activeCount":75},[3246],{"nctId":1373,"briefTitle":1374,"status":68,"phases":3247,"primaryCompletion":528,"completion":528,"start":1376,"enrollment":1377,"conditions":3248,"interventions":3249},[55],[30],[1380,1364],{"trials":3251,"activeCount":75},[],{"trials":3253,"activeCount":75},[],{"trials":3255,"activeCount":75},[],{"intervention":1260,"totalTrials":152,"cells":3257},{"EARLY_PHASE1":3258,"PHASE1":3260,"PHASE2":3262,"PHASE3":3268,"PHASE4":3270,"NA":3272},{"trials":3259,"activeCount":75},[],{"trials":3261,"activeCount":75},[],{"trials":3263,"activeCount":75},[3264],{"nctId":1252,"briefTitle":1253,"status":68,"phases":3265,"primaryCompletion":1255,"completion":1256,"start":182,"enrollment":1257,"conditions":3266,"interventions":3267},[55],[15],[1142,1260,1261,1262,1263,1264],{"trials":3269,"activeCount":75},[],{"trials":3271,"activeCount":75},[],{"trials":3273,"activeCount":75},[],{"intervention":1261,"totalTrials":152,"cells":3275},{"EARLY_PHASE1":3276,"PHASE1":3278,"PHASE2":3280,"PHASE3":3286,"PHASE4":3288,"NA":3290},{"trials":3277,"activeCount":75},[],{"trials":3279,"activeCount":75},[],{"trials":3281,"activeCount":75},[3282],{"nctId":1252,"briefTitle":1253,"status":68,"phases":3283,"primaryCompletion":1255,"completion":1256,"start":182,"enrollment":1257,"conditions":3284,"interventions":3285},[55],[15],[1142,1260,1261,1262,1263,1264],{"trials":3287,"activeCount":75},[],{"trials":3289,"activeCount":75},[],{"trials":3291,"activeCount":75},[],{"intervention":1262,"totalTrials":152,"cells":3293},{"EARLY_PHASE1":3294,"PHASE1":3296,"PHASE2":3298,"PHASE3":3304,"PHASE4":3306,"NA":3308},{"trials":3295,"activeCount":75},[],{"trials":3297,"activeCount":75},[],{"trials":3299,"activeCount":75},[3300],{"nctId":1252,"briefTitle":1253,"status":68,"phases":3301,"primaryCompletion":1255,"completion":1256,"start":182,"enrollment":1257,"conditions":3302,"interventions":3303},[55],[15],[1142,1260,1261,1262,1263,1264],{"trials":3305,"activeCount":75},[],{"trials":3307,"activeCount":75},[],{"trials":3309,"activeCount":75},[],{"intervention":1263,"totalTrials":152,"cells":3311},{"EARLY_PHASE1":3312,"PHASE1":3314,"PHASE2":3316,"PHASE3":3322,"PHASE4":3324,"NA":3326},{"trials":3313,"activeCount":75},[],{"trials":3315,"activeCount":75},[],{"trials":3317,"activeCount":75},[3318],{"nctId":1252,"briefTitle":1253,"status":68,"phases":3319,"primaryCompletion":1255,"completion":1256,"start":182,"enrollment":1257,"conditions":3320,"interventions":3321},[55],[15],[1142,1260,1261,1262,1263,1264],{"trials":3323,"activeCount":75},[],{"trials":3325,"activeCount":75},[],{"trials":3327,"activeCount":75},[],{"intervention":1264,"totalTrials":152,"cells":3329},{"EARLY_PHASE1":3330,"PHASE1":3332,"PHASE2":3334,"PHASE3":3340,"PHASE4":3342,"NA":3344},{"trials":3331,"activeCount":75},[],{"trials":3333,"activeCount":75},[],{"trials":3335,"activeCount":75},[3336],{"nctId":1252,"briefTitle":1253,"status":68,"phases":3337,"primaryCompletion":1255,"completion":1256,"start":182,"enrollment":1257,"conditions":3338,"interventions":3339},[55],[15],[1142,1260,1261,1262,1263,1264],{"trials":3341,"activeCount":75},[],{"trials":3343,"activeCount":75},[],{"trials":3345,"activeCount":75},[],{"intervention":440,"totalTrials":152,"cells":3347},{"EARLY_PHASE1":3348,"PHASE1":3350,"PHASE2":3352,"PHASE3":3358,"PHASE4":3360,"NA":3362},{"trials":3349,"activeCount":75},[],{"trials":3351,"activeCount":75},[],{"trials":3353,"activeCount":75},[3354],{"nctId":430,"briefTitle":431,"status":68,"phases":3355,"primaryCompletion":433,"completion":433,"start":434,"enrollment":435,"conditions":3356,"interventions":3357},[55],[437],[439,440],{"trials":3359,"activeCount":75},[],{"trials":3361,"activeCount":75},[],{"trials":3363,"activeCount":75},[],{"intervention":1002,"totalTrials":152,"cells":3365},{"EARLY_PHASE1":3366,"PHASE1":3368,"PHASE2":3370,"PHASE3":3376,"PHASE4":3378,"NA":3380},{"trials":3367,"activeCount":75},[],{"trials":3369,"activeCount":75},[],{"trials":3371,"activeCount":75},[3372],{"nctId":994,"briefTitle":995,"status":68,"phases":3373,"primaryCompletion":997,"completion":481,"start":998,"enrollment":72,"conditions":3374,"interventions":3375},[55],[1000],[1002,1003,1004,1002],{"trials":3377,"activeCount":75},[],{"trials":3379,"activeCount":75},[],{"trials":3381,"activeCount":75},[],{"intervention":1003,"totalTrials":152,"cells":3383},{"EARLY_PHASE1":3384,"PHASE1":3386,"PHASE2":3388,"PHASE3":3394,"PHASE4":3396,"NA":3398},{"trials":3385,"activeCount":75},[],{"trials":3387,"activeCount":75},[],{"trials":3389,"activeCount":75},[3390],{"nctId":994,"briefTitle":995,"status":68,"phases":3391,"primaryCompletion":997,"completion":481,"start":998,"enrollment":72,"conditions":3392,"interventions":3393},[55],[1000],[1002,1003,1004,1002],{"trials":3395,"activeCount":75},[],{"trials":3397,"activeCount":75},[],{"trials":3399,"activeCount":75},[],{"intervention":3401,"totalTrials":152,"cells":3402},"LEO 43204 Formulation 1",{"EARLY_PHASE1":3403,"PHASE1":3405,"PHASE2":3407,"PHASE3":3420,"PHASE4":3422,"NA":3424},{"trials":3404,"activeCount":75},[],{"trials":3406,"activeCount":75},[],{"trials":3408,"activeCount":75},[3409],{"nctId":3410,"briefTitle":3411,"status":68,"phases":3412,"primaryCompletion":167,"completion":167,"start":1127,"enrollment":692,"conditions":3413,"interventions":3414},"NCT01922050","A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis",[54,55],[21],[3401,3415,3416,3417,3418,3419],"LEO 43204 Formulation 2","LEO 43204 Formulation 1 Dose X","LEO 43204 Formulation 1 Dose Y","LEO 43204 Formulation 2 Dose XX","LEO 43204 Formulation 2 Dose YY",{"trials":3421,"activeCount":75},[],{"trials":3423,"activeCount":75},[],{"trials":3425,"activeCount":75},[],{"intervention":3415,"totalTrials":152,"cells":3427},{"EARLY_PHASE1":3428,"PHASE1":3430,"PHASE2":3432,"PHASE3":3438,"PHASE4":3440,"NA":3442},{"trials":3429,"activeCount":75},[],{"trials":3431,"activeCount":75},[],{"trials":3433,"activeCount":75},[3434],{"nctId":3410,"briefTitle":3411,"status":68,"phases":3435,"primaryCompletion":167,"completion":167,"start":1127,"enrollment":692,"conditions":3436,"interventions":3437},[54,55],[21],[3401,3415,3416,3417,3418,3419],{"trials":3439,"activeCount":75},[],{"trials":3441,"activeCount":75},[],{"trials":3443,"activeCount":75},[],{"intervention":3416,"totalTrials":152,"cells":3445},{"EARLY_PHASE1":3446,"PHASE1":3448,"PHASE2":3450,"PHASE3":3456,"PHASE4":3458,"NA":3460},{"trials":3447,"activeCount":75},[],{"trials":3449,"activeCount":75},[],{"trials":3451,"activeCount":75},[3452],{"nctId":3410,"briefTitle":3411,"status":68,"phases":3453,"primaryCompletion":167,"completion":167,"start":1127,"enrollment":692,"conditions":3454,"interventions":3455},[54,55],[21],[3401,3415,3416,3417,3418,3419],{"trials":3457,"activeCount":75},[],{"trials":3459,"activeCount":75},[],{"trials":3461,"activeCount":75},[],{"intervention":3417,"totalTrials":152,"cells":3463},{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3468,"PHASE3":3474,"PHASE4":3476,"NA":3478},{"trials":3465,"activeCount":75},[],{"trials":3467,"activeCount":75},[],{"trials":3469,"activeCount":75},[3470],{"nctId":3410,"briefTitle":3411,"status":68,"phases":3471,"primaryCompletion":167,"completion":167,"start":1127,"enrollment":692,"conditions":3472,"interventions":3473},[54,55],[21],[3401,3415,3416,3417,3418,3419],{"trials":3475,"activeCount":75},[],{"trials":3477,"activeCount":75},[],{"trials":3479,"activeCount":75},[],{"intervention":3418,"totalTrials":152,"cells":3481},{"EARLY_PHASE1":3482,"PHASE1":3484,"PHASE2":3486,"PHASE3":3492,"PHASE4":3494,"NA":3496},{"trials":3483,"activeCount":75},[],{"trials":3485,"activeCount":75},[],{"trials":3487,"activeCount":75},[3488],{"nctId":3410,"briefTitle":3411,"status":68,"phases":3489,"primaryCompletion":167,"completion":167,"start":1127,"enrollment":692,"conditions":3490,"interventions":3491},[54,55],[21],[3401,3415,3416,3417,3418,3419],{"trials":3493,"activeCount":75},[],{"trials":3495,"activeCount":75},[],{"trials":3497,"activeCount":75},[],{"intervention":3419,"totalTrials":152,"cells":3499},{"EARLY_PHASE1":3500,"PHASE1":3502,"PHASE2":3504,"PHASE3":3510,"PHASE4":3512,"NA":3514},{"trials":3501,"activeCount":75},[],{"trials":3503,"activeCount":75},[],{"trials":3505,"activeCount":75},[3506],{"nctId":3410,"briefTitle":3411,"status":68,"phases":3507,"primaryCompletion":167,"completion":167,"start":1127,"enrollment":692,"conditions":3508,"interventions":3509},[54,55],[21],[3401,3415,3416,3417,3418,3419],{"trials":3511,"activeCount":75},[],{"trials":3513,"activeCount":75},[],{"trials":3515,"activeCount":75},[],{"intervention":3517,"totalTrials":152,"cells":3518},"Aprepitant",{"EARLY_PHASE1":3519,"PHASE1":3521,"PHASE2":3523,"PHASE3":3533,"PHASE4":3535,"NA":3537},{"trials":3520,"activeCount":75},[],{"trials":3522,"activeCount":75},[],{"trials":3524,"activeCount":75},[3525],{"nctId":3526,"briefTitle":3527,"status":68,"phases":3528,"primaryCompletion":3529,"completion":3529,"start":1127,"enrollment":1459,"conditions":3530,"interventions":3532},"NCT01963793","Topical Aprepitant in Prurigo Patients",[55],"2014-07",[3531],"Pruritus",[3517],{"trials":3534,"activeCount":75},[],{"trials":3536,"activeCount":75},[],{"trials":3538,"activeCount":75},[],{"intervention":3540,"totalTrials":152,"cells":3541},"once daily for two consecutive days",{"EARLY_PHASE1":3542,"PHASE1":3544,"PHASE2":3546,"PHASE3":3554,"PHASE4":3556,"NA":3558},{"trials":3543,"activeCount":75},[],{"trials":3545,"activeCount":75},[],{"trials":3547,"activeCount":75},[3548],{"nctId":3549,"briefTitle":3550,"status":68,"phases":3551,"primaryCompletion":1127,"completion":1075,"start":2249,"enrollment":1088,"conditions":3552,"interventions":3553},"NCT01803477","Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm",[54,55],[21],[3540],{"trials":3555,"activeCount":75},[],{"trials":3557,"activeCount":75},[],{"trials":3559,"activeCount":75},[],{"intervention":3561,"totalTrials":152,"cells":3562},"2% TD1414 Cream",{"EARLY_PHASE1":3563,"PHASE1":3565,"PHASE2":3567,"PHASE3":3576,"PHASE4":3578,"NA":3580},{"trials":3564,"activeCount":75},[],{"trials":3566,"activeCount":75},[],{"trials":3568,"activeCount":75},[3569],{"nctId":3570,"briefTitle":3571,"status":68,"phases":3572,"primaryCompletion":783,"completion":783,"start":181,"enrollment":1459,"conditions":3573,"interventions":3575},"NCT00758862","The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo",[55],[3574,585],"Secondarily Infected Traumatic Lesions (SITL)",[3561],{"trials":3577,"activeCount":75},[],{"trials":3579,"activeCount":75},[],{"trials":3581,"activeCount":75},[],{"intervention":3583,"totalTrials":152,"cells":3584},"Daivobet® gel applied then removed after 10 minutes",{"EARLY_PHASE1":3585,"PHASE1":3587,"PHASE2":3589,"PHASE3":3601,"PHASE4":3603,"NA":3605},{"trials":3586,"activeCount":75},[],{"trials":3588,"activeCount":75},[],{"trials":3590,"activeCount":75},[3591],{"nctId":3592,"briefTitle":3593,"status":68,"phases":3594,"primaryCompletion":2725,"completion":2725,"start":3595,"enrollment":1257,"conditions":3596,"interventions":3597},"NCT01607853","A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris",[55],"2012-06",[15],[3583,3598,3599,3600],"Daivobet® gel applied then removed after 20 minutes","Daivobet® gel applied for 24 hours","Daivobet® gel vehicle applied for 24 hours",{"trials":3602,"activeCount":75},[],{"trials":3604,"activeCount":75},[],{"trials":3606,"activeCount":75},[],{"intervention":3598,"totalTrials":152,"cells":3608},{"EARLY_PHASE1":3609,"PHASE1":3611,"PHASE2":3613,"PHASE3":3619,"PHASE4":3621,"NA":3623},{"trials":3610,"activeCount":75},[],{"trials":3612,"activeCount":75},[],{"trials":3614,"activeCount":75},[3615],{"nctId":3592,"briefTitle":3593,"status":68,"phases":3616,"primaryCompletion":2725,"completion":2725,"start":3595,"enrollment":1257,"conditions":3617,"interventions":3618},[55],[15],[3583,3598,3599,3600],{"trials":3620,"activeCount":75},[],{"trials":3622,"activeCount":75},[],{"trials":3624,"activeCount":75},[],{"intervention":3599,"totalTrials":152,"cells":3626},{"EARLY_PHASE1":3627,"PHASE1":3629,"PHASE2":3631,"PHASE3":3637,"PHASE4":3639,"NA":3641},{"trials":3628,"activeCount":75},[],{"trials":3630,"activeCount":75},[],{"trials":3632,"activeCount":75},[3633],{"nctId":3592,"briefTitle":3593,"status":68,"phases":3634,"primaryCompletion":2725,"completion":2725,"start":3595,"enrollment":1257,"conditions":3635,"interventions":3636},[55],[15],[3583,3598,3599,3600],{"trials":3638,"activeCount":75},[],{"trials":3640,"activeCount":75},[],{"trials":3642,"activeCount":75},[],{"intervention":3600,"totalTrials":152,"cells":3644},{"EARLY_PHASE1":3645,"PHASE1":3647,"PHASE2":3649,"PHASE3":3655,"PHASE4":3657,"NA":3659},{"trials":3646,"activeCount":75},[],{"trials":3648,"activeCount":75},[],{"trials":3650,"activeCount":75},[3651],{"nctId":3592,"briefTitle":3593,"status":68,"phases":3652,"primaryCompletion":2725,"completion":2725,"start":3595,"enrollment":1257,"conditions":3653,"interventions":3654},[55],[15],[3583,3598,3599,3600],{"trials":3656,"activeCount":75},[],{"trials":3658,"activeCount":75},[],{"trials":3660,"activeCount":75},[],{"intervention":3662,"totalTrials":152,"cells":3663},"Isotretinoin",{"EARLY_PHASE1":3664,"PHASE1":3666,"PHASE2":3668,"PHASE3":3680,"PHASE4":3682,"NA":3684},{"trials":3665,"activeCount":75},[],{"trials":3667,"activeCount":75},[],{"trials":3669,"activeCount":75},[3670],{"nctId":3671,"briefTitle":3672,"status":68,"phases":3673,"primaryCompletion":3674,"completion":3675,"start":3676,"enrollment":19,"conditions":3677,"interventions":3679},"NCT04154293","A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis",[55],"2021-08-20","2021-08-30","2019-12-03",[3678],"Congenital Ichthyosis",[3662],{"trials":3681,"activeCount":75},[],{"trials":3683,"activeCount":75},[],{"trials":3685,"activeCount":75},[],{"intervention":3687,"totalTrials":152,"cells":3688},"LEO43204",{"EARLY_PHASE1":3689,"PHASE1":3691,"PHASE2":3693,"PHASE3":3702,"PHASE4":3704,"NA":3706},{"trials":3690,"activeCount":75},[],{"trials":3692,"activeCount":75},[],{"trials":3694,"activeCount":75},[3695],{"nctId":3696,"briefTitle":3697,"status":68,"phases":3698,"primaryCompletion":3699,"completion":3699,"start":493,"enrollment":16,"conditions":3700,"interventions":3701},"NCT02575950","Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne",[55],"2017-04",[1000],[3687],{"trials":3703,"activeCount":75},[],{"trials":3705,"activeCount":75},[],{"trials":3707,"activeCount":75},[],{"intervention":3709,"totalTrials":152,"cells":3710},"Calcipotriol plus betamethasone dipropionate (LEO 80185) gel",{"EARLY_PHASE1":3711,"PHASE1":3713,"PHASE2":3715,"PHASE3":3724,"PHASE4":3726,"NA":3728},{"trials":3712,"activeCount":75},[],{"trials":3714,"activeCount":75},[],{"trials":3716,"activeCount":75},[3717],{"nctId":3718,"briefTitle":3719,"status":68,"phases":3720,"completion":606,"start":542,"enrollment":3721,"conditions":3722,"interventions":3723},"NCT00263718","Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris",[55],360,[15],[3709],{"trials":3725,"activeCount":75},[],{"trials":3727,"activeCount":75},[],{"trials":3729,"activeCount":75},[],{"intervention":2693,"totalTrials":152,"cells":3731},{"EARLY_PHASE1":3732,"PHASE1":3734,"PHASE2":3736,"PHASE3":3742,"PHASE4":3744,"NA":3746},{"trials":3733,"activeCount":75},[],{"trials":3735,"activeCount":75},[],{"trials":3737,"activeCount":75},[3738],{"nctId":2687,"briefTitle":2688,"status":68,"phases":3739,"primaryCompletion":1648,"completion":1648,"start":1376,"enrollment":2690,"conditions":3740,"interventions":3741},[55],[18],[2655,2693],{"trials":3743,"activeCount":75},[],{"trials":3745,"activeCount":75},[],{"trials":3747,"activeCount":75},[],{"intervention":1178,"totalTrials":152,"cells":3749},{"EARLY_PHASE1":3750,"PHASE1":3752,"PHASE2":3754,"PHASE3":3760,"PHASE4":3762,"NA":3764},{"trials":3751,"activeCount":75},[],{"trials":3753,"activeCount":75},[],{"trials":3755,"activeCount":75},[3756],{"nctId":1170,"briefTitle":1171,"status":68,"phases":3757,"primaryCompletion":1173,"completion":1173,"start":494,"enrollment":1174,"conditions":3758,"interventions":3759},[55],[1176],[1178,1179,1148,1180,1181,1182],{"trials":3761,"activeCount":75},[],{"trials":3763,"activeCount":75},[],{"trials":3765,"activeCount":75},[],{"intervention":1179,"totalTrials":152,"cells":3767},{"EARLY_PHASE1":3768,"PHASE1":3770,"PHASE2":3772,"PHASE3":3778,"PHASE4":3780,"NA":3782},{"trials":3769,"activeCount":75},[],{"trials":3771,"activeCount":75},[],{"trials":3773,"activeCount":75},[3774],{"nctId":1170,"briefTitle":1171,"status":68,"phases":3775,"primaryCompletion":1173,"completion":1173,"start":494,"enrollment":1174,"conditions":3776,"interventions":3777},[55],[1176],[1178,1179,1148,1180,1181,1182],{"trials":3779,"activeCount":75},[],{"trials":3781,"activeCount":75},[],{"trials":3783,"activeCount":75},[],{"intervention":1180,"totalTrials":152,"cells":3785},{"EARLY_PHASE1":3786,"PHASE1":3788,"PHASE2":3790,"PHASE3":3796,"PHASE4":3798,"NA":3800},{"trials":3787,"activeCount":75},[],{"trials":3789,"activeCount":75},[],{"trials":3791,"activeCount":75},[3792],{"nctId":1170,"briefTitle":1171,"status":68,"phases":3793,"primaryCompletion":1173,"completion":1173,"start":494,"enrollment":1174,"conditions":3794,"interventions":3795},[55],[1176],[1178,1179,1148,1180,1181,1182],{"trials":3797,"activeCount":75},[],{"trials":3799,"activeCount":75},[],{"trials":3801,"activeCount":75},[],{"intervention":1181,"totalTrials":152,"cells":3803},{"EARLY_PHASE1":3804,"PHASE1":3806,"PHASE2":3808,"PHASE3":3814,"PHASE4":3816,"NA":3818},{"trials":3805,"activeCount":75},[],{"trials":3807,"activeCount":75},[],{"trials":3809,"activeCount":75},[3810],{"nctId":1170,"briefTitle":1171,"status":68,"phases":3811,"primaryCompletion":1173,"completion":1173,"start":494,"enrollment":1174,"conditions":3812,"interventions":3813},[55],[1176],[1178,1179,1148,1180,1181,1182],{"trials":3815,"activeCount":75},[],{"trials":3817,"activeCount":75},[],{"trials":3819,"activeCount":75},[],{"intervention":3821,"totalTrials":152,"cells":3822},"Ingenol mebutate gel",{"EARLY_PHASE1":3823,"PHASE1":3825,"PHASE2":3827,"PHASE3":3837,"PHASE4":3839,"NA":3841},{"trials":3824,"activeCount":75},[],{"trials":3826,"activeCount":75},[],{"trials":3828,"activeCount":75},[3829],{"nctId":3830,"briefTitle":3831,"status":68,"phases":3832,"primaryCompletion":3833,"completion":3833,"start":2887,"enrollment":3834,"conditions":3835,"interventions":3836},"NCT01820260","Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis",[54,55],"2014-08",395,[21],[3821],{"trials":3838,"activeCount":75},[],{"trials":3840,"activeCount":75},[],{"trials":3842,"activeCount":75},[],{"intervention":3844,"totalTrials":152,"cells":3845},"LEO 124249 ointment 30 mg\u002Fg",{"EARLY_PHASE1":3846,"PHASE1":3848,"PHASE2":3850,"PHASE3":3860,"PHASE4":3862,"NA":3864},{"trials":3847,"activeCount":75},[],{"trials":3849,"activeCount":75},[],{"trials":3851,"activeCount":75},[3852],{"nctId":3853,"briefTitle":3854,"status":68,"phases":3855,"primaryCompletion":2497,"completion":2497,"start":1108,"enrollment":3856,"conditions":3857,"interventions":3859},"NCT02695940","Trial Twice Daily Application of LEO 124249 Ointment 30 mg\u002Fg in Treatment of Mild to Moderate Inverse Psoriasis",[55],69,[3858],"Inverse Psoriasis",[3844],{"trials":3861,"activeCount":75},[],{"trials":3863,"activeCount":75},[],{"trials":3865,"activeCount":75},[],{"intervention":1120,"totalTrials":152,"cells":3867},{"EARLY_PHASE1":3868,"PHASE1":3870,"PHASE2":3872,"PHASE3":3878,"PHASE4":3880,"NA":3882},{"trials":3869,"activeCount":75},[],{"trials":3871,"activeCount":75},[],{"trials":3873,"activeCount":75},[3874],{"nctId":1113,"briefTitle":1114,"status":68,"phases":3875,"primaryCompletion":1095,"completion":1096,"start":481,"enrollment":1116,"conditions":3876,"interventions":3877},[55],[15],[1064,1119,1120],{"trials":3879,"activeCount":75},[],{"trials":3881,"activeCount":75},[],{"trials":3883,"activeCount":75},[],{"intervention":1192,"totalTrials":152,"cells":3885},{"EARLY_PHASE1":3886,"PHASE1":3888,"PHASE2":3890,"PHASE3":3896,"PHASE4":3898,"NA":3900},{"trials":3887,"activeCount":75},[],{"trials":3889,"activeCount":75},[],{"trials":3891,"activeCount":75},[3892],{"nctId":1184,"briefTitle":1185,"status":68,"phases":3893,"primaryCompletion":1187,"completion":1187,"start":1188,"enrollment":265,"conditions":3894,"interventions":3895},[55],[1176],[1191,1192],{"trials":3897,"activeCount":75},[],{"trials":3899,"activeCount":75},[],{"trials":3901,"activeCount":75},[],{"intervention":3903,"totalTrials":152,"cells":3904},"TD1414 2% cream",{"EARLY_PHASE1":3905,"PHASE1":3907,"PHASE2":3909,"PHASE3":3920,"PHASE4":3922,"NA":3924},{"trials":3906,"activeCount":75},[],{"trials":3908,"activeCount":75},[],{"trials":3910,"activeCount":75},[3911],{"nctId":3912,"briefTitle":3913,"status":68,"phases":3914,"primaryCompletion":1255,"completion":1600,"start":1601,"enrollment":3915,"conditions":3916,"interventions":3918},"NCT00626795","Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)",[55],773,[585,3917],"Secondarily Infected Traumatic Lesions",[3903,3903,3919],"Bactroban® (mupirocin) 2% cream",{"trials":3921,"activeCount":75},[],{"trials":3923,"activeCount":75},[],{"trials":3925,"activeCount":75},[],{"intervention":3919,"totalTrials":152,"cells":3927},{"EARLY_PHASE1":3928,"PHASE1":3930,"PHASE2":3932,"PHASE3":3938,"PHASE4":3940,"NA":3942},{"trials":3929,"activeCount":75},[],{"trials":3931,"activeCount":75},[],{"trials":3933,"activeCount":75},[3934],{"nctId":3912,"briefTitle":3913,"status":68,"phases":3935,"primaryCompletion":1255,"completion":1600,"start":1601,"enrollment":3915,"conditions":3936,"interventions":3937},[55],[585,3917],[3903,3903,3919],{"trials":3939,"activeCount":75},[],{"trials":3941,"activeCount":75},[],{"trials":3943,"activeCount":75},[],{"intervention":887,"totalTrials":152,"cells":3945},{"EARLY_PHASE1":3946,"PHASE1":3948,"PHASE2":3950,"PHASE3":3956,"PHASE4":3958,"NA":3960},{"trials":3947,"activeCount":75},[],{"trials":3949,"activeCount":75},[],{"trials":3951,"activeCount":75},[3952],{"nctId":878,"briefTitle":879,"status":68,"phases":3953,"primaryCompletion":881,"completion":882,"start":883,"enrollment":884,"conditions":3954,"interventions":3955},[55],[18],[846,887,888],{"trials":3957,"activeCount":75},[],{"trials":3959,"activeCount":75},[],{"trials":3961,"activeCount":75},[],{"intervention":888,"totalTrials":152,"cells":3963},{"EARLY_PHASE1":3964,"PHASE1":3966,"PHASE2":3968,"PHASE3":3974,"PHASE4":3976,"NA":3978},{"trials":3965,"activeCount":75},[],{"trials":3967,"activeCount":75},[],{"trials":3969,"activeCount":75},[3970],{"nctId":878,"briefTitle":879,"status":68,"phases":3971,"primaryCompletion":881,"completion":882,"start":883,"enrollment":884,"conditions":3972,"interventions":3973},[55],[18],[846,887,888],{"trials":3975,"activeCount":75},[],{"trials":3977,"activeCount":75},[],{"trials":3979,"activeCount":75},[],{"intervention":3981,"totalTrials":152,"cells":3982},"Picato",{"EARLY_PHASE1":3983,"PHASE1":3985,"PHASE2":3987,"PHASE3":3996,"PHASE4":3998,"NA":4000},{"trials":3984,"activeCount":75},[],{"trials":3986,"activeCount":75},[],{"trials":3988,"activeCount":75},[3989],{"nctId":3990,"briefTitle":3991,"status":68,"phases":3992,"primaryCompletion":1013,"completion":1013,"start":1209,"enrollment":72,"conditions":3993,"interventions":3995},"NCT02377999","Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts",[55],[3994],"Anogenital Warts",[3981],{"trials":3997,"activeCount":75},[],{"trials":3999,"activeCount":75},[],{"trials":4001,"activeCount":75},[],{"intervention":1274,"totalTrials":152,"cells":4003},{"EARLY_PHASE1":4004,"PHASE1":4006,"PHASE2":4008,"PHASE3":4014,"PHASE4":4016,"NA":4018},{"trials":4005,"activeCount":75},[],{"trials":4007,"activeCount":75},[],{"trials":4009,"activeCount":75},[4010],{"nctId":1266,"briefTitle":1267,"status":68,"phases":4011,"primaryCompletion":1256,"completion":782,"start":781,"enrollment":1257,"conditions":4012,"interventions":4013},[55],[15],[1271,1272,1273,1274,1275,1276],{"trials":4015,"activeCount":75},[],{"trials":4017,"activeCount":75},[],{"trials":4019,"activeCount":75},[],{"intervention":1275,"totalTrials":152,"cells":4021},{"EARLY_PHASE1":4022,"PHASE1":4024,"PHASE2":4026,"PHASE3":4032,"PHASE4":4034,"NA":4036},{"trials":4023,"activeCount":75},[],{"trials":4025,"activeCount":75},[],{"trials":4027,"activeCount":75},[4028],{"nctId":1266,"briefTitle":1267,"status":68,"phases":4029,"primaryCompletion":1256,"completion":782,"start":781,"enrollment":1257,"conditions":4030,"interventions":4031},[55],[15],[1271,1272,1273,1274,1275,1276],{"trials":4033,"activeCount":75},[],{"trials":4035,"activeCount":75},[],{"trials":4037,"activeCount":75},[],{"intervention":450,"totalTrials":152,"cells":4039},{"EARLY_PHASE1":4040,"PHASE1":4042,"PHASE2":4044,"PHASE3":4050,"PHASE4":4052,"NA":4054},{"trials":4041,"activeCount":75},[],{"trials":4043,"activeCount":75},[],{"trials":4045,"activeCount":75},[4046],{"nctId":442,"briefTitle":443,"status":68,"phases":4047,"primaryCompletion":433,"completion":433,"start":445,"enrollment":435,"conditions":4048,"interventions":4049},[55],[447],[449,450],{"trials":4051,"activeCount":75},[],{"trials":4053,"activeCount":75},[],{"trials":4055,"activeCount":75},[],{"intervention":1285,"totalTrials":152,"cells":4057},{"EARLY_PHASE1":4058,"PHASE1":4060,"PHASE2":4062,"PHASE3":4068,"PHASE4":4070,"NA":4072},{"trials":4059,"activeCount":75},[],{"trials":4061,"activeCount":75},[],{"trials":4063,"activeCount":75},[4064],{"nctId":1278,"briefTitle":1279,"status":68,"phases":4065,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":1257,"conditions":4066,"interventions":4067},[55],[15],[1285,1286,1287,1142],{"trials":4069,"activeCount":75},[],{"trials":4071,"activeCount":75},[],{"trials":4073,"activeCount":75},[],{"intervention":1286,"totalTrials":152,"cells":4075},{"EARLY_PHASE1":4076,"PHASE1":4078,"PHASE2":4080,"PHASE3":4086,"PHASE4":4088,"NA":4090},{"trials":4077,"activeCount":75},[],{"trials":4079,"activeCount":75},[],{"trials":4081,"activeCount":75},[4082],{"nctId":1278,"briefTitle":1279,"status":68,"phases":4083,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":1257,"conditions":4084,"interventions":4085},[55],[15],[1285,1286,1287,1142],{"trials":4087,"activeCount":75},[],{"trials":4089,"activeCount":75},[],{"trials":4091,"activeCount":75},[],{"intervention":1287,"totalTrials":152,"cells":4093},{"EARLY_PHASE1":4094,"PHASE1":4096,"PHASE2":4098,"PHASE3":4104,"PHASE4":4106,"NA":4108},{"trials":4095,"activeCount":75},[],{"trials":4097,"activeCount":75},[],{"trials":4099,"activeCount":75},[4100],{"nctId":1278,"briefTitle":1279,"status":68,"phases":4101,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":1257,"conditions":4102,"interventions":4103},[55],[15],[1285,1286,1287,1142],{"trials":4105,"activeCount":75},[],{"trials":4107,"activeCount":75},[],{"trials":4109,"activeCount":75},[],{"intervention":4111,"totalTrials":421,"cells":4112},"LEO 27847",{"EARLY_PHASE1":4113,"PHASE1":4115,"PHASE2":4140,"PHASE3":4142,"PHASE4":4144,"NA":4146},{"trials":4114,"activeCount":75},[],{"trials":4116,"activeCount":75},[4117,4125,4133],{"nctId":4118,"briefTitle":4119,"status":68,"phases":4120,"primaryCompletion":2782,"completion":3037,"start":1648,"enrollment":4121,"conditions":4122,"interventions":4124},"NCT01167309","LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients",[54],72,[4123],"Secondary Hyperparathyroidism",[4111],{"nctId":4126,"briefTitle":4127,"status":68,"phases":4128,"primaryCompletion":4129,"completion":4129,"start":2790,"enrollment":3101,"conditions":4130,"interventions":4132},"NCT01141179","The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847",[54],"2011-02",[4131],"Renal Impairment",[4111],{"nctId":4134,"briefTitle":4135,"status":68,"phases":4136,"primaryCompletion":4137,"completion":2774,"start":2852,"enrollment":435,"conditions":4138,"interventions":4139},"NCT01007383","LEO 27847 - A Study in Healthy Male Subjects",[54],"2010-03",[24],[4111],{"trials":4141,"activeCount":75},[],{"trials":4143,"activeCount":75},[],{"trials":4145,"activeCount":75},[],{"trials":4147,"activeCount":75},[],{"intervention":2448,"totalTrials":334,"cells":4149},{"EARLY_PHASE1":4150,"PHASE1":4152,"PHASE2":4162,"PHASE3":4164,"PHASE4":4166,"NA":4168},{"trials":4151,"activeCount":75},[],{"trials":4153,"activeCount":75},[4154,4158],{"nctId":2440,"briefTitle":2441,"status":68,"phases":4155,"primaryCompletion":2443,"completion":2443,"start":2444,"enrollment":1491,"conditions":4156,"interventions":4157},[54],[2446],[2433,2448],{"nctId":2473,"briefTitle":2474,"status":282,"phases":4159,"primaryCompletion":2476,"completion":2476,"start":2477,"enrollment":379,"conditions":4160,"interventions":4161},[54],[15],[2448,2433],{"trials":4163,"activeCount":75},[],{"trials":4165,"activeCount":75},[],{"trials":4167,"activeCount":75},[],{"trials":4169,"activeCount":75},[],{"intervention":4171,"totalTrials":334,"cells":4172},"LEO 158968",{"EARLY_PHASE1":4173,"PHASE1":4175,"PHASE2":4198,"PHASE3":4200,"PHASE4":4202,"NA":4204},{"trials":4174,"activeCount":75},[],{"trials":4176,"activeCount":75},[4177,4187],{"nctId":4178,"briefTitle":4179,"status":68,"phases":4180,"primaryCompletion":4181,"completion":4182,"start":4183,"enrollment":4184,"conditions":4185,"interventions":4186},"NCT05682352","Investigating the Safety of LEO 158968 in Healthy Volunteers",[54],"2024-05-07","2024-08-01","2023-02-07",120,[24],[4171,4171],{"nctId":4188,"briefTitle":4189,"status":68,"phases":4190,"primaryCompletion":4191,"completion":4191,"start":4192,"enrollment":31,"conditions":4193,"interventions":4197},"NCT06444867","A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968",[54],"2025-09-18","2025-01-07",[4194,4195,4196],"Joint Pain","Gout Flares","Joint Inflammation",[4171],{"trials":4199,"activeCount":75},[],{"trials":4201,"activeCount":75},[],{"trials":4203,"activeCount":75},[],{"trials":4205,"activeCount":75},[],{"intervention":1081,"totalTrials":334,"cells":4207},{"EARLY_PHASE1":4208,"PHASE1":4210,"PHASE2":4225,"PHASE3":4227,"PHASE4":4229,"NA":4231},{"trials":4209,"activeCount":75},[],{"trials":4211,"activeCount":75},[4212,4221],{"nctId":4213,"briefTitle":4214,"status":68,"phases":4215,"primaryCompletion":494,"completion":494,"start":1222,"enrollment":4216,"conditions":4217,"interventions":4218},"NCT02355639","A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin",[54],16,[1176],[4219,4220,1081],"Clobetasol propionate 0.05 % ointment","Betamethasone dipropionate 0.064 % ointment",{"nctId":1071,"briefTitle":1072,"status":68,"phases":4222,"primaryCompletion":1074,"completion":1075,"start":1076,"enrollment":1077,"conditions":4223,"interventions":4224},[54],[15],[1064,1080,1081],{"trials":4226,"activeCount":75},[],{"trials":4228,"activeCount":75},[],{"trials":4230,"activeCount":75},[],{"trials":4232,"activeCount":75},[],{"intervention":4234,"totalTrials":334,"cells":4235},"LEO32731",{"EARLY_PHASE1":4236,"PHASE1":4238,"PHASE2":4253,"PHASE3":4255,"PHASE4":4257,"NA":4259},{"trials":4237,"activeCount":75},[],{"trials":4239,"activeCount":75},[4240,4247],{"nctId":4241,"briefTitle":4242,"status":68,"phases":4243,"primaryCompletion":4244,"completion":4244,"start":1221,"enrollment":287,"conditions":4245,"interventions":4246},"NCT02514694","LEO 32731 - A Phase I Study in Healthy Subjects",[54],"2015-12",[15],[4234],{"nctId":4248,"briefTitle":4249,"status":68,"phases":4250,"primaryCompletion":1222,"completion":1222,"start":527,"enrollment":1257,"conditions":4251,"interventions":4252},"NCT02126371","LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects",[54],[15],[4234],{"trials":4254,"activeCount":75},[],{"trials":4256,"activeCount":75},[],{"trials":4258,"activeCount":75},[],{"trials":4260,"activeCount":75},[],{"intervention":4262,"totalTrials":334,"cells":4263},"Water",{"EARLY_PHASE1":4264,"PHASE1":4266,"PHASE2":4286,"PHASE3":4288,"PHASE4":4290,"NA":4292},{"trials":4265,"activeCount":75},[],{"trials":4267,"activeCount":75},[4268,4277],{"nctId":4269,"briefTitle":4270,"status":68,"phases":4271,"primaryCompletion":3037,"completion":3037,"start":2666,"enrollment":4272,"conditions":4273,"interventions":4274},"NCT01430533","Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation",[54],240,[24],[4275,4276,4262],"azelaic acid pre foam formulation","Vehicle pre foam formulation",{"nctId":4278,"briefTitle":4279,"status":68,"phases":4280,"primaryCompletion":3037,"completion":3037,"start":2666,"enrollment":72,"conditions":4281,"interventions":4282},"NCT01430312","21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation",[54],[24],[4283,4284,4262,4285],"azelaic acid pre-foam formulation","Vehicle pre-foam formulation","Sodium lauryl sulfate",{"trials":4287,"activeCount":75},[],{"trials":4289,"activeCount":75},[],{"trials":4291,"activeCount":75},[],{"trials":4293,"activeCount":75},[],{"intervention":173,"totalTrials":334,"cells":4295},{"EARLY_PHASE1":4296,"PHASE1":4298,"PHASE2":4310,"PHASE3":4312,"PHASE4":4314,"NA":4316},{"trials":4297,"activeCount":75},[],{"trials":4299,"activeCount":75},[4300,4304],{"nctId":164,"briefTitle":165,"status":68,"phases":4301,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":4302,"interventions":4303},[54],[18],[173,174],{"nctId":4305,"briefTitle":4306,"status":68,"phases":4307,"primaryCompletion":168,"completion":1222,"start":3529,"enrollment":346,"conditions":4308,"interventions":4309},"NCT02219633","Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)",[54],[18],[173],{"trials":4311,"activeCount":75},[],{"trials":4313,"activeCount":75},[],{"trials":4315,"activeCount":75},[],{"trials":4317,"activeCount":75},[],{"intervention":4319,"totalTrials":334,"cells":4320},"Daivonex® ointment",{"EARLY_PHASE1":4321,"PHASE1":4323,"PHASE2":4348,"PHASE3":4350,"PHASE4":4352,"NA":4354},{"trials":4322,"activeCount":75},[],{"trials":4324,"activeCount":75},[4325,4337],{"nctId":4326,"briefTitle":4327,"status":68,"phases":4328,"primaryCompletion":3037,"completion":3037,"start":998,"enrollment":1257,"conditions":4329,"interventions":4330},"NCT01466478","An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris",[54],[15],[4331,4332,4333,4334,4335,4319,4336],"Ointment A: LEO 29102 2.5 mg\u002Fg plus calcipotriol 50 µg\u002Fg ointment","Ointment B: LEO 29102 2.5 mg\u002Fg ointment","Ointment C: Calcipotriol 50 µg\u002Fg ointment","Ointment D: LEO 29102 2.5 mg\u002Fg plus calcipotriol 50 µg\u002Fg ointment","Ointment G: LEO 29102 2.5 mg\u002Fg plus calcipotriol 50 µg\u002Fg ointment","Diprosone® ointment",{"nctId":4338,"briefTitle":4339,"status":68,"phases":4340,"primaryCompletion":3595,"completion":3595,"start":997,"enrollment":1257,"conditions":4341,"interventions":4342},"NCT01580488","A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris",[54],[15],[4343,4344,4345,4346,4319,4347],"B LEO 35299 20 mg\u002Fg cream","C LEO 35299 20 mg\u002Fg cream","E LEO 35299 10 mg\u002Fg solution","F LEO 35299 10 mg\u002Fg solution","Daivonex® ointment vehicle",{"trials":4349,"activeCount":75},[],{"trials":4351,"activeCount":75},[],{"trials":4353,"activeCount":75},[],{"trials":4355,"activeCount":75},[],{"intervention":349,"totalTrials":152,"cells":4357},{"EARLY_PHASE1":4358,"PHASE1":4360,"PHASE2":4366,"PHASE3":4368,"PHASE4":4370,"NA":4372},{"trials":4359,"activeCount":75},[],{"trials":4361,"activeCount":75},[4362],{"nctId":341,"briefTitle":342,"status":68,"phases":4363,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":4364,"interventions":4365},[54],[18],[349,308],{"trials":4367,"activeCount":75},[],{"trials":4369,"activeCount":75},[],{"trials":4371,"activeCount":75},[],{"trials":4373,"activeCount":75},[],{"intervention":1244,"totalTrials":152,"cells":4375},{"EARLY_PHASE1":4376,"PHASE1":4378,"PHASE2":4384,"PHASE3":4386,"PHASE4":4388,"NA":4390},{"trials":4377,"activeCount":75},[],{"trials":4379,"activeCount":75},[4380],{"nctId":1238,"briefTitle":1239,"status":68,"phases":4381,"primaryCompletion":1127,"completion":1127,"start":1241,"enrollment":265,"conditions":4382,"interventions":4383},[54],[15],[1244,1245,1246,1142,1247,1248],{"trials":4385,"activeCount":75},[],{"trials":4387,"activeCount":75},[],{"trials":4389,"activeCount":75},[],{"trials":4391,"activeCount":75},[],{"intervention":1245,"totalTrials":152,"cells":4393},{"EARLY_PHASE1":4394,"PHASE1":4396,"PHASE2":4402,"PHASE3":4404,"PHASE4":4406,"NA":4408},{"trials":4395,"activeCount":75},[],{"trials":4397,"activeCount":75},[4398],{"nctId":1238,"briefTitle":1239,"status":68,"phases":4399,"primaryCompletion":1127,"completion":1127,"start":1241,"enrollment":265,"conditions":4400,"interventions":4401},[54],[15],[1244,1245,1246,1142,1247,1248],{"trials":4403,"activeCount":75},[],{"trials":4405,"activeCount":75},[],{"trials":4407,"activeCount":75},[],{"trials":4409,"activeCount":75},[],{"intervention":1246,"totalTrials":152,"cells":4411},{"EARLY_PHASE1":4412,"PHASE1":4414,"PHASE2":4420,"PHASE3":4422,"PHASE4":4424,"NA":4426},{"trials":4413,"activeCount":75},[],{"trials":4415,"activeCount":75},[4416],{"nctId":1238,"briefTitle":1239,"status":68,"phases":4417,"primaryCompletion":1127,"completion":1127,"start":1241,"enrollment":265,"conditions":4418,"interventions":4419},[54],[15],[1244,1245,1246,1142,1247,1248],{"trials":4421,"activeCount":75},[],{"trials":4423,"activeCount":75},[],{"trials":4425,"activeCount":75},[],{"trials":4427,"activeCount":75},[],{"intervention":1247,"totalTrials":152,"cells":4429},{"EARLY_PHASE1":4430,"PHASE1":4432,"PHASE2":4438,"PHASE3":4440,"PHASE4":4442,"NA":4444},{"trials":4431,"activeCount":75},[],{"trials":4433,"activeCount":75},[4434],{"nctId":1238,"briefTitle":1239,"status":68,"phases":4435,"primaryCompletion":1127,"completion":1127,"start":1241,"enrollment":265,"conditions":4436,"interventions":4437},[54],[15],[1244,1245,1246,1142,1247,1248],{"trials":4439,"activeCount":75},[],{"trials":4441,"activeCount":75},[],{"trials":4443,"activeCount":75},[],{"trials":4445,"activeCount":75},[],{"intervention":1248,"totalTrials":152,"cells":4447},{"EARLY_PHASE1":4448,"PHASE1":4450,"PHASE2":4456,"PHASE3":4458,"PHASE4":4460,"NA":4462},{"trials":4449,"activeCount":75},[],{"trials":4451,"activeCount":75},[4452],{"nctId":1238,"briefTitle":1239,"status":68,"phases":4453,"primaryCompletion":1127,"completion":1127,"start":1241,"enrollment":265,"conditions":4454,"interventions":4455},[54],[15],[1244,1245,1246,1142,1247,1248],{"trials":4457,"activeCount":75},[],{"trials":4459,"activeCount":75},[],{"trials":4461,"activeCount":75},[],{"trials":4463,"activeCount":75},[],{"intervention":4219,"totalTrials":152,"cells":4465},{"EARLY_PHASE1":4466,"PHASE1":4468,"PHASE2":4474,"PHASE3":4476,"PHASE4":4478,"NA":4480},{"trials":4467,"activeCount":75},[],{"trials":4469,"activeCount":75},[4470],{"nctId":4213,"briefTitle":4214,"status":68,"phases":4471,"primaryCompletion":494,"completion":494,"start":1222,"enrollment":4216,"conditions":4472,"interventions":4473},[54],[1176],[4219,4220,1081],{"trials":4475,"activeCount":75},[],{"trials":4477,"activeCount":75},[],{"trials":4479,"activeCount":75},[],{"trials":4481,"activeCount":75},[],{"intervention":4220,"totalTrials":152,"cells":4483},{"EARLY_PHASE1":4484,"PHASE1":4486,"PHASE2":4492,"PHASE3":4494,"PHASE4":4496,"NA":4498},{"trials":4485,"activeCount":75},[],{"trials":4487,"activeCount":75},[4488],{"nctId":4213,"briefTitle":4214,"status":68,"phases":4489,"primaryCompletion":494,"completion":494,"start":1222,"enrollment":4216,"conditions":4490,"interventions":4491},[54],[1176],[4219,4220,1081],{"trials":4493,"activeCount":75},[],{"trials":4495,"activeCount":75},[],{"trials":4497,"activeCount":75},[],{"trials":4499,"activeCount":75},[],{"intervention":4501,"totalTrials":152,"cells":4502},"LEO 142397",{"EARLY_PHASE1":4503,"PHASE1":4505,"PHASE2":4516,"PHASE3":4518,"PHASE4":4520,"NA":4522},{"trials":4504,"activeCount":75},[],{"trials":4506,"activeCount":75},[4507],{"nctId":4508,"briefTitle":4509,"status":756,"phases":4510,"primaryCompletion":4511,"completion":4512,"start":4513,"enrollment":75,"conditions":4514,"interventions":4515},"NCT03995550","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Doses of LEO 142397 in Healthy People, Including Japanese",[54],"2020-01-27","2020-07-16","2019-07-03",[24],[4501],{"trials":4517,"activeCount":75},[],{"trials":4519,"activeCount":75},[],{"trials":4521,"activeCount":75},[],{"trials":4523,"activeCount":75},[],{"intervention":4275,"totalTrials":152,"cells":4525},{"EARLY_PHASE1":4526,"PHASE1":4528,"PHASE2":4534,"PHASE3":4536,"PHASE4":4538,"NA":4540},{"trials":4527,"activeCount":75},[],{"trials":4529,"activeCount":75},[4530],{"nctId":4269,"briefTitle":4270,"status":68,"phases":4531,"primaryCompletion":3037,"completion":3037,"start":2666,"enrollment":4272,"conditions":4532,"interventions":4533},[54],[24],[4275,4276,4262],{"trials":4535,"activeCount":75},[],{"trials":4537,"activeCount":75},[],{"trials":4539,"activeCount":75},[],{"trials":4541,"activeCount":75},[],{"intervention":4276,"totalTrials":152,"cells":4543},{"EARLY_PHASE1":4544,"PHASE1":4546,"PHASE2":4552,"PHASE3":4554,"PHASE4":4556,"NA":4558},{"trials":4545,"activeCount":75},[],{"trials":4547,"activeCount":75},[4548],{"nctId":4269,"briefTitle":4270,"status":68,"phases":4549,"primaryCompletion":3037,"completion":3037,"start":2666,"enrollment":4272,"conditions":4550,"interventions":4551},[54],[24],[4275,4276,4262],{"trials":4553,"activeCount":75},[],{"trials":4555,"activeCount":75},[],{"trials":4557,"activeCount":75},[],{"trials":4559,"activeCount":75},[],{"intervention":1163,"totalTrials":152,"cells":4561},{"EARLY_PHASE1":4562,"PHASE1":4564,"PHASE2":4570,"PHASE3":4572,"PHASE4":4574,"NA":4576},{"trials":4563,"activeCount":75},[],{"trials":4565,"activeCount":75},[4566],{"nctId":1155,"briefTitle":1156,"status":68,"phases":4567,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":4568,"interventions":4569},[54],[15],[1148,1163,1164,1165,1166],{"trials":4571,"activeCount":75},[],{"trials":4573,"activeCount":75},[],{"trials":4575,"activeCount":75},[],{"trials":4577,"activeCount":75},[],{"intervention":1164,"totalTrials":152,"cells":4579},{"EARLY_PHASE1":4580,"PHASE1":4582,"PHASE2":4588,"PHASE3":4590,"PHASE4":4592,"NA":4594},{"trials":4581,"activeCount":75},[],{"trials":4583,"activeCount":75},[4584],{"nctId":1155,"briefTitle":1156,"status":68,"phases":4585,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":4586,"interventions":4587},[54],[15],[1148,1163,1164,1165,1166],{"trials":4589,"activeCount":75},[],{"trials":4591,"activeCount":75},[],{"trials":4593,"activeCount":75},[],{"trials":4595,"activeCount":75},[],{"intervention":1165,"totalTrials":152,"cells":4597},{"EARLY_PHASE1":4598,"PHASE1":4600,"PHASE2":4606,"PHASE3":4608,"PHASE4":4610,"NA":4612},{"trials":4599,"activeCount":75},[],{"trials":4601,"activeCount":75},[4602],{"nctId":1155,"briefTitle":1156,"status":68,"phases":4603,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":4604,"interventions":4605},[54],[15],[1148,1163,1164,1165,1166],{"trials":4607,"activeCount":75},[],{"trials":4609,"activeCount":75},[],{"trials":4611,"activeCount":75},[],{"trials":4613,"activeCount":75},[],{"intervention":1166,"totalTrials":152,"cells":4615},{"EARLY_PHASE1":4616,"PHASE1":4618,"PHASE2":4624,"PHASE3":4626,"PHASE4":4628,"NA":4630},{"trials":4617,"activeCount":75},[],{"trials":4619,"activeCount":75},[4620],{"nctId":1155,"briefTitle":1156,"status":68,"phases":4621,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":4622,"interventions":4623},[54],[15],[1148,1163,1164,1165,1166],{"trials":4625,"activeCount":75},[],{"trials":4627,"activeCount":75},[],{"trials":4629,"activeCount":75},[],{"trials":4631,"activeCount":75},[],{"intervention":4633,"totalTrials":152,"cells":4634},"LEO 43204 Gel, 0.037%",{"EARLY_PHASE1":4635,"PHASE1":4637,"PHASE2":4647,"PHASE3":4649,"PHASE4":4651,"NA":4653},{"trials":4636,"activeCount":75},[],{"trials":4638,"activeCount":75},[4639],{"nctId":4640,"briefTitle":4641,"status":68,"phases":4642,"primaryCompletion":4643,"completion":4644,"start":1490,"enrollment":1257,"conditions":4645,"interventions":4646},"NCT02600598","Biological Effects of LEO 43204 in Actinic Keratosis",[54],"2016-12-27","2017-01-16",[21],[4633,4633],{"trials":4648,"activeCount":75},[],{"trials":4650,"activeCount":75},[],{"trials":4652,"activeCount":75},[],{"trials":4654,"activeCount":75},[],{"intervention":2467,"totalTrials":152,"cells":4656},{"EARLY_PHASE1":4657,"PHASE1":4659,"PHASE2":4665,"PHASE3":4667,"PHASE4":4669,"NA":4671},{"trials":4658,"activeCount":75},[],{"trials":4660,"activeCount":75},[4661],{"nctId":2459,"briefTitle":2460,"status":68,"phases":4662,"primaryCompletion":2462,"completion":2462,"start":2463,"enrollment":2464,"conditions":4663,"interventions":4664},[54],[24],[2467,2468,2469,2470,2471,2433],{"trials":4666,"activeCount":75},[],{"trials":4668,"activeCount":75},[],{"trials":4670,"activeCount":75},[],{"trials":4672,"activeCount":75},[],{"intervention":2468,"totalTrials":152,"cells":4674},{"EARLY_PHASE1":4675,"PHASE1":4677,"PHASE2":4683,"PHASE3":4685,"PHASE4":4687,"NA":4689},{"trials":4676,"activeCount":75},[],{"trials":4678,"activeCount":75},[4679],{"nctId":2459,"briefTitle":2460,"status":68,"phases":4680,"primaryCompletion":2462,"completion":2462,"start":2463,"enrollment":2464,"conditions":4681,"interventions":4682},[54],[24],[2467,2468,2469,2470,2471,2433],{"trials":4684,"activeCount":75},[],{"trials":4686,"activeCount":75},[],{"trials":4688,"activeCount":75},[],{"trials":4690,"activeCount":75},[],{"intervention":2469,"totalTrials":152,"cells":4692},{"EARLY_PHASE1":4693,"PHASE1":4695,"PHASE2":4701,"PHASE3":4703,"PHASE4":4705,"NA":4707},{"trials":4694,"activeCount":75},[],{"trials":4696,"activeCount":75},[4697],{"nctId":2459,"briefTitle":2460,"status":68,"phases":4698,"primaryCompletion":2462,"completion":2462,"start":2463,"enrollment":2464,"conditions":4699,"interventions":4700},[54],[24],[2467,2468,2469,2470,2471,2433],{"trials":4702,"activeCount":75},[],{"trials":4704,"activeCount":75},[],{"trials":4706,"activeCount":75},[],{"trials":4708,"activeCount":75},[],{"intervention":2470,"totalTrials":152,"cells":4710},{"EARLY_PHASE1":4711,"PHASE1":4713,"PHASE2":4719,"PHASE3":4721,"PHASE4":4723,"NA":4725},{"trials":4712,"activeCount":75},[],{"trials":4714,"activeCount":75},[4715],{"nctId":2459,"briefTitle":2460,"status":68,"phases":4716,"primaryCompletion":2462,"completion":2462,"start":2463,"enrollment":2464,"conditions":4717,"interventions":4718},[54],[24],[2467,2468,2469,2470,2471,2433],{"trials":4720,"activeCount":75},[],{"trials":4722,"activeCount":75},[],{"trials":4724,"activeCount":75},[],{"trials":4726,"activeCount":75},[],{"intervention":2471,"totalTrials":152,"cells":4728},{"EARLY_PHASE1":4729,"PHASE1":4731,"PHASE2":4737,"PHASE3":4739,"PHASE4":4741,"NA":4743},{"trials":4730,"activeCount":75},[],{"trials":4732,"activeCount":75},[4733],{"nctId":2459,"briefTitle":2460,"status":68,"phases":4734,"primaryCompletion":2462,"completion":2462,"start":2463,"enrollment":2464,"conditions":4735,"interventions":4736},[54],[24],[2467,2468,2469,2470,2471,2433],{"trials":4738,"activeCount":75},[],{"trials":4740,"activeCount":75},[],{"trials":4742,"activeCount":75},[],{"trials":4744,"activeCount":75},[],{"intervention":4746,"totalTrials":152,"cells":4747},"Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues",{"EARLY_PHASE1":4748,"PHASE1":4750,"PHASE2":4758,"PHASE3":4760,"PHASE4":4762,"NA":4764},{"trials":4749,"activeCount":75},[],{"trials":4751,"activeCount":75},[4752],{"nctId":4753,"briefTitle":4754,"status":68,"phases":4755,"primaryCompletion":2790,"completion":1648,"start":2774,"enrollment":1257,"conditions":4756,"interventions":4757},"NCT01105286","A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Psoriasis",[54],[15],[4746],{"trials":4759,"activeCount":75},[],{"trials":4761,"activeCount":75},[],{"trials":4763,"activeCount":75},[],{"trials":4765,"activeCount":75},[],{"intervention":4767,"totalTrials":152,"cells":4768},"Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle",{"EARLY_PHASE1":4769,"PHASE1":4771,"PHASE2":4779,"PHASE3":4781,"PHASE4":4783,"NA":4785},{"trials":4770,"activeCount":75},[],{"trials":4772,"activeCount":75},[4773],{"nctId":4774,"briefTitle":4775,"status":68,"phases":4776,"primaryCompletion":4137,"completion":4137,"start":1543,"enrollment":1257,"conditions":4777,"interventions":4778},"NCT01043224","A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris",[54],[15],[4767],{"trials":4780,"activeCount":75},[],{"trials":4782,"activeCount":75},[],{"trials":4784,"activeCount":75},[],{"trials":4786,"activeCount":75},[],{"intervention":4788,"totalTrials":152,"cells":4789},"Microarray patch A",{"EARLY_PHASE1":4790,"PHASE1":4792,"PHASE2":4804,"PHASE3":4806,"PHASE4":4808,"NA":4810},{"trials":4791,"activeCount":75},[],{"trials":4793,"activeCount":75},[4794],{"nctId":4795,"briefTitle":4796,"status":68,"phases":4797,"primaryCompletion":4798,"completion":4798,"start":4799,"enrollment":94,"conditions":4800,"interventions":4801},"NCT03898583","Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol\u002FBetamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.",[54],"2019-10-29","2019-04-15",[15],[4788,4802,4803],"Microarray patch B","Daivobet",{"trials":4805,"activeCount":75},[],{"trials":4807,"activeCount":75},[],{"trials":4809,"activeCount":75},[],{"trials":4811,"activeCount":75},[],{"intervention":4802,"totalTrials":152,"cells":4813},{"EARLY_PHASE1":4814,"PHASE1":4816,"PHASE2":4822,"PHASE3":4824,"PHASE4":4826,"NA":4828},{"trials":4815,"activeCount":75},[],{"trials":4817,"activeCount":75},[4818],{"nctId":4795,"briefTitle":4796,"status":68,"phases":4819,"primaryCompletion":4798,"completion":4798,"start":4799,"enrollment":94,"conditions":4820,"interventions":4821},[54],[15],[4788,4802,4803],{"trials":4823,"activeCount":75},[],{"trials":4825,"activeCount":75},[],{"trials":4827,"activeCount":75},[],{"trials":4829,"activeCount":75},[],{"intervention":4803,"totalTrials":152,"cells":4831},{"EARLY_PHASE1":4832,"PHASE1":4834,"PHASE2":4840,"PHASE3":4842,"PHASE4":4844,"NA":4846},{"trials":4833,"activeCount":75},[],{"trials":4835,"activeCount":75},[4836],{"nctId":4795,"briefTitle":4796,"status":68,"phases":4837,"primaryCompletion":4798,"completion":4798,"start":4799,"enrollment":94,"conditions":4838,"interventions":4839},[54],[15],[4788,4802,4803],{"trials":4841,"activeCount":75},[],{"trials":4843,"activeCount":75},[],{"trials":4845,"activeCount":75},[],{"trials":4847,"activeCount":75},[],{"intervention":4849,"totalTrials":152,"cells":4850},"PEP005",{"EARLY_PHASE1":4851,"PHASE1":4853,"PHASE2":4861,"PHASE3":4863,"PHASE4":4865,"NA":4867},{"trials":4852,"activeCount":75},[],{"trials":4854,"activeCount":75},[4855],{"nctId":4856,"briefTitle":4857,"status":68,"phases":4858,"primaryCompletion":3595,"completion":3595,"start":2673,"enrollment":287,"conditions":4859,"interventions":4860},"NCT01387711","PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology",[54],[21],[4849],{"trials":4862,"activeCount":75},[],{"trials":4864,"activeCount":75},[],{"trials":4866,"activeCount":75},[],{"trials":4868,"activeCount":75},[],{"intervention":861,"totalTrials":152,"cells":4870},{"EARLY_PHASE1":4871,"PHASE1":4873,"PHASE2":4879,"PHASE3":4881,"PHASE4":4883,"NA":4885},{"trials":4872,"activeCount":75},[],{"trials":4874,"activeCount":75},[4875],{"nctId":853,"briefTitle":854,"status":68,"phases":4876,"primaryCompletion":856,"completion":857,"start":858,"enrollment":72,"conditions":4877,"interventions":4878},[54],[18],[846,861,533,862,863,864],{"trials":4880,"activeCount":75},[],{"trials":4882,"activeCount":75},[],{"trials":4884,"activeCount":75},[],{"trials":4886,"activeCount":75},[],{"intervention":862,"totalTrials":152,"cells":4888},{"EARLY_PHASE1":4889,"PHASE1":4891,"PHASE2":4897,"PHASE3":4899,"PHASE4":4901,"NA":4903},{"trials":4890,"activeCount":75},[],{"trials":4892,"activeCount":75},[4893],{"nctId":853,"briefTitle":854,"status":68,"phases":4894,"primaryCompletion":856,"completion":857,"start":858,"enrollment":72,"conditions":4895,"interventions":4896},[54],[18],[846,861,533,862,863,864],{"trials":4898,"activeCount":75},[],{"trials":4900,"activeCount":75},[],{"trials":4902,"activeCount":75},[],{"trials":4904,"activeCount":75},[],{"intervention":863,"totalTrials":152,"cells":4906},{"EARLY_PHASE1":4907,"PHASE1":4909,"PHASE2":4915,"PHASE3":4917,"PHASE4":4919,"NA":4921},{"trials":4908,"activeCount":75},[],{"trials":4910,"activeCount":75},[4911],{"nctId":853,"briefTitle":854,"status":68,"phases":4912,"primaryCompletion":856,"completion":857,"start":858,"enrollment":72,"conditions":4913,"interventions":4914},[54],[18],[846,861,533,862,863,864],{"trials":4916,"activeCount":75},[],{"trials":4918,"activeCount":75},[],{"trials":4920,"activeCount":75},[],{"trials":4922,"activeCount":75},[],{"intervention":864,"totalTrials":152,"cells":4924},{"EARLY_PHASE1":4925,"PHASE1":4927,"PHASE2":4933,"PHASE3":4935,"PHASE4":4937,"NA":4939},{"trials":4926,"activeCount":75},[],{"trials":4928,"activeCount":75},[4929],{"nctId":853,"briefTitle":854,"status":68,"phases":4930,"primaryCompletion":856,"completion":857,"start":858,"enrollment":72,"conditions":4931,"interventions":4932},[54],[18],[846,861,533,862,863,864],{"trials":4934,"activeCount":75},[],{"trials":4936,"activeCount":75},[],{"trials":4938,"activeCount":75},[],{"trials":4940,"activeCount":75},[],{"intervention":4942,"totalTrials":152,"cells":4943},"Clobetasol propionate 0.05% ointment",{"EARLY_PHASE1":4944,"PHASE1":4946,"PHASE2":4958,"PHASE3":4960,"PHASE4":4962,"NA":4964},{"trials":4945,"activeCount":75},[],{"trials":4947,"activeCount":75},[4948],{"nctId":4949,"briefTitle":4950,"status":68,"phases":4951,"primaryCompletion":1173,"completion":1173,"start":2630,"enrollment":72,"conditions":4952,"interventions":4955},"NCT02392130","A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin",[54],[4953,4954],"Skin Tissue Diseases","Connective Tissue Diseases",[4942,4956,4957],"LEO 130852A gel 1%","LEO 130852A placebo gel",{"trials":4959,"activeCount":75},[],{"trials":4961,"activeCount":75},[],{"trials":4963,"activeCount":75},[],{"trials":4965,"activeCount":75},[],{"intervention":4956,"totalTrials":152,"cells":4967},{"EARLY_PHASE1":4968,"PHASE1":4970,"PHASE2":4976,"PHASE3":4978,"PHASE4":4980,"NA":4982},{"trials":4969,"activeCount":75},[],{"trials":4971,"activeCount":75},[4972],{"nctId":4949,"briefTitle":4950,"status":68,"phases":4973,"primaryCompletion":1173,"completion":1173,"start":2630,"enrollment":72,"conditions":4974,"interventions":4975},[54],[4953,4954],[4942,4956,4957],{"trials":4977,"activeCount":75},[],{"trials":4979,"activeCount":75},[],{"trials":4981,"activeCount":75},[],{"trials":4983,"activeCount":75},[],{"intervention":4957,"totalTrials":152,"cells":4985},{"EARLY_PHASE1":4986,"PHASE1":4988,"PHASE2":4994,"PHASE3":4996,"PHASE4":4998,"NA":5000},{"trials":4987,"activeCount":75},[],{"trials":4989,"activeCount":75},[4990],{"nctId":4949,"briefTitle":4950,"status":68,"phases":4991,"primaryCompletion":1173,"completion":1173,"start":2630,"enrollment":72,"conditions":4992,"interventions":4993},[54],[4953,4954],[4942,4956,4957],{"trials":4995,"activeCount":75},[],{"trials":4997,"activeCount":75},[],{"trials":4999,"activeCount":75},[],{"trials":5001,"activeCount":75},[],{"intervention":4331,"totalTrials":152,"cells":5003},{"EARLY_PHASE1":5004,"PHASE1":5006,"PHASE2":5012,"PHASE3":5014,"PHASE4":5016,"NA":5018},{"trials":5005,"activeCount":75},[],{"trials":5007,"activeCount":75},[5008],{"nctId":4326,"briefTitle":4327,"status":68,"phases":5009,"primaryCompletion":3037,"completion":3037,"start":998,"enrollment":1257,"conditions":5010,"interventions":5011},[54],[15],[4331,4332,4333,4334,4335,4319,4336],{"trials":5013,"activeCount":75},[],{"trials":5015,"activeCount":75},[],{"trials":5017,"activeCount":75},[],{"trials":5019,"activeCount":75},[],{"intervention":4332,"totalTrials":152,"cells":5021},{"EARLY_PHASE1":5022,"PHASE1":5024,"PHASE2":5030,"PHASE3":5032,"PHASE4":5034,"NA":5036},{"trials":5023,"activeCount":75},[],{"trials":5025,"activeCount":75},[5026],{"nctId":4326,"briefTitle":4327,"status":68,"phases":5027,"primaryCompletion":3037,"completion":3037,"start":998,"enrollment":1257,"conditions":5028,"interventions":5029},[54],[15],[4331,4332,4333,4334,4335,4319,4336],{"trials":5031,"activeCount":75},[],{"trials":5033,"activeCount":75},[],{"trials":5035,"activeCount":75},[],{"trials":5037,"activeCount":75},[],{"intervention":4333,"totalTrials":152,"cells":5039},{"EARLY_PHASE1":5040,"PHASE1":5042,"PHASE2":5048,"PHASE3":5050,"PHASE4":5052,"NA":5054},{"trials":5041,"activeCount":75},[],{"trials":5043,"activeCount":75},[5044],{"nctId":4326,"briefTitle":4327,"status":68,"phases":5045,"primaryCompletion":3037,"completion":3037,"start":998,"enrollment":1257,"conditions":5046,"interventions":5047},[54],[15],[4331,4332,4333,4334,4335,4319,4336],{"trials":5049,"activeCount":75},[],{"trials":5051,"activeCount":75},[],{"trials":5053,"activeCount":75},[],{"trials":5055,"activeCount":75},[],{"intervention":4334,"totalTrials":152,"cells":5057},{"EARLY_PHASE1":5058,"PHASE1":5060,"PHASE2":5066,"PHASE3":5068,"PHASE4":5070,"NA":5072},{"trials":5059,"activeCount":75},[],{"trials":5061,"activeCount":75},[5062],{"nctId":4326,"briefTitle":4327,"status":68,"phases":5063,"primaryCompletion":3037,"completion":3037,"start":998,"enrollment":1257,"conditions":5064,"interventions":5065},[54],[15],[4331,4332,4333,4334,4335,4319,4336],{"trials":5067,"activeCount":75},[],{"trials":5069,"activeCount":75},[],{"trials":5071,"activeCount":75},[],{"trials":5073,"activeCount":75},[],{"intervention":4335,"totalTrials":152,"cells":5075},{"EARLY_PHASE1":5076,"PHASE1":5078,"PHASE2":5084,"PHASE3":5086,"PHASE4":5088,"NA":5090},{"trials":5077,"activeCount":75},[],{"trials":5079,"activeCount":75},[5080],{"nctId":4326,"briefTitle":4327,"status":68,"phases":5081,"primaryCompletion":3037,"completion":3037,"start":998,"enrollment":1257,"conditions":5082,"interventions":5083},[54],[15],[4331,4332,4333,4334,4335,4319,4336],{"trials":5085,"activeCount":75},[],{"trials":5087,"activeCount":75},[],{"trials":5089,"activeCount":75},[],{"trials":5091,"activeCount":75},[],{"intervention":4336,"totalTrials":152,"cells":5093},{"EARLY_PHASE1":5094,"PHASE1":5096,"PHASE2":5102,"PHASE3":5104,"PHASE4":5106,"NA":5108},{"trials":5095,"activeCount":75},[],{"trials":5097,"activeCount":75},[5098],{"nctId":4326,"briefTitle":4327,"status":68,"phases":5099,"primaryCompletion":3037,"completion":3037,"start":998,"enrollment":1257,"conditions":5100,"interventions":5101},[54],[15],[4331,4332,4333,4334,4335,4319,4336],{"trials":5103,"activeCount":75},[],{"trials":5105,"activeCount":75},[],{"trials":5107,"activeCount":75},[],{"trials":5109,"activeCount":75},[],{"intervention":5111,"totalTrials":152,"cells":5112},"Botulinum Toxin Type A",{"EARLY_PHASE1":5113,"PHASE1":5115,"PHASE2":5125,"PHASE3":5127,"PHASE4":5129,"NA":5131},{"trials":5114,"activeCount":75},[],{"trials":5116,"activeCount":75},[5117],{"nctId":5118,"briefTitle":5119,"status":68,"phases":5120,"primaryCompletion":1490,"completion":1490,"start":1013,"enrollment":5121,"conditions":5122,"interventions":5123},"NCT02577185","An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A",[54],10,[15],[5111,5124],"Sodium chloride 9 mg\u002Fml",{"trials":5126,"activeCount":75},[],{"trials":5128,"activeCount":75},[],{"trials":5130,"activeCount":75},[],{"trials":5132,"activeCount":75},[],{"intervention":5124,"totalTrials":152,"cells":5134},{"EARLY_PHASE1":5135,"PHASE1":5137,"PHASE2":5143,"PHASE3":5145,"PHASE4":5147,"NA":5149},{"trials":5136,"activeCount":75},[],{"trials":5138,"activeCount":75},[5139],{"nctId":5118,"briefTitle":5119,"status":68,"phases":5140,"primaryCompletion":1490,"completion":1490,"start":1013,"enrollment":5121,"conditions":5141,"interventions":5142},[54],[15],[5111,5124],{"trials":5144,"activeCount":75},[],{"trials":5146,"activeCount":75},[],{"trials":5148,"activeCount":75},[],{"trials":5150,"activeCount":75},[],{"intervention":5152,"totalTrials":152,"cells":5153},"LEO 153339",{"EARLY_PHASE1":5154,"PHASE1":5156,"PHASE2":5167,"PHASE3":5169,"PHASE4":5171,"NA":5173},{"trials":5155,"activeCount":75},[],{"trials":5157,"activeCount":75},[5158],{"nctId":5159,"briefTitle":5160,"status":68,"phases":5161,"primaryCompletion":5162,"completion":5162,"start":5163,"enrollment":5164,"conditions":5165,"interventions":5166},"NCT04883333","A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults",[54],"2022-07-18","2021-05-17",108,[24],[5152],{"trials":5168,"activeCount":75},[],{"trials":5170,"activeCount":75},[],{"trials":5172,"activeCount":75},[],{"trials":5174,"activeCount":75},[],{"intervention":2961,"totalTrials":152,"cells":5176},{"EARLY_PHASE1":5177,"PHASE1":5179,"PHASE2":5185,"PHASE3":5187,"PHASE4":5189,"NA":5191},{"trials":5178,"activeCount":75},[],{"trials":5180,"activeCount":75},[5181],{"nctId":2956,"briefTitle":2957,"status":68,"phases":5182,"primaryCompletion":1221,"completion":1221,"start":1209,"enrollment":346,"conditions":5183,"interventions":5184},[54],[18],[2961,2949,2962,2963],{"trials":5186,"activeCount":75},[],{"trials":5188,"activeCount":75},[],{"trials":5190,"activeCount":75},[],{"trials":5192,"activeCount":75},[],{"intervention":2962,"totalTrials":152,"cells":5194},{"EARLY_PHASE1":5195,"PHASE1":5197,"PHASE2":5203,"PHASE3":5205,"PHASE4":5207,"NA":5209},{"trials":5196,"activeCount":75},[],{"trials":5198,"activeCount":75},[5199],{"nctId":2956,"briefTitle":2957,"status":68,"phases":5200,"primaryCompletion":1221,"completion":1221,"start":1209,"enrollment":346,"conditions":5201,"interventions":5202},[54],[18],[2961,2949,2962,2963],{"trials":5204,"activeCount":75},[],{"trials":5206,"activeCount":75},[],{"trials":5208,"activeCount":75},[],{"trials":5210,"activeCount":75},[],{"intervention":2963,"totalTrials":152,"cells":5212},{"EARLY_PHASE1":5213,"PHASE1":5215,"PHASE2":5221,"PHASE3":5223,"PHASE4":5225,"NA":5227},{"trials":5214,"activeCount":75},[],{"trials":5216,"activeCount":75},[5217],{"nctId":2956,"briefTitle":2957,"status":68,"phases":5218,"primaryCompletion":1221,"completion":1221,"start":1209,"enrollment":346,"conditions":5219,"interventions":5220},[54],[18],[2961,2949,2962,2963],{"trials":5222,"activeCount":75},[],{"trials":5224,"activeCount":75},[],{"trials":5226,"activeCount":75},[],{"trials":5228,"activeCount":75},[],{"intervention":5230,"totalTrials":152,"cells":5231},"LEO 27989 ointment",{"EARLY_PHASE1":5232,"PHASE1":5234,"PHASE2":5246,"PHASE3":5248,"PHASE4":5250,"NA":5252},{"trials":5233,"activeCount":75},[],{"trials":5235,"activeCount":75},[5236],{"nctId":5237,"briefTitle":5238,"status":68,"phases":5239,"primaryCompletion":5240,"completion":5240,"start":4129,"enrollment":3101,"conditions":5241,"interventions":5242},"NCT01297166","A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris",[54],"2011-04",[15],[5230,5243,5244,5245],"Calcipotriol plus LEO 27989 ointment","Calcipotriol ointment","Vehicle ointment",{"trials":5247,"activeCount":75},[],{"trials":5249,"activeCount":75},[],{"trials":5251,"activeCount":75},[],{"trials":5253,"activeCount":75},[],{"intervention":5243,"totalTrials":152,"cells":5255},{"EARLY_PHASE1":5256,"PHASE1":5258,"PHASE2":5264,"PHASE3":5266,"PHASE4":5268,"NA":5270},{"trials":5257,"activeCount":75},[],{"trials":5259,"activeCount":75},[5260],{"nctId":5237,"briefTitle":5238,"status":68,"phases":5261,"primaryCompletion":5240,"completion":5240,"start":4129,"enrollment":3101,"conditions":5262,"interventions":5263},[54],[15],[5230,5243,5244,5245],{"trials":5265,"activeCount":75},[],{"trials":5267,"activeCount":75},[],{"trials":5269,"activeCount":75},[],{"trials":5271,"activeCount":75},[],{"intervention":5244,"totalTrials":152,"cells":5273},{"EARLY_PHASE1":5274,"PHASE1":5276,"PHASE2":5282,"PHASE3":5284,"PHASE4":5286,"NA":5288},{"trials":5275,"activeCount":75},[],{"trials":5277,"activeCount":75},[5278],{"nctId":5237,"briefTitle":5238,"status":68,"phases":5279,"primaryCompletion":5240,"completion":5240,"start":4129,"enrollment":3101,"conditions":5280,"interventions":5281},[54],[15],[5230,5243,5244,5245],{"trials":5283,"activeCount":75},[],{"trials":5285,"activeCount":75},[],{"trials":5287,"activeCount":75},[],{"trials":5289,"activeCount":75},[],{"intervention":5245,"totalTrials":152,"cells":5291},{"EARLY_PHASE1":5292,"PHASE1":5294,"PHASE2":5300,"PHASE3":5302,"PHASE4":5304,"NA":5306},{"trials":5293,"activeCount":75},[],{"trials":5295,"activeCount":75},[5296],{"nctId":5237,"briefTitle":5238,"status":68,"phases":5297,"primaryCompletion":5240,"completion":5240,"start":4129,"enrollment":3101,"conditions":5298,"interventions":5299},[54],[15],[5230,5243,5244,5245],{"trials":5301,"activeCount":75},[],{"trials":5303,"activeCount":75},[],{"trials":5305,"activeCount":75},[],{"trials":5307,"activeCount":75},[],{"intervention":4343,"totalTrials":152,"cells":5309},{"EARLY_PHASE1":5310,"PHASE1":5312,"PHASE2":5318,"PHASE3":5320,"PHASE4":5322,"NA":5324},{"trials":5311,"activeCount":75},[],{"trials":5313,"activeCount":75},[5314],{"nctId":4338,"briefTitle":4339,"status":68,"phases":5315,"primaryCompletion":3595,"completion":3595,"start":997,"enrollment":1257,"conditions":5316,"interventions":5317},[54],[15],[4343,4344,4345,4346,4319,4347],{"trials":5319,"activeCount":75},[],{"trials":5321,"activeCount":75},[],{"trials":5323,"activeCount":75},[],{"trials":5325,"activeCount":75},[],{"intervention":4344,"totalTrials":152,"cells":5327},{"EARLY_PHASE1":5328,"PHASE1":5330,"PHASE2":5336,"PHASE3":5338,"PHASE4":5340,"NA":5342},{"trials":5329,"activeCount":75},[],{"trials":5331,"activeCount":75},[5332],{"nctId":4338,"briefTitle":4339,"status":68,"phases":5333,"primaryCompletion":3595,"completion":3595,"start":997,"enrollment":1257,"conditions":5334,"interventions":5335},[54],[15],[4343,4344,4345,4346,4319,4347],{"trials":5337,"activeCount":75},[],{"trials":5339,"activeCount":75},[],{"trials":5341,"activeCount":75},[],{"trials":5343,"activeCount":75},[],{"intervention":4345,"totalTrials":152,"cells":5345},{"EARLY_PHASE1":5346,"PHASE1":5348,"PHASE2":5354,"PHASE3":5356,"PHASE4":5358,"NA":5360},{"trials":5347,"activeCount":75},[],{"trials":5349,"activeCount":75},[5350],{"nctId":4338,"briefTitle":4339,"status":68,"phases":5351,"primaryCompletion":3595,"completion":3595,"start":997,"enrollment":1257,"conditions":5352,"interventions":5353},[54],[15],[4343,4344,4345,4346,4319,4347],{"trials":5355,"activeCount":75},[],{"trials":5357,"activeCount":75},[],{"trials":5359,"activeCount":75},[],{"trials":5361,"activeCount":75},[],{"intervention":4346,"totalTrials":152,"cells":5363},{"EARLY_PHASE1":5364,"PHASE1":5366,"PHASE2":5372,"PHASE3":5374,"PHASE4":5376,"NA":5378},{"trials":5365,"activeCount":75},[],{"trials":5367,"activeCount":75},[5368],{"nctId":4338,"briefTitle":4339,"status":68,"phases":5369,"primaryCompletion":3595,"completion":3595,"start":997,"enrollment":1257,"conditions":5370,"interventions":5371},[54],[15],[4343,4344,4345,4346,4319,4347],{"trials":5373,"activeCount":75},[],{"trials":5375,"activeCount":75},[],{"trials":5377,"activeCount":75},[],{"trials":5379,"activeCount":75},[],{"intervention":4347,"totalTrials":152,"cells":5381},{"EARLY_PHASE1":5382,"PHASE1":5384,"PHASE2":5390,"PHASE3":5392,"PHASE4":5394,"NA":5396},{"trials":5383,"activeCount":75},[],{"trials":5385,"activeCount":75},[5386],{"nctId":4338,"briefTitle":4339,"status":68,"phases":5387,"primaryCompletion":3595,"completion":3595,"start":997,"enrollment":1257,"conditions":5388,"interventions":5389},[54],[15],[4343,4344,4345,4346,4319,4347],{"trials":5391,"activeCount":75},[],{"trials":5393,"activeCount":75},[],{"trials":5395,"activeCount":75},[],{"trials":5397,"activeCount":75},[],{"intervention":5399,"totalTrials":152,"cells":5400},"LEO 32731 cream",{"EARLY_PHASE1":5401,"PHASE1":5403,"PHASE2":5412,"PHASE3":5414,"PHASE4":5416,"NA":5418},{"trials":5402,"activeCount":75},[],{"trials":5404,"activeCount":75},[5405],{"nctId":5406,"briefTitle":5407,"status":68,"phases":5408,"primaryCompletion":1108,"completion":1108,"start":1221,"enrollment":346,"conditions":5409,"interventions":5410},"NCT02496546","An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)",[54],[18],[5399,5411],"LEO 32731 cream vehicle",{"trials":5413,"activeCount":75},[],{"trials":5415,"activeCount":75},[],{"trials":5417,"activeCount":75},[],{"trials":5419,"activeCount":75},[],{"intervention":5411,"totalTrials":152,"cells":5421},{"EARLY_PHASE1":5422,"PHASE1":5424,"PHASE2":5430,"PHASE3":5432,"PHASE4":5434,"NA":5436},{"trials":5423,"activeCount":75},[],{"trials":5425,"activeCount":75},[5426],{"nctId":5406,"briefTitle":5407,"status":68,"phases":5427,"primaryCompletion":1108,"completion":1108,"start":1221,"enrollment":346,"conditions":5428,"interventions":5429},[54],[18],[5399,5411],{"trials":5431,"activeCount":75},[],{"trials":5433,"activeCount":75},[],{"trials":5435,"activeCount":75},[],{"trials":5437,"activeCount":75},[],{"intervention":5439,"totalTrials":152,"cells":5440},"Azelaic Acid Foam",{"EARLY_PHASE1":5441,"PHASE1":5443,"PHASE2":5454,"PHASE3":5456,"PHASE4":5458,"NA":5460},{"trials":5442,"activeCount":75},[],{"trials":5444,"activeCount":75},[5445],{"nctId":5446,"briefTitle":5447,"status":68,"phases":5448,"primaryCompletion":1735,"completion":1735,"start":5449,"enrollment":5450,"conditions":5451,"interventions":5452},"NCT01257919","Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea",[54],"2011-01",21,[30],[5439,5453],"Azelaic Acid Gel",{"trials":5455,"activeCount":75},[],{"trials":5457,"activeCount":75},[],{"trials":5459,"activeCount":75},[],{"trials":5461,"activeCount":75},[],{"intervention":5453,"totalTrials":152,"cells":5463},{"EARLY_PHASE1":5464,"PHASE1":5466,"PHASE2":5472,"PHASE3":5474,"PHASE4":5476,"NA":5478},{"trials":5465,"activeCount":75},[],{"trials":5467,"activeCount":75},[5468],{"nctId":5446,"briefTitle":5447,"status":68,"phases":5469,"primaryCompletion":1735,"completion":1735,"start":5449,"enrollment":5450,"conditions":5470,"interventions":5471},[54],[30],[5439,5453],{"trials":5473,"activeCount":75},[],{"trials":5475,"activeCount":75},[],{"trials":5477,"activeCount":75},[],{"trials":5479,"activeCount":75},[],{"intervention":5481,"totalTrials":152,"cells":5482},"topical formulation of tacrolimus",{"EARLY_PHASE1":5483,"PHASE1":5485,"PHASE2":5496,"PHASE3":5498,"PHASE4":5500,"NA":5502},{"trials":5484,"activeCount":75},[],{"trials":5486,"activeCount":75},[5487],{"nctId":5488,"briefTitle":5489,"status":68,"phases":5490,"primaryCompletion":5491,"completion":5492,"start":5493,"enrollment":1257,"conditions":5494,"interventions":5495},"NCT03673527","Tacrolimus Blood Levels After Topical Application of Tacrolimus on Healthy Skin",[54],"2019-02-04","2019-02-11","2018-11-22",[24],[5481],{"trials":5497,"activeCount":75},[],{"trials":5499,"activeCount":75},[],{"trials":5501,"activeCount":75},[],{"trials":5503,"activeCount":75},[],{"intervention":5505,"totalTrials":152,"cells":5506},"LEO 80185 gel, vehicle, liquid paraffin",{"EARLY_PHASE1":5507,"PHASE1":5509,"PHASE2":5517,"PHASE3":5519,"PHASE4":5521,"NA":5523},{"trials":5508,"activeCount":75},[],{"trials":5510,"activeCount":75},[5511],{"nctId":5512,"briefTitle":5513,"status":68,"phases":5514,"primaryCompletion":494,"completion":494,"start":2630,"enrollment":1534,"conditions":5515,"interventions":5516},"NCT02379793","Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects",[54],[1176],[5505],{"trials":5518,"activeCount":75},[],{"trials":5520,"activeCount":75},[],{"trials":5522,"activeCount":75},[],{"trials":5524,"activeCount":75},[],{"intervention":2847,"totalTrials":152,"cells":5526},{"EARLY_PHASE1":5527,"PHASE1":5529,"PHASE2":5535,"PHASE3":5537,"PHASE4":5539,"NA":5541},{"trials":5528,"activeCount":75},[],{"trials":5530,"activeCount":75},[5531],{"nctId":2842,"briefTitle":2843,"status":68,"phases":5532,"primaryCompletion":2790,"completion":2790,"start":1650,"enrollment":1160,"conditions":5533,"interventions":5534},[54],[18],[1271,2847],{"trials":5536,"activeCount":75},[],{"trials":5538,"activeCount":75},[],{"trials":5540,"activeCount":75},[],{"trials":5542,"activeCount":75},[],{"intervention":5544,"totalTrials":152,"cells":5545},"Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues.",{"EARLY_PHASE1":5546,"PHASE1":5548,"PHASE2":5557,"PHASE3":5559,"PHASE4":5561,"NA":5563},{"trials":5547,"activeCount":75},[],{"trials":5549,"activeCount":75},[5550],{"nctId":5551,"briefTitle":5552,"status":68,"phases":5553,"primaryCompletion":2790,"completion":2790,"start":2774,"enrollment":1257,"conditions":5554,"interventions":5556},"NCT01105234","An Irritation Study With New Calcipotriol Ointment Formulations in Healthy Subjects",[54],[5555],"Irritation",[5544],{"trials":5558,"activeCount":75},[],{"trials":5560,"activeCount":75},[],{"trials":5562,"activeCount":75},[],{"trials":5564,"activeCount":75},[],{"intervention":1462,"totalTrials":152,"cells":5566},{"EARLY_PHASE1":5567,"PHASE1":5569,"PHASE2":5575,"PHASE3":5577,"PHASE4":5579,"NA":5581},{"trials":5568,"activeCount":75},[],{"trials":5570,"activeCount":75},[5571],{"nctId":1454,"briefTitle":1455,"status":68,"phases":5572,"primaryCompletion":1457,"completion":1457,"start":1458,"enrollment":1459,"conditions":5573,"interventions":5574},[54],[15],[1438,1462],{"trials":5576,"activeCount":75},[],{"trials":5578,"activeCount":75},[],{"trials":5580,"activeCount":75},[],{"trials":5582,"activeCount":75},[],{"intervention":1494,"totalTrials":152,"cells":5584},{"EARLY_PHASE1":5585,"PHASE1":5587,"PHASE2":5593,"PHASE3":5595,"PHASE4":5597,"NA":5599},{"trials":5586,"activeCount":75},[],{"trials":5588,"activeCount":75},[5589],{"nctId":1487,"briefTitle":1488,"status":68,"phases":5590,"primaryCompletion":1490,"completion":1490,"start":1013,"enrollment":1491,"conditions":5591,"interventions":5592},[54],[15],[1480,1494],{"trials":5594,"activeCount":75},[],{"trials":5596,"activeCount":75},[],{"trials":5598,"activeCount":75},[],{"trials":5600,"activeCount":75},[],{"intervention":4283,"totalTrials":152,"cells":5602},{"EARLY_PHASE1":5603,"PHASE1":5605,"PHASE2":5611,"PHASE3":5613,"PHASE4":5615,"NA":5617},{"trials":5604,"activeCount":75},[],{"trials":5606,"activeCount":75},[5607],{"nctId":4278,"briefTitle":4279,"status":68,"phases":5608,"primaryCompletion":3037,"completion":3037,"start":2666,"enrollment":72,"conditions":5609,"interventions":5610},[54],[24],[4283,4284,4262,4285],{"trials":5612,"activeCount":75},[],{"trials":5614,"activeCount":75},[],{"trials":5616,"activeCount":75},[],{"trials":5618,"activeCount":75},[],{"intervention":4284,"totalTrials":152,"cells":5620},{"EARLY_PHASE1":5621,"PHASE1":5623,"PHASE2":5629,"PHASE3":5631,"PHASE4":5633,"NA":5635},{"trials":5622,"activeCount":75},[],{"trials":5624,"activeCount":75},[5625],{"nctId":4278,"briefTitle":4279,"status":68,"phases":5626,"primaryCompletion":3037,"completion":3037,"start":2666,"enrollment":72,"conditions":5627,"interventions":5628},[54],[24],[4283,4284,4262,4285],{"trials":5630,"activeCount":75},[],{"trials":5632,"activeCount":75},[],{"trials":5634,"activeCount":75},[],{"trials":5636,"activeCount":75},[],{"intervention":4285,"totalTrials":152,"cells":5638},{"EARLY_PHASE1":5639,"PHASE1":5641,"PHASE2":5647,"PHASE3":5649,"PHASE4":5651,"NA":5653},{"trials":5640,"activeCount":75},[],{"trials":5642,"activeCount":75},[5643],{"nctId":4278,"briefTitle":4279,"status":68,"phases":5644,"primaryCompletion":3037,"completion":3037,"start":2666,"enrollment":72,"conditions":5645,"interventions":5646},[54],[24],[4283,4284,4262,4285],{"trials":5648,"activeCount":75},[],{"trials":5650,"activeCount":75},[],{"trials":5652,"activeCount":75},[],{"trials":5654,"activeCount":75},[],{"intervention":5656,"totalTrials":152,"cells":5657},"Ingenol mebutate gel 0.05%",{"EARLY_PHASE1":5658,"PHASE1":5660,"PHASE2":5670,"PHASE3":5672,"PHASE4":5674,"NA":5676},{"trials":5659,"activeCount":75},[],{"trials":5661,"activeCount":75},[5662],{"nctId":5663,"briefTitle":5664,"status":68,"phases":5665,"primaryCompletion":5666,"completion":527,"start":1427,"enrollment":5667,"conditions":5668,"interventions":5669},"NCT01892137","Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%",[54],"2014-03",137,[21],[5656],{"trials":5671,"activeCount":75},[],{"trials":5673,"activeCount":75},[],{"trials":5675,"activeCount":75},[],{"trials":5677,"activeCount":75},[],{"intervention":5679,"totalTrials":152,"cells":5680},"LEO 134310",{"EARLY_PHASE1":5681,"PHASE1":5683,"PHASE2":5695,"PHASE3":5697,"PHASE4":5699,"NA":5701},{"trials":5682,"activeCount":75},[],{"trials":5684,"activeCount":75},[5685],{"nctId":5686,"briefTitle":5687,"status":68,"phases":5688,"primaryCompletion":5689,"completion":5689,"start":5690,"enrollment":2580,"conditions":5691,"interventions":5692},"NCT03669757","Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis",[54],"2019-02-01","2018-09-27",[15],[5679,5679,5679,5679,5693,5694],"LEO 134310 vehicle","0.1% betamethasone valerate ointment",{"trials":5696,"activeCount":75},[],{"trials":5698,"activeCount":75},[],{"trials":5700,"activeCount":75},[],{"trials":5702,"activeCount":75},[],{"intervention":5693,"totalTrials":152,"cells":5704},{"EARLY_PHASE1":5705,"PHASE1":5707,"PHASE2":5713,"PHASE3":5715,"PHASE4":5717,"NA":5719},{"trials":5706,"activeCount":75},[],{"trials":5708,"activeCount":75},[5709],{"nctId":5686,"briefTitle":5687,"status":68,"phases":5710,"primaryCompletion":5689,"completion":5689,"start":5690,"enrollment":2580,"conditions":5711,"interventions":5712},[54],[15],[5679,5679,5679,5679,5693,5694],{"trials":5714,"activeCount":75},[],{"trials":5716,"activeCount":75},[],{"trials":5718,"activeCount":75},[],{"trials":5720,"activeCount":75},[],{"intervention":5694,"totalTrials":152,"cells":5722},{"EARLY_PHASE1":5723,"PHASE1":5725,"PHASE2":5731,"PHASE3":5733,"PHASE4":5735,"NA":5737},{"trials":5724,"activeCount":75},[],{"trials":5726,"activeCount":75},[5727],{"nctId":5686,"briefTitle":5687,"status":68,"phases":5728,"primaryCompletion":5689,"completion":5689,"start":5690,"enrollment":2580,"conditions":5729,"interventions":5730},[54],[15],[5679,5679,5679,5679,5693,5694],{"trials":5732,"activeCount":75},[],{"trials":5734,"activeCount":75},[],{"trials":5736,"activeCount":75},[],{"trials":5738,"activeCount":75},[],{"intervention":5740,"totalTrials":152,"cells":5741},"LEO 43204 gel 0.018%",{"EARLY_PHASE1":5742,"PHASE1":5744,"PHASE2":5754,"PHASE3":5756,"PHASE4":5758,"NA":5760},{"trials":5743,"activeCount":75},[],{"trials":5745,"activeCount":75},[5746],{"nctId":5747,"briefTitle":5748,"status":68,"phases":5749,"primaryCompletion":1221,"completion":1221,"start":2638,"enrollment":255,"conditions":5750,"interventions":5751},"NCT02424305","Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions",[54],[21],[5740,5752,5753],"LEO 43204 gel 0.1%","LEO 43204 gel 0.037%",{"trials":5755,"activeCount":75},[],{"trials":5757,"activeCount":75},[],{"trials":5759,"activeCount":75},[],{"trials":5761,"activeCount":75},[],{"intervention":5752,"totalTrials":152,"cells":5763},{"EARLY_PHASE1":5764,"PHASE1":5766,"PHASE2":5772,"PHASE3":5774,"PHASE4":5776,"NA":5778},{"trials":5765,"activeCount":75},[],{"trials":5767,"activeCount":75},[5768],{"nctId":5747,"briefTitle":5748,"status":68,"phases":5769,"primaryCompletion":1221,"completion":1221,"start":2638,"enrollment":255,"conditions":5770,"interventions":5771},[54],[21],[5740,5752,5753],{"trials":5773,"activeCount":75},[],{"trials":5775,"activeCount":75},[],{"trials":5777,"activeCount":75},[],{"trials":5779,"activeCount":75},[],{"intervention":5753,"totalTrials":152,"cells":5781},{"EARLY_PHASE1":5782,"PHASE1":5784,"PHASE2":5790,"PHASE3":5792,"PHASE4":5794,"NA":5796},{"trials":5783,"activeCount":75},[],{"trials":5785,"activeCount":75},[5786],{"nctId":5747,"briefTitle":5748,"status":68,"phases":5787,"primaryCompletion":1221,"completion":1221,"start":2638,"enrollment":255,"conditions":5788,"interventions":5789},[54],[21],[5740,5752,5753],{"trials":5791,"activeCount":75},[],{"trials":5793,"activeCount":75},[],{"trials":5795,"activeCount":75},[],{"trials":5797,"activeCount":75},[],{"intervention":5799,"totalTrials":152,"cells":5800},"Ingenol once daily for two consecutive days",{"EARLY_PHASE1":5801,"PHASE1":5803,"PHASE2":5812,"PHASE3":5814,"PHASE4":5816,"NA":5818},{"trials":5802,"activeCount":75},[],{"trials":5804,"activeCount":75},[5805],{"nctId":5806,"briefTitle":5807,"status":68,"phases":5808,"primaryCompletion":2665,"completion":2887,"start":1096,"enrollment":5809,"conditions":5810,"interventions":5811},"NCT01703078","Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis",[54],41,[21],[5799],{"trials":5813,"activeCount":75},[],{"trials":5815,"activeCount":75},[],{"trials":5817,"activeCount":75},[],{"trials":5819,"activeCount":75},[],{"intervention":5821,"totalTrials":152,"cells":5822},"Calcipotriol plus BDP gel in different doses",{"EARLY_PHASE1":5823,"PHASE1":5825,"PHASE2":5833,"PHASE3":5835,"PHASE4":5837,"NA":5839},{"trials":5824,"activeCount":75},[],{"trials":5826,"activeCount":75},[5827],{"nctId":5828,"briefTitle":5829,"status":68,"phases":5830,"primaryCompletion":1128,"completion":1128,"start":2887,"enrollment":1257,"conditions":5831,"interventions":5832},"NCT01837576","An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris",[54],[15],[5821],{"trials":5834,"activeCount":75},[],{"trials":5836,"activeCount":75},[],{"trials":5838,"activeCount":75},[],{"trials":5840,"activeCount":75},[],{"intervention":5842,"totalTrials":152,"cells":5843},"Tralokinumab administered as 1 × X mL with Device A",{"EARLY_PHASE1":5844,"PHASE1":5846,"PHASE2":5857,"PHASE3":5859,"PHASE4":5861,"NA":5863},{"trials":5845,"activeCount":75},[],{"trials":5847,"activeCount":75},[5848],{"nctId":5849,"briefTitle":5850,"status":68,"phases":5851,"primaryCompletion":5852,"completion":5852,"start":5853,"enrollment":5854,"conditions":5855,"interventions":5856},"NCT04674826","A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects",[54],"2021-12-29","2021-02-08",101,[24],[5842],{"trials":5858,"activeCount":75},[],{"trials":5860,"activeCount":75},[],{"trials":5862,"activeCount":75},[],{"trials":5864,"activeCount":75},[],{"intervention":5866,"totalTrials":152,"cells":5867},"LEO 27847 oral solution",{"EARLY_PHASE1":5868,"PHASE1":5870,"PHASE2":5878,"PHASE3":5880,"PHASE4":5882,"NA":5884},{"trials":5869,"activeCount":75},[],{"trials":5871,"activeCount":75},[5872],{"nctId":5873,"briefTitle":5874,"status":68,"phases":5875,"primaryCompletion":528,"completion":1736,"start":1648,"enrollment":1459,"conditions":5876,"interventions":5877},"NCT01143298","LEO 27847 - Single Dose Bioavailability Study of Oral Solution Versus Tablet in Healthy Subjects",[54],[24],[5866],{"trials":5879,"activeCount":75},[],{"trials":5881,"activeCount":75},[],{"trials":5883,"activeCount":75},[],{"trials":5885,"activeCount":75},[],{"intervention":2623,"totalTrials":152,"cells":5887},{"EARLY_PHASE1":5888,"PHASE1":5890,"PHASE2":5896,"PHASE3":5898,"PHASE4":5900,"NA":5902},{"trials":5889,"activeCount":75},[],{"trials":5891,"activeCount":75},[5892],{"nctId":2617,"briefTitle":2618,"status":68,"phases":5893,"primaryCompletion":493,"completion":493,"start":1512,"enrollment":2620,"conditions":5894,"interventions":5895},[54],[21],[2610,2623],{"trials":5897,"activeCount":75},[],{"trials":5899,"activeCount":75},[],{"trials":5901,"activeCount":75},[],{"trials":5903,"activeCount":75},[],{"intervention":5905,"totalTrials":61,"cells":5906},"Ingenol mebutate",{"EARLY_PHASE1":5907,"PHASE1":5909,"PHASE2":5924,"PHASE3":5934,"PHASE4":5945,"NA":5947},{"trials":5908,"activeCount":75},[],{"trials":5910,"activeCount":75},[5911,5917],{"nctId":5912,"briefTitle":5913,"status":68,"phases":5914,"primaryCompletion":481,"completion":481,"start":2666,"enrollment":1257,"conditions":5915,"interventions":5916},"NCT01449513","PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy",[54],[21],[5905],{"nctId":5918,"briefTitle":5919,"status":68,"phases":5920,"primaryCompletion":167,"completion":167,"start":345,"enrollment":5921,"conditions":5922,"interventions":5923},"NCT02124239","Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions",[54],79,[21],[5905],{"trials":5925,"activeCount":75},[5926],{"nctId":5927,"briefTitle":5928,"status":68,"phases":5929,"primaryCompletion":3529,"completion":3529,"start":1396,"enrollment":5930,"conditions":5931,"interventions":5932},"NCT01998984","Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis",[55],266,[21],[5933],"ingenol mebutate",{"trials":5935,"activeCount":75},[5936],{"nctId":5937,"briefTitle":5938,"status":68,"phases":5939,"primaryCompletion":1108,"completion":5940,"start":494,"enrollment":5941,"conditions":5942,"interventions":5943},"NCT02361216","Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest",[56],"2017-03",729,[21],[5944],"Ingenol Mebutate",{"trials":5946,"activeCount":75},[],{"trials":5948,"activeCount":75},[5949,5956,5966,5973],{"nctId":5950,"briefTitle":5951,"status":68,"phases":5952,"primaryCompletion":1075,"completion":1075,"start":1427,"enrollment":5953,"conditions":5954,"interventions":5955},"NCT02090465","Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks",[],840,[21],[5944],{"nctId":5957,"briefTitle":5958,"status":68,"phases":5959,"primaryCompletion":4244,"completion":4244,"start":3529,"enrollment":5960,"conditions":5961,"interventions":5962},"NCT02362152","The Real Life Topical Field Treatment of Actinic Keratosis Study",[],1168,[21],[5905,5963,5964,5965],"5-fluorouracil","Imiquimod","Diclofenac",{"nctId":5967,"briefTitle":5968,"status":68,"phases":5969,"primaryCompletion":1512,"completion":1512,"start":345,"enrollment":5970,"conditions":5971,"interventions":5972},"NCT04202445","TreatMent of ActInic KerAtosis Lesions : pharmacoepiDemiological Study of the Impact in Real Life of ingenOl Mebutate Gel (Picato®) on Patients Satisfaction",[],1218,[21],[5905],{"nctId":5974,"briefTitle":5975,"status":68,"phases":5976,"primaryCompletion":1055,"completion":1055,"start":5977,"enrollment":5978,"conditions":5979,"interventions":5980},"NCT02594436","The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice",[],"2015-12-01",440,[21],[5905],{"intervention":5982,"totalTrials":8,"cells":5983},"Daivobet® Gel",{"EARLY_PHASE1":5984,"PHASE1":5986,"PHASE2":5988,"PHASE3":5994,"PHASE4":6000,"NA":6002},{"trials":5985,"activeCount":75},[],{"trials":5987,"activeCount":75},[],{"trials":5989,"activeCount":75},[5990],{"nctId":1170,"briefTitle":1171,"status":68,"phases":5991,"primaryCompletion":1173,"completion":1173,"start":494,"enrollment":1174,"conditions":5992,"interventions":5993},[55],[1176],[1178,1179,1148,1180,1181,1182],{"trials":5995,"activeCount":75},[5996],{"nctId":1218,"briefTitle":1219,"status":68,"phases":5997,"primaryCompletion":1221,"completion":1221,"start":1222,"enrollment":1223,"conditions":5998,"interventions":5999},[56],[15],[1226,1182],{"trials":6001,"activeCount":75},[],{"trials":6003,"activeCount":75},[6004,6012],{"nctId":6005,"briefTitle":6006,"status":68,"phases":6007,"primaryCompletion":6008,"completion":6008,"start":5240,"enrollment":6009,"conditions":6010,"interventions":6011},"NCT01320774","Efficacy, Tolerability and Handling of Daivobet® Gel in Patients With Psoriasis Vulgaris",[],"2012-01",588,[15],[5982],{"nctId":6013,"briefTitle":6014,"status":68,"phases":6015,"primaryCompletion":527,"completion":3529,"start":2725,"enrollment":6016,"conditions":6017,"interventions":6018},"NCT01707368","Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation",[],561,[15,414],[5982],{"intervention":787,"totalTrials":421,"cells":6020},{"EARLY_PHASE1":6021,"PHASE1":6023,"PHASE2":6025,"PHASE3":6031,"PHASE4":6033,"NA":6039},{"trials":6022,"activeCount":75},[],{"trials":6024,"activeCount":75},[],{"trials":6026,"activeCount":75},[6027],{"nctId":1382,"briefTitle":1383,"status":68,"phases":6028,"primaryCompletion":1385,"completion":1385,"start":1386,"enrollment":1387,"conditions":6029,"interventions":6030},[55],[30],[787,1364],{"trials":6032,"activeCount":75},[],{"trials":6034,"activeCount":75},[6035],{"nctId":778,"briefTitle":779,"status":68,"phases":6036,"primaryCompletion":781,"completion":782,"start":783,"enrollment":784,"conditions":6037,"interventions":6038},[57],[30],[787,765,788],{"trials":6040,"activeCount":75},[6041],{"nctId":6042,"briefTitle":6043,"status":68,"phases":6044,"primaryCompletion":6045,"completion":6046,"start":6047,"enrollment":6048,"conditions":6049,"interventions":6051},"NCT03193372","A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea",[],"2017-08-08","2017-11-15","2017-07-20",2200,[6050],"Rosacea",[6052],"Azelaic Acid",{"intervention":737,"totalTrials":421,"cells":6054},{"EARLY_PHASE1":6055,"PHASE1":6057,"PHASE2":6059,"PHASE3":6061,"PHASE4":6067,"NA":6073},{"trials":6056,"activeCount":75},[],{"trials":6058,"activeCount":75},[],{"trials":6060,"activeCount":75},[],{"trials":6062,"activeCount":75},[6063],{"nctId":2288,"briefTitle":2289,"status":68,"phases":6064,"primaryCompletion":1735,"completion":1735,"start":1736,"enrollment":2291,"conditions":6065,"interventions":6066},[56],[2293],[737,2277],{"trials":6068,"activeCount":75},[6069],{"nctId":729,"briefTitle":730,"status":68,"phases":6070,"primaryCompletion":732,"completion":732,"start":733,"enrollment":734,"conditions":6071,"interventions":6072},[57],[15],[737,716],{"trials":6074,"activeCount":75},[6075],{"nctId":6076,"briefTitle":6077,"status":68,"phases":6078,"primaryCompletion":2790,"completion":2790,"start":1543,"enrollment":6079,"conditions":6080,"interventions":6081},"NCT01052467","Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)",[],724,[2293],[6082],"Xamiol® Gel",{"intervention":6084,"totalTrials":334,"cells":6085},"Diflucortolone valerate",{"EARLY_PHASE1":6086,"PHASE1":6088,"PHASE2":6090,"PHASE3":6092,"PHASE4":6094,"NA":6096},{"trials":6087,"activeCount":75},[],{"trials":6089,"activeCount":75},[],{"trials":6091,"activeCount":75},[],{"trials":6093,"activeCount":75},[],{"trials":6095,"activeCount":75},[],{"trials":6097,"activeCount":75},[6098,6108],{"nctId":6099,"briefTitle":6100,"status":68,"phases":6101,"primaryCompletion":6102,"completion":6102,"start":6103,"enrollment":6104,"conditions":6105,"interventions":6107},"NCT03788863","A Study to Learn More About the Relationship Between the Development of a Gap in the Upper Lip (Cleft Lip) or in the Roof of the Mouth (Cleft Palate) in Newborns and the Use of Glucocorticoids by the Mother During Pregnancy: a Meta-analysis",[],"2018-11-29","2018-11-16",99999,[6106],"Relationship Between the Exposure of Glucocorticoids During Pregnancy and Orofacial Cleft Development",[6084],{"nctId":6109,"briefTitle":6110,"status":68,"phases":6111,"primaryCompletion":6112,"completion":6113,"start":6114,"enrollment":6115,"conditions":6116,"interventions":6117},"NCT02627989","An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switched to Ointment (W\u002FO Emulsion) Formulation of Very Strong Class Topical Corticosteroids",[],"2016-11-17","2017-01-17","2015-12-10",55,[610],[6084,6084],{"intervention":6119,"totalTrials":334,"cells":6120},"Seocalcitol",{"EARLY_PHASE1":6121,"PHASE1":6123,"PHASE2":6125,"PHASE3":6127,"PHASE4":6139,"NA":6141},{"trials":6122,"activeCount":75},[],{"trials":6124,"activeCount":75},[],{"trials":6126,"activeCount":75},[],{"trials":6128,"activeCount":75},[6129],{"nctId":6130,"briefTitle":6131,"status":282,"phases":6132,"completion":6133,"start":6134,"enrollment":6135,"conditions":6136,"interventions":6138},"NCT00051545","Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma",[56],"2004-06","1999-11",608,[6137],"Liver Neoplasms",[6119],{"trials":6140,"activeCount":75},[],{"trials":6142,"activeCount":75},[6143],{"nctId":6144,"briefTitle":6145,"status":282,"phases":6146,"completion":582,"start":6147,"enrollment":6148,"conditions":6149,"interventions":6150},"NCT00051532","Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma",[58],"1999-09",700,[6137],[6119],{"intervention":6152,"totalTrials":152,"cells":6153},"Calcipotriol\u002Fbetamethasone dipropionate gel",{"EARLY_PHASE1":6154,"PHASE1":6156,"PHASE2":6158,"PHASE3":6160,"PHASE4":6162,"NA":6164},{"trials":6155,"activeCount":75},[],{"trials":6157,"activeCount":75},[],{"trials":6159,"activeCount":75},[],{"trials":6161,"activeCount":75},[],{"trials":6163,"activeCount":75},[],{"trials":6165,"activeCount":75},[6166],{"nctId":6167,"briefTitle":6168,"status":68,"phases":6169,"primaryCompletion":6170,"completion":6170,"start":1187,"enrollment":6171,"conditions":6172,"interventions":6173},"NCT02636101","Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study",[],"2018-02-15",603,[15],[6152],{"intervention":6175,"totalTrials":152,"cells":6176},"Azelaic Acid Gel including: Finacea",{"EARLY_PHASE1":6177,"PHASE1":6179,"PHASE2":6181,"PHASE3":6183,"PHASE4":6185,"NA":6187},{"trials":6178,"activeCount":75},[],{"trials":6180,"activeCount":75},[],{"trials":6182,"activeCount":75},[],{"trials":6184,"activeCount":75},[],{"trials":6186,"activeCount":75},[],{"trials":6188,"activeCount":75},[6189],{"nctId":6190,"briefTitle":6191,"status":68,"phases":6192,"primaryCompletion":6193,"completion":6193,"start":6194,"enrollment":6195,"conditions":6196,"interventions":6197},"NCT02602470","Preferences & Treatment Satisfaction Drivers in Rosacea Patients",[],"2016-03-10","2015-01-08",206,[6050],[6175,6198,6199,6200,6201,6202,6203],"Azelaic Acid Cream","Metronidazole gel","Metronidazole cream","Metronidazole Emulsion","Metronidazole Lotion","Brimonidine Tartrate Gel",{"intervention":6198,"totalTrials":152,"cells":6205},{"EARLY_PHASE1":6206,"PHASE1":6208,"PHASE2":6210,"PHASE3":6212,"PHASE4":6214,"NA":6216},{"trials":6207,"activeCount":75},[],{"trials":6209,"activeCount":75},[],{"trials":6211,"activeCount":75},[],{"trials":6213,"activeCount":75},[],{"trials":6215,"activeCount":75},[],{"trials":6217,"activeCount":75},[6218],{"nctId":6190,"briefTitle":6191,"status":68,"phases":6219,"primaryCompletion":6193,"completion":6193,"start":6194,"enrollment":6195,"conditions":6220,"interventions":6221},[],[6050],[6175,6198,6199,6200,6201,6202,6203],{"intervention":6199,"totalTrials":152,"cells":6223},{"EARLY_PHASE1":6224,"PHASE1":6226,"PHASE2":6228,"PHASE3":6230,"PHASE4":6232,"NA":6234},{"trials":6225,"activeCount":75},[],{"trials":6227,"activeCount":75},[],{"trials":6229,"activeCount":75},[],{"trials":6231,"activeCount":75},[],{"trials":6233,"activeCount":75},[],{"trials":6235,"activeCount":75},[6236],{"nctId":6190,"briefTitle":6191,"status":68,"phases":6237,"primaryCompletion":6193,"completion":6193,"start":6194,"enrollment":6195,"conditions":6238,"interventions":6239},[],[6050],[6175,6198,6199,6200,6201,6202,6203],{"intervention":6200,"totalTrials":152,"cells":6241},{"EARLY_PHASE1":6242,"PHASE1":6244,"PHASE2":6246,"PHASE3":6248,"PHASE4":6250,"NA":6252},{"trials":6243,"activeCount":75},[],{"trials":6245,"activeCount":75},[],{"trials":6247,"activeCount":75},[],{"trials":6249,"activeCount":75},[],{"trials":6251,"activeCount":75},[],{"trials":6253,"activeCount":75},[6254],{"nctId":6190,"briefTitle":6191,"status":68,"phases":6255,"primaryCompletion":6193,"completion":6193,"start":6194,"enrollment":6195,"conditions":6256,"interventions":6257},[],[6050],[6175,6198,6199,6200,6201,6202,6203],{"intervention":6201,"totalTrials":152,"cells":6259},{"EARLY_PHASE1":6260,"PHASE1":6262,"PHASE2":6264,"PHASE3":6266,"PHASE4":6268,"NA":6270},{"trials":6261,"activeCount":75},[],{"trials":6263,"activeCount":75},[],{"trials":6265,"activeCount":75},[],{"trials":6267,"activeCount":75},[],{"trials":6269,"activeCount":75},[],{"trials":6271,"activeCount":75},[6272],{"nctId":6190,"briefTitle":6191,"status":68,"phases":6273,"primaryCompletion":6193,"completion":6193,"start":6194,"enrollment":6195,"conditions":6274,"interventions":6275},[],[6050],[6175,6198,6199,6200,6201,6202,6203],{"intervention":6202,"totalTrials":152,"cells":6277},{"EARLY_PHASE1":6278,"PHASE1":6280,"PHASE2":6282,"PHASE3":6284,"PHASE4":6286,"NA":6288},{"trials":6279,"activeCount":75},[],{"trials":6281,"activeCount":75},[],{"trials":6283,"activeCount":75},[],{"trials":6285,"activeCount":75},[],{"trials":6287,"activeCount":75},[],{"trials":6289,"activeCount":75},[6290],{"nctId":6190,"briefTitle":6191,"status":68,"phases":6291,"primaryCompletion":6193,"completion":6193,"start":6194,"enrollment":6195,"conditions":6292,"interventions":6293},[],[6050],[6175,6198,6199,6200,6201,6202,6203],{"intervention":6203,"totalTrials":152,"cells":6295},{"EARLY_PHASE1":6296,"PHASE1":6298,"PHASE2":6300,"PHASE3":6302,"PHASE4":6304,"NA":6306},{"trials":6297,"activeCount":75},[],{"trials":6299,"activeCount":75},[],{"trials":6301,"activeCount":75},[],{"trials":6303,"activeCount":75},[],{"trials":6305,"activeCount":75},[],{"trials":6307,"activeCount":75},[6308],{"nctId":6190,"briefTitle":6191,"status":68,"phases":6309,"primaryCompletion":6193,"completion":6193,"start":6194,"enrollment":6195,"conditions":6310,"interventions":6311},[],[6050],[6175,6198,6199,6200,6201,6202,6203],{"intervention":6313,"totalTrials":152,"cells":6314},"calcipotriol\u002Fbetamethasone dipropionate gel in Applicator",{"EARLY_PHASE1":6315,"PHASE1":6317,"PHASE2":6319,"PHASE3":6321,"PHASE4":6323,"NA":6325},{"trials":6316,"activeCount":75},[],{"trials":6318,"activeCount":75},[],{"trials":6320,"activeCount":75},[],{"trials":6322,"activeCount":75},[],{"trials":6324,"activeCount":75},[],{"trials":6326,"activeCount":75},[6327],{"nctId":6328,"briefTitle":6329,"status":68,"phases":6330,"primaryCompletion":6331,"completion":6331,"start":6332,"enrollment":6333,"conditions":6334,"interventions":6335},"NCT02856542","Real-life Evaluation of the Daivobet® Gel Applicator",[],"2017-06","2016-05-23",1560,[414],[6313],{"intervention":5963,"totalTrials":152,"cells":6337},{"EARLY_PHASE1":6338,"PHASE1":6340,"PHASE2":6342,"PHASE3":6344,"PHASE4":6346,"NA":6348},{"trials":6339,"activeCount":75},[],{"trials":6341,"activeCount":75},[],{"trials":6343,"activeCount":75},[],{"trials":6345,"activeCount":75},[],{"trials":6347,"activeCount":75},[],{"trials":6349,"activeCount":75},[6350],{"nctId":5957,"briefTitle":5958,"status":68,"phases":6351,"primaryCompletion":4244,"completion":4244,"start":3529,"enrollment":5960,"conditions":6352,"interventions":6353},[],[21],[5905,5963,5964,5965],{"intervention":5964,"totalTrials":152,"cells":6355},{"EARLY_PHASE1":6356,"PHASE1":6358,"PHASE2":6360,"PHASE3":6362,"PHASE4":6364,"NA":6366},{"trials":6357,"activeCount":75},[],{"trials":6359,"activeCount":75},[],{"trials":6361,"activeCount":75},[],{"trials":6363,"activeCount":75},[],{"trials":6365,"activeCount":75},[],{"trials":6367,"activeCount":75},[6368],{"nctId":5957,"briefTitle":5958,"status":68,"phases":6369,"primaryCompletion":4244,"completion":4244,"start":3529,"enrollment":5960,"conditions":6370,"interventions":6371},[],[21],[5905,5963,5964,5965],{"intervention":5965,"totalTrials":152,"cells":6373},{"EARLY_PHASE1":6374,"PHASE1":6376,"PHASE2":6378,"PHASE3":6380,"PHASE4":6382,"NA":6384},{"trials":6375,"activeCount":75},[],{"trials":6377,"activeCount":75},[],{"trials":6379,"activeCount":75},[],{"trials":6381,"activeCount":75},[],{"trials":6383,"activeCount":75},[],{"trials":6385,"activeCount":75},[6386],{"nctId":5957,"briefTitle":5958,"status":68,"phases":6387,"primaryCompletion":4244,"completion":4244,"start":3529,"enrollment":5960,"conditions":6388,"interventions":6389},[],[21],[5905,5963,5964,5965],{"intervention":6391,"totalTrials":152,"cells":6392},"Enstilar®",{"EARLY_PHASE1":6393,"PHASE1":6395,"PHASE2":6397,"PHASE3":6399,"PHASE4":6401,"NA":6403},{"trials":6394,"activeCount":75},[],{"trials":6396,"activeCount":75},[],{"trials":6398,"activeCount":75},[],{"trials":6400,"activeCount":75},[],{"trials":6402,"activeCount":75},[],{"trials":6404,"activeCount":75},[6405],{"nctId":6406,"briefTitle":6407,"status":68,"phases":6408,"primaryCompletion":5940,"completion":5940,"start":2497,"enrollment":6409,"conditions":6410,"interventions":6411},"NCT02881346","Efficacy and Tolerability of Enstilar® in Daily Practice",[],410,[414],[6391],{"intervention":6413,"totalTrials":152,"cells":6414},"Leukotriene B4",{"EARLY_PHASE1":6415,"PHASE1":6417,"PHASE2":6419,"PHASE3":6421,"PHASE4":6423,"NA":6425},{"trials":6416,"activeCount":75},[],{"trials":6418,"activeCount":75},[],{"trials":6420,"activeCount":75},[],{"trials":6422,"activeCount":75},[],{"trials":6424,"activeCount":75},[],{"trials":6426,"activeCount":75},[6427],{"nctId":6428,"briefTitle":6429,"status":68,"phases":6430,"primaryCompletion":2496,"completion":2496,"start":6431,"enrollment":379,"conditions":6432,"interventions":6434},"NCT03192280","Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and\u002For Texture Following the Induction of a Local Inflammatory Skin Response",[58],"2017-06-19",[6433],"Skin Inflammation",[6413],{"intervention":6436,"totalTrials":152,"cells":6437},"Enstilar® aerosol foam",{"EARLY_PHASE1":6438,"PHASE1":6440,"PHASE2":6442,"PHASE3":6444,"PHASE4":6446,"NA":6448},{"trials":6439,"activeCount":75},[],{"trials":6441,"activeCount":75},[],{"trials":6443,"activeCount":75},[],{"trials":6445,"activeCount":75},[],{"trials":6447,"activeCount":75},[],{"trials":6449,"activeCount":75},[6450],{"nctId":6451,"briefTitle":6452,"status":68,"phases":6453,"primaryCompletion":6454,"completion":6454,"start":6455,"enrollment":6456,"conditions":6457,"interventions":6458},"NCT02935582","PSOREAL - Managing PSOriasis in the REAL World",[],"2020-12-30","2017-01",1214,[15],[6436,6459],"Other topical",{"intervention":6459,"totalTrials":152,"cells":6461},{"EARLY_PHASE1":6462,"PHASE1":6464,"PHASE2":6466,"PHASE3":6468,"PHASE4":6470,"NA":6472},{"trials":6463,"activeCount":75},[],{"trials":6465,"activeCount":75},[],{"trials":6467,"activeCount":75},[],{"trials":6469,"activeCount":75},[],{"trials":6471,"activeCount":75},[],{"trials":6473,"activeCount":75},[6474],{"nctId":6451,"briefTitle":6452,"status":68,"phases":6475,"primaryCompletion":6454,"completion":6454,"start":6455,"enrollment":6456,"conditions":6476,"interventions":6477},[],[15],[6436,6459],{"intervention":6479,"totalTrials":152,"cells":6480},"Ingenol mebutate 0.015 percent or 0.05 percent gel",{"EARLY_PHASE1":6481,"PHASE1":6483,"PHASE2":6485,"PHASE3":6487,"PHASE4":6489,"NA":6491},{"trials":6482,"activeCount":75},[],{"trials":6484,"activeCount":75},[],{"trials":6486,"activeCount":75},[],{"trials":6488,"activeCount":75},[],{"trials":6490,"activeCount":75},[],{"trials":6492,"activeCount":75},[6493],{"nctId":6494,"briefTitle":6495,"status":68,"phases":6496,"primaryCompletion":6497,"completion":6497,"start":344,"enrollment":6498,"conditions":6499,"interventions":6500},"NCT02421471","PMS to Evaluate the Safety and Efficacy of Picato® Gel",[],"2018-01-19",1324,[21],[6479],{"intervention":6502,"totalTrials":152,"cells":6503},"Any topical drug treatment",{"EARLY_PHASE1":6504,"PHASE1":6506,"PHASE2":6508,"PHASE3":6510,"PHASE4":6512,"NA":6514},{"trials":6505,"activeCount":75},[],{"trials":6507,"activeCount":75},[],{"trials":6509,"activeCount":75},[],{"trials":6511,"activeCount":75},[],{"trials":6513,"activeCount":75},[],{"trials":6515,"activeCount":75},[6516],{"nctId":6517,"briefTitle":6518,"status":68,"phases":6519,"primaryCompletion":6520,"completion":6520,"start":6521,"enrollment":6522,"conditions":6523,"interventions":6524},"NCT03402828","Body PSOriasis: Long-term Relapse CONTROL",[],"2020-05-15","2018-06-11",764,[15],[6502],{"intervention":6526,"totalTrials":152,"cells":6527},"Tinzaparin",{"EARLY_PHASE1":6528,"PHASE1":6530,"PHASE2":6532,"PHASE3":6534,"PHASE4":6536,"NA":6538},{"trials":6529,"activeCount":75},[],{"trials":6531,"activeCount":75},[],{"trials":6533,"activeCount":75},[],{"trials":6535,"activeCount":75},[],{"trials":6537,"activeCount":75},[],{"trials":6539,"activeCount":75},[6540],{"nctId":6541,"briefTitle":6542,"status":68,"phases":6543,"primaryCompletion":6544,"completion":6544,"start":2638,"enrollment":6545,"conditions":6546,"interventions":6547},"NCT03099031","Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)",[],"2017-05-15",420,[531],[6526]]